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Abstract 
 
Measles wild-type virus (MeV) is the etiological agent of measles, a highly 
contagious life-threatening disease. We previously reported that a novel L-
chiral dideoxy bicyclic pyrimidine nucleoside analogue (L-ddBCNA),hereby 
named cf2642, inhibited both MeV and vaccinia virus (VACV) infection in 
vitro, with a structure activity relationship indicating a host target. The aim of 
this project was to elucidate the mechanism of action by which cf2642 
inhibits the MeV life cycle, focusing on endocytosis and particularly 
macropinocytosis that has recently been demonstrated to be exploited by 
this virus to gain cell entry. 
Initial cytotoxicity analysis of cf2642 in HeLa and Vero cells stably 
expressing the human Signalling Lymphocyte Activation Molecule (SLAM) 
receptor for MeV (VeroSLAM) demonstrated cell line dependent toxicity. 
The drug caused the generalized peripheral scattering of early and late 
endosomes/lysosomes in both cell lines, but did not affect traffic from the 
plasma membrane to lysosomes of the fluid phase/macropinocytosis probe 
dextran. MeV induced syncytia and autophagy in VeroSLAM cells was also 
inhibited by cf2642, indicating that another cellular target(s) was being 
affected.  
Given that cf2642 may have a cell-target(s), and that MeV and VACV use 
macropinocytosis as a mode of cell entry, the relationship between these 
two was tested. MeV stimulated macropinocytosis in VeroSLAM cells and 
this effect was abrogatedrapidly and completely by cf2642. In an attempt to 
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mimic the effects of MeV activation of SLAM receptors a non-infectious 
setting, a SLAM clustering model was developed using anti-SLAM 
antibodies to cluster these receptors. This caused a significant stimulation in 
macropinocytosis that was abolished by cf2642. Confocal microscopy 
highlighted both MeV and SLAM clustering induced effects on actin 
morphology that were also abrogated by cf2642. A virus entry/spread assay 
using MeV expressing GFP in combination with time of addition assays 
highlighted the inhibitory effect of the drug on virus spread and illustrated 
that a cellular target(s) that was important during the entire virus life cycle 
was targeted.  
Overall, the data indicates that cf2642 renders its antiviral activity by 
inhibiting MeV spread and possibly virus entry occurring via 
macropinocytosis. This is postulated to be via a general mechanism on 
plasma membrane and internal membranes that are critical for the virus life 
cycle. 
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Chapter 1 - Introduction 
1.1. Background - Summary of previous studies by Dr. Laura Farleigh 
Preliminary studies involving the analysis of L-ddBCNA antiviral activity was 
performed by Dr. Laura Farleigh as part of her PhD research parts of which 
were pubished in 2014(Farleigh, 20140). A brief summary of her findings is 
given below.  
Initial experiments studying the effects of L-ddBCNA against VACV 
expressing luciferase demonstrated antiviral activity at an early (2 hr) time 
point. However, this was not due to the effects on viral entry or early 
transcription, as demonstrated by experiments using fluorescent VACV 
particles and in vitro virus transcription assays respectively. Time of addition 
assays showed that L-ddBCNAs inhibited VACV even when added at 8 hr 
post infection, meaning that a cellular process utilized by the virus during its 
entire life cycle was being targeted. Further evidence for a cellular target for 
L-ddBCNAs was provided by cell-range assays wherein varying levels of 
antiviral activity against VACV and measles virus was observed across a 
broad range of cell lines tested.   
Based on the notion that cell-targeting effects of L-ddBCNAs may not be 
limited to VACV alone, the activity of these drugs was also tested against a 
few other enveloped and non-enveloped DNA and RNA viruses namely 
herpes simplex virus type 1 and 2 (HSV 1/2), adenovirus, measles wild-type 
strain (MeV) and influenza virus. Antiviral activity was observed only against 
MeV, which demonstrated that a cellular process that is crucial for both 
VACV and MeV was being affected.   
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To assess whether chemical modifications of the drugs has any role in their 
antiviral activity, a structure activity relationship (SAR) study was done by 
testing the effects of different L-ddBCNAs against both MeV and VACV. The 
results demonstrated that the antiviral activity of these compounds was 
dependent on the length of their lipophilic side chain, and the lead 
compound cf2642 with a 5 C side chain length inhibited both VACV and 
MeV at IC50 of 0.2 µM and 7.5µM respectively. The SAR study was 
performed using three different biological assays namely 2 hr VACV 
luciferase assay, 4 days VACV plaque assay and 48 hr MeV TCID50 
(median tissue culture infectious dose) assay and since all these assays 
involved intracellular transport and membrane trafficking, it was speculated 
that ddBCNAs was likely affecting cellular membrane compartments crucial 
for both VACV and MeV.  
Treatment with L-ddBCNAs resulted in varying degrees of cytotoxicity across 
a range of cell lines and the cells remained viable even up to 4 days post 
treatment if the tissue culture medium was replaced at regular intervals. This 
was attributed to the fact that L-ddBCNAs resulted in acidic pH of 
extracellular medium. More importantly, it was shown that the antiviral 
activity was not the direct result of drug induced cytotoxicity.  
Bringing together the findings from this research project, it was 
hypothesized that the antiviral activity of L-ddBCNAs/cf2642 may be 
attributed to their cell-targeting activity that in turn affects both VACV and 
MeV.  Since the effect against VACV was observed at an early (2 hr) time 
point, this was speculated to be a result of effects on early viral DNA 
transcription sites within cells, or membrane compartments involved therein. 
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During early stages of virus infection, MeV induces a cellular process called 
autophagy which in turn leads to syncytia formation. Since L-
ddBCNAs/cf2642 inhibited MeV induced syncytia formation, it was 
hypothesized that the anti-MeV activity could due to effects on autophagy-
related membrane compartments (Farleigh, 2014). 
1.2. Measles 
Measles, one of the most contagious diseases known to man, is caused by 
infection with MeV. The disease is characterized by fever and a 
maculopapularrash, often accompanied by cough, coryza and conjunctivitis. 
MeV is a single-stranded negative-sense RNA virus belonging to the family 
Paramyxoviridae, genus Morbillivirus(Yanagi et al., 2006). The long 
incubation period of 10-14 days and airborne route of transmission allows 
the virus to infect large populations with high efficiency (Rima and Duprex, 
2006).  
Despite the overall decrease of measles related deaths between 2000 and 
2007 because of efficient vaccination strategies, the disease later reached 
epidemic proportions in several parts of Europe (Plemper and Snyder, 
2009). Measles contributed to an estimated 100,000 deaths globally in 
2017, with the highest mortality rate observed among children under the age 
of five. (Alya Dabbagh, 2018). A 95% vaccination rate within a given 
population is often required to maintain herd immunity against measles 
(Farrugia and Quinti, 2018). The recent measles outbreaks in the US during 
January-April 2019 resulted in a total of 704 positive cases and was mostly 
associated with unvaccinated U.S residents returning after international 
travel (Manisha Patel, 2019). In such cases, measles spreads rapidly 
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among the unvaccinated individuals, resulting in sporadic outbreaks. The 
lack of a specific antiviral against measles only adds to the problem 
(Hopkins Tanne, 2019).  
 
1.1.1. Classification 
MeV is an enveloped, single-stranded, non-segmented, negative-sense 
RNA virus belonging to the order Mononegavirales, family Paramyxoviridae 
(Yanagi et al., 2006). Members of this group are characterized by their 
typical pleomorphic morphology when viewed under an electron 
microscope. The order Mononegavirales that also includes other virus 
families namely Rhabdoviridae, Bornaviridae and Filoviridae, includes all 
non-segmented negative strand RNA viruses.   
The family Paramyxoviridae is further divided into two subfamilies namely 
Pneumovirinae which includes notable viruses like respiratory syncytial virus 
(RSV), metapneumovirus, avian pneumovirus; and Paramyxovirinae, 
whichis in turn divided into five different genera. MeV belongs to the genus 
Morbillivirusthat also contains animal viruses like canine distemper virus, 
rinderpest virus and pestes de petits ruminants virus among others. The 
other genera include the genus Respirovirus which includes Sendai virus 
and human parainfluenza virus types 1 and 3; genus Rubulaviruswhich 
includes the type speciesmumps virus; genus Avulaviruscontainingavian 
paramyxoviruses and Newcastle disease virus and finally the genus 
Henipah which includes the Hendra and Nipah viruses which are associated 
with fatal encephalitis in infected people (Rima and Duprex, 2011a). Among 
the members of genus Morbillivirus, both canine distemper virusand MeV 
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have high affinity for lymphocytes and can spread rapidly from the lymphoid 
organs to epithelial cells. This in turn enables these viruses to establish 
immunosuppression in their hosts, often lasting for years’ post infection 
(Krumm et al., 2014).   
1.1.2. Structureand genome organization 
MeV is a pleomorphic enveloped virus ranging in size from 100 to 300 nm. 
The envelope is a lipid bilayer containing the viral transmembrane 
glycoproteins hemagglutinin (H) and fusion (F) that are derived from host 
cells upon the release of infectious virions. The H and F proteins together 
constitute the virus fusion complex. The matrix (M) proteins lies beneath the 
envelope and the viral negative sense RNA genome is packaged within the 
particle in the form of a helical nucleocapsid (N). The nucleocapsid is 
associated with the phosphoprotein (P) and large polymerase protein (L) 
which together constitute the ribonucleoprotein (RNP) complex. (Fig 1.1)  
(Bhella et al., 2004). Apart from these six structural proteins, two non-
structural proteins namely the V and C proteins are also produced by 
translation of the P gene at alternate start codons. The 186 amino acid (aa) 
C protein (MeV-C) is known to aid MeV replication by inhibiting host 
mediated type-1 interferon responses (Shaffer et al., 2003). In addition, the 
MeV-C protein has also been implicated in autophagy induction by both 
Measles vaccine Edmonstonstrain (MeVEd) and MeV(Richetta et al., 2013). 
The RNA genome is bound by 2649 copies of the N protein, meaning that 
each N protein associates with exactly six nucleotides (rule of six) of the 
genomic RNA (Calain and Roux, 1993).  
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Fig 1.1 Structure of MeV. Measles virus structure showing hemagglutinin 
and Fusion glycoproteins on their surface and matrix protein within the 
particle. The helical single stranded RNA genome is bound by the 
nucleocapsid protein and phosphoprotein. The large polymerase is the RNA 
dependent RNA polymerase enzyme.    
 
1.1.3. MeV entry 
MeV entry into cells occurs via the fusion of virus and the plasma membrane of the host 
cell. This membrane fusion-mediated virus entry pathway involves interactions between 
the virus H, F proteins and a specific cellular receptor called SLAM/CD150 (Moss and 
Griffin, 2012). The virion initially binds to the cell surface via the virus H protein - cell 
receptor interaction that causes the virus particle to be closely juxtaposed to the cell 
membrane. This causes the F protein to undergo conformational changes which initiates 
fusion of the two membranes, resulting in release of the viral RNP complex into the cell. 
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The F protein is an integral type 1-membrane protein and is a homotrimer. The precursor 
F0 is first cleaved by the host cell protease furin to form two subunits F1 and F2 that are 
held together by disulphide bonds. The highly hydrophobic N-terminal region of the F1 
subunit protrudes out from the virus envelope and forms the fusion peptide which is in 
turn inserted into the cell membrane to initiate the fusion process (S.J Flint, 2008). Fusion 
occurs directly with the plasma membrane at neutral pH and not in endocytic vesicles. This 
is unlike few other enveloped viruses like Influenza that are known to utilize CME to gain 
cell entry (Luo, 2012). A direct consequence of MeV fusion process is the formation of 
multinucleated giant cells, a typical cytopathic effect (CPE) of MeV infection (Yanagi et al., 
2006). 
In addition to the above mentioned membrane fusion-mediated entry, some research 
groups have speculated the possibility that MeV may also use a macropinocytosis-like 
pathway to gain cell entry (Crimeen-Irwin et al., 2003, Frecha et al., 2011). Indeed, two 
different groups have recently provided experimental evidence to support this (Delpeut et 
al., 2017)(Goncalves-Carneiro et al., 2017). This is discussed in detail in section 1.4. 
Two major cell entry receptors have been identified for measles viruses, CD46 (cluster of 
differentiation 46) and CD150/SLAM (Signaling Lymphocyte Activation Molecule). MeV-Ed 
uses the CD46 receptor for cell entry and can also bind to SLAM (Naniche et al., 1993). 
CD46 is a transmembrane protein that is expressed on all nucleated cells in humans and 
protect cells from complement mediated lysis by binding to the complement proteins c3b 
and c4b (Riley-Vargas et al., 2004). On the other hand, MeV can only bind to the 
CD150/SLAM for entry. SLAM is a member of the immunoglobulin superfamily and is 
expressed mainly in immature thymocytes, memory T cells, macrophages and mature 
dendritic cells and mitogen activated B and T lymphocytes. The SLAM receptor is described 
in details in Section 1.2.1.  
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MeV also uses a yet another receptor called Nectin4, an adherens junction protein that is 
expressed on the basolateral side of epithelial cells. Nectin-4 is not used for cell entry but 
for release/transmission of the virus, mainly because this receptor cannot be accessed by 
MeV from the apical surface of epithelial cells. Instead, MeV infected lymphocytes or 
dendritic cells transmits the virus to epithelial cells expressing the Nectin4 receptor, 
thereby enabling translocation to the airways and transmission via respiratory 
secretions/droplets  (de Vries et al., 2012, Racaniello, 2011). The different types of cellular 
receptors used by measles viruses are shown in Table 1.1.  
 
Table 1.1 Cellular receptors for measles virus 
Receptors Representative 
cell type 
Comments  References 
SLAM/CD150 Activated T and 
B lymphocytes, 
mature dendritic 
cells, 
macrophages 
Used by both 
MeV and MeV-
Ed 
(Berger et 
al., 2010b, 
Tatsuo et 
al., 2000) 
CD46 Ubiquitous cell 
surface 
receptor 
Used by MeV-
Ed and 
laboratory 
adapted MeV 
strains 
(Dorig et 
al., 1993, 
Santiago et 
al., 2010) 
Nectin-4/PVLR4 
(poliovirus 
receptor-related 
4 
 
Expressed in 
several tissues 
including 
primary airway 
epithelial cells. 
Used by all 
measles virus 
strains 
(Mühlebach 
et al., 2011, 
Noyce and 
Richardson, 
2012a) 
 
C-type lectins: 
DC-SIGN, 
Langerin  
Dendritic cells 
and 
Langerhans 
cells  
Used as 
attachment 
receptors for all 
measles virus 
strains.   
(de Witte et 
al., 2006, 
van der 
Vlist et al., 
2011) 
 
Apart from cell entry receptors, MeV also utilize two C-type lectins namely 
DC-SIGN (Dendritic Cell-Specific Intercellular adhesion molecule-3-
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Grabbing Non-integrin) and Langerin as cell attachment receptors. DC-
SIGN is used for transmission of MeV from infected dendritic cells to T 
lymphocytes and Langerin has been shown to aid in antigen presentation by 
Langerhans cells to CD4+ T-lymphocytes (de Vries et al., 2012). 
 
 
1.1.4. Replication 
Fusion of the virus envelope with cellular plasma membrane during entry, 
results inrelease of virus RNP complex into the cytoplasm. MeV replication 
occurs within cytoplasmic inclusion bodies or viral factories which are 
primarily located in the perinuclear regions, especially during early stages of 
replication (Zhou et al., 2019). Initially, transcription of the MeV negative 
sense RNA genome is carried out by virus encoded RdRpcomplex to 
produce positive sense mRNAs (Figure 1.2). Transcription is essentially 
guided by short conserved polyadenylation signals that flank each 
transcriptional element and follows a characteristic “stopstart” pattern by 
which genes near the 3’ end are transcribed more abundantly, compared to 
the 5’ end(Harrison et al., 2010, Whelan et al., 2004).Translation of virus 
proteins then occur using the host cell machinery. MeV genomic RNA 
replication occurs via a two-step process wherein the genomic RNA is first 
used to produce positive-sense antigenomes which is then used as a 
template to produce further negative-sense genomic RNA that subsequently 
gets incorporated in the RNP complex of mature virus particles(Rima and 
Duprex, 2009, Lamb, 2006). This is followed by the RNP assembly which 
occurs in the cytoplasm and is tightly linked to viral RNA synthesis. After 
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assembly, the RNP complex is released by budding at specific sites in the 
cell plasma membrane, thereby incorporating the virus envelope 
proteins(Griffin, 2007). Infectious MeV particles are formed only after the 
assembly of all structural and non-structural proteins of the virus, including 
viral glycoproteins and RNPs, are assembled at designated sites near the 
cell plasma membrane. The assembly process is initiated by the virus M 
protein that directly bind to the plasma membrane and interacts with RNP 
complex and viral glycoproteins via their cytoplasmic tail(Harrison et al., 
2010). 
 
Fig 1.2 MeV life cycle. Upon entry of MeV particles into the cell via membrane 
fusion, the virus genome is transcribed by a virus encoded RdRp enzyme and 
the virus proteins are translated by host cell machinery. Replication of viral 
genome occurs using the positive-sense viral RNA as a template. Post virus 
assembly near the plasma membrane, the MeV particles are release by 
budding, which then proceed to infect new cells.  
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1.1.5. Pathogenesis and clinical symptoms 
 
Transmission of MeV occurs via respiratory droplets that are mainly 
produced during coughing or sneezing by infected individuals. Small-particle 
aerosols may also contribute to transmission since they can remain 
suspended in the air for long durations. The incubation period (time between 
exposure to the virus and appearance of symptoms) of measles ranges from 
10-14 days. Infected individuals start shedding virus during this period and 
continue for many days after the onset of rash. This facilitates measles 
spread well before the onset of symptoms, thereby affecting quarantine 
measures (Moss and Griffin, 2012).  
Upon the transmission of MeV via aerosols, the virus is first exposed to 
mucosa of the respiratory tract in susceptible hosts. This is followed by virus 
entry into circulating SLAM positive alveolar macrophages and dendritic 
cells, which ferry the virus across the epithelial barrier (Lemon et al., 2011). 
These infected dendritic cells/macrophages then transport the virus to the 
draining lymph nodes, leading to the infection of B and T lymphocytes, 
thereby establishing primary viremia. Virus dissemination occurs through the 
BALT (bronchus-associated lymphoid tissue) and spreads to the thymus, 
spleen and other secondary lymphoid organs, culminating in secondary 
viremia and acute immunosuppression (Ludlow et al., 2010). This is 
followed by virus spread to the skin, kidneys, liver, gastrointestinal tract and 
within the entire respiratory tract. Virus shedding occurs when MeV infects 
primary airway epithelial cells of the upper respiratory tract that express the 
Nectin-4 receptor on their basolateral surface. MeV particles are thought to 
be transported to these sites within infected lymphocytes and myeloid cells 
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that are decorated with MeV glycoproteins on their surface. Once, MeV 
gains entry into the airway epithelial cells, a final round of virus amplification 
occurs which then facilitates virus shedding via aerosols (Noyce and 
Richardson, 2012b).  
Measles complications include secondary bacterial infections that occur due 
to prolonged periods of immunosuppression and also neurological diseases 
like acute demyelinating encephalomyelitis (ADEM), measles inclusion body 
encephalitis (MIBE) and subacute sclerosing pan encephalitis (SSPE) 
(Yanagi et al., 2006). SSPE is a lethal late complication that usually occurs 
years after the initial infection. Other complications include bacterial otitis 
media and bronchopneumonia (Plemper and Snyder, 2009).  
 
1.1.6. Diagnosis 
 
Pattern recognition of measles symptoms can be made by considering 
patients presenting with Koplik’s spots, which is the pathognomonic for this 
disease. This is often accompanied by fever, a generalized rash and 
sometimes clinically compatible symptoms like cough, coryza and 
conjunctivitis (Gans et al., 2018). People presenting with such symptoms 
are often considered for measles diagnosis, especially when the disease is 
currently circulating in the area or if the patients have recently travelled to 
measles endemic areas (Moss and Griffin, 2012). Serological tests are often 
used for laboratory confirmation of measles. This may include either a 
positive test for measles IgM or a 4-times rise in measles specific IgG 
antibodies between acute and convalescent sera. Other tests include MeV 
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isolation from clinical samples and detection of MeV RNA using real-time 
reverse transcriptase PCR (Bellini and Helfand, 2003).  
1.1.7. Antigenicity 
 
RNA viruses are prone to have high mutation rates due to their error prone 
RNA dependent RNA polymerase activity (Sanjuán et al., 2010). Yet MeV 
are antigenically monotypic and do not undergo antigenic drift as other RNA 
viruses like Influenza. This is partly because the MeV H and F proteins are 
essentially unable to tolerate significant mutations due to evolutionary 
constraints (Fulton et al., 2015). The public health significance of this is that, 
neutralizing antibodies that are produced upon measles vaccination or wild 
type measles infections offer lifelong protection against all MeV genotypes 
(Moss and Griffin, 2012).  
1.3. Signalling Lymphocyte Activation Molecule (SLAM/CD150) 
The human SLAM immunoglobulin superfamily comprises nine (SLAMF1 - 
F9) different leucocyte cell-surface proteins that are involved in the 
activation and differentiation of T lymphocytes, natural killer cells (NK cells) 
and antigen presenting cells (macrophages and dendritic cells). They serve 
as costimulatory molecules for immune cells in the adaptive immune system 
and also aid in lineage-commitment of thymocytes to CD4+/CD8+ T cells 
and NK cell development (Sintes and Engel, 2011). SLAM is involved mainly 
in IL-2 independent T cell expansion and IFN production by activated T 
cells.  
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1.3.1. Structure of SLAM 
SLAM receptors are self-ligands, meaning they can participate in either 
homotypic or heterotypic cell-cell interactions. The SLAM receptor consists 
of two extracellular immunoglobulin (Ig)-like domains namely variable (V) 
and constant (C2), a single transmembrane domain and a cytoplasmic tail 
with several tyrosine-based motifs (Fig 1.2). The SLAM-associated proteins 
(SAP) family of adaptors are recruited to the cytoplasmic domain in 
response to phosphorylation of the tyrosine motifs (Veillette et al., 2007).    
The V domain of SLAM is important as a receptor for MeV entry because of the 
specificity of MeV H interaction with this region. The inability of MeV to infect mice 
has been attributed to the differences in the V domain of SLAM (Sidorenko and 
Clark, 2003).  
 
 
 
Fig 1.3 Structure of SLAM/CD150 receptor.MeV uses CD150/SLAM for 
cell entry. It is expressed on immune cells, including activated lymphocytes, 
dendritic cells and macrophages. The extracellular domain of SLAM is 
composed of variable (V) and constant (C2) Ig-like repeats. The intracellular 
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domain consists of a transmembrane domain with tyrosine phosphorylation 
motifs.   
 
1.3.2. Role of SLAM in phagocytosis 
It has been shown that SLAM acts as a microbial sensor in macrophages 
that help in the elimination of Gram-negative bacteria like E-coli. This role of 
SLAM has been attributed to its regulation in phagosome maturation and 
production of free radical species by the NADPH oxidase (nicotinamide 
adenine dinucleotide phosphate-oxidase) NOX2. It does so by first recruiting 
the Vps34-Vps15-beclin1 complex to the phagosomes which catalyzes the 
conversion of phosphatidylinositol (PtdIns) to phosphatidylinositol 3 
phosphate (PtdIns3P).  This in turn results in the recruitment of EEA-1 and 
the small GTPase Rab5 to the phagosomes and the subsequent production 
of reactive oxygen species (ROS), culminating in the elimination or 
phagocytosis of the engulfed bacteria (Berger et al., 2010a).  
The SLAM mediated recruitment of Vps34-Vps15-beclin1 complex during 
phagocytosis overlap with another intracellular pathway called autophagy. 
Autophagy is a catabolic cellular process wherein superfluous intracellular 
components are enveloped in double membraned vesicles called 
autophagosomes and shuttled to the lysosomes for degradation. Autophagy 
mainly serves to alleviate cells from stressed conditions and is also shown 
to aid in cellular defense against invading microorganisms (Kudchodkar and 
Levine, 2009). Moreover, the toll like receptor (TLR) mediated triggering of 
phagocytosis has been shown to recruit autophagy proteins such as LC3 to 
phagosomes and the activation of ROS by NOX2 is required for the 
activation of antibacterial autophagy in human epithelial cells (Huang et al., 
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2009). This might indicate a possible role of SLAM in canonical autophagy 
pathway and that requires further investigation. 
1.3.3. Role of SLAM in MeV entry 
MeV enters SLAM positive immune cells by promoting the direct fusion of 
viral and cell membranes. This membrane fusion reaction occurs at neutral 
pH and is initiated by the MeV hemagglutinin (H) and fusion (F) proteins. 
The merging of membranes is carried out by the F protein which exists as a 
metastable homo-trimer and needs to be proteolytically activated by stable 
interactions between the measles H protein and SLAM receptor on the cell 
membrane (Navaratnarajah et al., 2011). Receptor binding results in major 
conformational changes in the pre-fusion F protein that triggers the insertion 
of the fusion peptide into the plasma membrane, causing membrane fusion 
via the formation of a fusion pore. The fusion pore gradually expands, 
eventually resulting in virus-cell membrane fusion and virus entry (Plemper 
et al., 2011b).  
 
1.3.4. Role of SLAM in MeV induced immunosuppression 
MeV infections are commonly associated with severe prolonged 
immunosuppression that render the infected population highly susceptible to 
infection by opportunistic pathogens. This is also the main reason behind 
the high mortality rates among young children and elderly. Much of these 
effects can be attributed to the MeV - SLAM interaction.  During measles 
infection, the activation of cell-mediated immunity results in the clonal 
proliferation of T lymphocytes. TH1 cells (T helper cells -1) express higher 
amounts of SLAM than TH2 cells and hence might be more susceptible to 
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measles infection. The resulting TH1 to TH2 shift results in an antibody 
mediated immune response rather than cell-mediated response (Sidorenko 
and Clark, 2003). This shift may also be mediated by the decrease in IL12 
and IFN-gamma production occurring during measles infection (Griffin, 
2010). 
1.4. Measles endocytosis 
The  recent publication by Carneiro et al discusses an alternate role of 
SLAM in mediating MeV entry via a complex pathway involving 
macropinocytosis (Goncalves-Carneiro et al., 2017). Electron microscopy 
studies revealed extensive filopodia formation and cell contraction in MeV 
infected A549-SLAM cells (a human lung epithelia cell line stably expressing 
the human SLAM receptor) within 20 min post infection. Although the cells 
returned to their normal state at 60 min post infection, the authors 
hypothesized that this alteration in cell morphology might have a role in 
aiding MeV entry. MeV entry was not affected by the knockdown of proteins 
regulating endocytosis such as caveolin-1, clathrin and dynamin-mediated 
pathways of endocytosis, which indicated that these pathways were not 
utilized by the virus for entry. Colocalization of Dextran labelled endosomal 
structures called macropinosomes and MeV-N (MeV nucleoprotein) labelled 
MeV particles indicated that the virus was taken up by macropinocytosis. 
The activation of F protein at the cell surface may initiate virus entry by 
either membrane fusion or macropinocytosis and this might depend on 
whether the interaction with the SLAM receptor is mediated by the whole 
virus particle or MeV H-F complexes. Moreover, this pathway may be 
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beneficial for MeV entry into SLAM positive cells at the respiratory mucosa, 
which is an important phase in MeV pathogenesis.  
Another recent study also reported similar findings linking MeV entry to 
macropinocytosis. Here they demonstrate that MeV interaction with cells 
during early time points post administration of the virus, results in increased 
uptake of fluorophore-conjugated dextran, via a macropinocytosis-like 
pathway.  Virus entry was inhibited in the presence of the macropinocytosis 
inhibitor 5-(N-ethyl-N-propyl)amiloride (EIPA) and inhibitors of actin 
polymerization like cytochalasin-D and the authors speculate that MeV entry 
could occur via macropinocytosis, in addition to the well characterized 
membrane fusion mediated entry pathway for MeV. (Delpeut et al., 2017). 
Actin dynamics is also important during different stages of MeV life cycle 
involving virus particle trafficking and release, as shown by the effects of 
drugs that stabilize or disrupt actin filaments (Dietzel et al., 2013).  
The interaction of MeV-Ed with its CD46 receptor is known to cause 
receptor crosslinking which in turn causes the internalization of CD46 by 
macropinocytosis via similar extensions of pseudopodia as seen with SLAM 
and MeV interaction discussed above (Crimeen-Irwin et al., 2003).  
1.5. The need for effective antivirals against MeV 
Despite the existence of an effective vaccine, measles continues to be a 
global health issue. There are several reasons for this, most important being 
the elective exemption from vaccination owing of personal, parenteral or 
religious beliefs. This was the consequence of a report published by 
Wakefield et al that associated the administration of measles mumps rubella 
(MMR) vaccine to autism and intestinal disease in children (Plemper and 
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Snyder, 2009, Wakefield et al., 1998). Although this claim was refuted by 
subsequent epidemiological case studies (Taylor et al., 1999, Dudley et al., 
2018, Hviid et al., 2019), the direct consequence of low vaccination 
coverage was a lack of herd immunity which is crucial for the prevention of 
measles outbreaks. A herd immunity of greater than 95% is crucial for the 
prevention of periodic measles outbreaks (Orenstein and Gay, 2004). Thus, 
to effectively prevent measles outbreaks, maximum vaccination coverage 
with the population would need to be ensured. The availability of an effective 
antiviral could be used for post-exposure prophylaxis when-in, the patients 
and their immediate contacts can be administered the drug to prevent 
spread of the disease (Plemper and Snyder, 2009).  
Currently, there are no specific and effective antivirals available for the 
treatment of measles. Ribavirin and IFNα, administered alone or in 
combination, have been used for the treatment measles. However, in most 
cases, this has been shown only to ameliorate the symptoms (Macaya-Ruiz 
et al., 2006). High dose Vitamin A has shown some promise in the treatment 
of measles (Plemper and Snyder, 2009).  
1.6. ddBCNAs 
Antiviral nucleoside analogues are the modified synthetic variants of 
naturally occurring nucleosides that are designed to specifically inhibit an 
integral part of virus cycle, mostly by affecting DNA/RNA replication or by 
inhibition of virus-encoded enzymes involved in nucleoside metabolism 
(Jordheim et al., 2013). Ever since its development in the 1960’s, a range of 
nucleoside analogues have been developed to inhibit a wide range of 
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viruses including HIV, hepatitis b virus and herpes virus infections (De 
Clercq and Li, 2016).  
1.6.1. Background  
The use of 5-substituted pyrimidine nucleoside analogues as antiviral drugs 
began initially with the synthesis of 5-iodo-2′-deoxyuridine (IDU) by Prussof 
et al (Prusoff, 1959). This was followed by the synthesis of several variants 
of this compound differing in their 5-substituents, notably the drug brivudine 
((E)-5-(2-bromovinyl)-20-deoxyuridine (BVDU)) which is a potent inhibitor of 
HSV -1(Andrei et al., 1992) and VZV(Andrei et al., 1995). The MoA of BVDU 
was attributed to the specific phosphorylation by virus encoded thymidine 
kinase, which converts BVDU to its 5′-monophosphate and diphosphate 
forms. Its subsequent phosphorylation to BVDU-TP by cellular nucleoside 
kinases, allows the incorporation of BVDU-TP into the growing viral DNA 
chain, thereby inhibiting viral replication and transcription (De Clercq, 2004) 
(Fig 1.3) 
 
 
Fig 1.4. Antiviral activity of BVDU. HSV-1 and VZV thymidine kinases 
phosphorylate BVDU to BVDU monophosphate (BVDU-MP) and BVDU 
triphosphate (BVDU-DP) which is then converted to BVDU triphosphate 
(BVDU-TP) by the cellular kinase nucleoside 5’-diphosphate (NDP), leading 
to its incorporation in viral DNA. (Incorporated from (De Clercq, 2004)) 
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Subsequently, the activity of 5-ethynyl substituted deoxyuridines was also 
investigated and found to possess antiviral activity against HSV 1, HSV 2 
and VACV. However, the IC50 of these drugs was found to be close their 
cytotoxic concentration (De Clercq et al., 1981) and it was also noted that 
the antiviral activity of 5-alkynyl deoxyuridines decreased with increasing 
length of the side chains, the optimum length being <5 C atoms (McGuigan 
et al., 2001).   
1.6.2. Alkyl furano pyrimidines 
Furano pyrimidines were produced as by products during the synthesis of 5-
alykynyl-2’-deoxyuridines and it was found that certain long chain alkyl 
homologues of these parent compounds possessed antiviral activity against 
VZV in vitro at nano molar concentrations(McGuigan et al., 1999). A series 
of compounds were synthesized with varying alkyl side chain lengths and 
SAR studies revealed the absolute requirement of long alkyl side chains of 
length C8-C10 for antiviral activity. The activity of the lead compound was 
300-fold higher over the control drug Acyclovir and did not show any 
cytotoxicity in vitro. Mode of action (MoA) studies revealed that antiviral 
activity of the lead compound was specific only for VZV and not for other 
DNA viruses like HSV 1 and 2, VACVand cytomegalovirus (CMV). Hence 
the MoA was most likely to be dependent on the VZV thymidine kinase 
mediated phosphorylation of the drug to its 5’-triphosphate forms (McGuigan 
et al., 1999).  
Following this lead, the McGuigan group then synthesized 2’,3’-dideoxy 
variants of these alkyl furano pyrimidines, producing a series of lipophilic 
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alkyl furano pyrimidine dideoxy nucleoside analogues with varying side 
chain lengths. The lead compound (Figure 1.3 and hereby referred as 
cf2095) now lost its antiviral activity against VZV, but was found to be active 
against human cytomegalovirus with an IC50 of 0.5µM (McGuigan et al., 
2004). The loss of activity versus VZV was attributed the lack of 3’-OH 
group which could have been important for the VZV thymidine kinase 
specificity of the drug. Moreover, the SAR profile and time of addition 
experiments suggested a non-nucleoside based MoA (McGuigan et al., 
2004).   
1.6.3. L-ddBCNAs 
To improve the antiviral activity of cf2095, a series of L-chiral versions of this 
compound with varying ether side chains lengths were synthesized. A SAR 
study revealed that there was an actual correlation between the lengths of 
the ether side chains and the activity of these compounds (Figure 1.4 B). 
The lead compound with structure n-C9H18−O−n-C5H11 (Figure 1.4 A and 
hereby referred as cf2642) with a 5 -Carbon ether side chain lost its activity 
against HCMV but now showed antiviral activity against both measles wild 
type virus (IC50-7.5μM) and VACV(IC50-0.2μM) across three different 
biological assays. This in turn indicated a possible cellular target that might 
be affected (McGuigan et al., 2013) (see section 1.1. for more information). 
All the experiments performed as part of this PhD research work are done 
investigating the nature of the putative cellular target or process affected by 
cf2642. 
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Fig 1.5 SAR of ddBCNA versus Orthopox and Paramyxoviruses:(A) 
Structure of the D-ddBCNA parent compound cf2095 and its enantiomer, the 
lead L-ddBCNA compound cf2642 (B) Graph shows the SAR profile of 
cf2642 for three different biological assays namely 4 day-Plaque assay and 
2hr-luciferase reporter assay for VACVand 3 day-TCID50 assay for MeV. 
The comparative activity of 5 different L- ddBCNAs with increasing ether 
side chain length (n= 2 to 6) and cidofovir / ribavirin controls is shown. The 
effect of Ribavirin versus MeV (IC50 1160uM) is beyond the scale of this 
graph and hence is not indicated. The graph represents the results of three 
independent experiments. Source: (McGuigan et al., 2013, Farleigh, 2014) 
 
In summary, the development of different variants of alkyl furano pyrimidines 
is shown in Fig 1.5.  
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Fig 1.6. Development of lead L-ddBCNA cf2642. A summary of the 
development of ddBCNAs beginning from the synthesis of 2’-alkyl furano 
pyrimidinesis shown. 
 
1.7. Cell-targeting antivirals 
Pathogen-directed antivirals, although effective in some cases, can give rise 
to drug-resistant mutants. This is especially the case with RNA viruses that 
are more prone to mutations. One way to tackle this is to develop cell/host 
directed antivirals that target a specific component that is hijacked by the 
virus during its lifecycle (Schwegmann and Brombacher, 2008). An added 
advantage is that such antivirals often tend of have a broad spectrum of 
activity against viruses using a common cellular pathway(Yan et al., 2013).  
1.8. Endocytosis 
The plasma membrane of a cell restricts the free entry of substances into 
the cytoplasm. While transmembrane proteins allow the transport of amino 
acids, sugars etc. into cells, the transport of larger substances, 
macromolecules, metabolites, lipids and proteins into cells are facilitated by 
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endocytosis. The term endocytosis refers to the process by which cells 
internalize fluids, macromolecules, nutrients, membrane proteins, lipids, 
solutes etc. from the extracellular milieu by the de novo formation of vesicles 
formed by plasma membrane invaginations (Hoeller et al., 2005). Material 
has been shown to enter the cells via a number of different endocytic 
pathways regulated by distinct proteins such as clathrin and caveolin and 
emanating from distinct sites of the plasma membrane such as lipid rafts.  
Primary functions of endocytosis are to recycle and degrade for a number of 
physiological reasons including membrane turnover, providing cells with 
nutrients following traffic to lysosomes and degradation, antigen 
presentation in specialized immune cells and downregulation of receptors 
such as signaling growth factors (Doherty and McMahon, 2009).   
1.8.1. Clathrin Mediated Endocytosis (CME) 
Clathrin-mediated endocytosis engulfs components from the extracellular 
milieu by the formation of plasma membrane invaginations that are coated 
with characteristic triskelion shaped proteins called clathrin that surround 
other cytosolic proteins that are recruited to the plasma membrane. These 
include adaptor proteins that are known to recognize specific sections of the 
cytosolic domains of receptors to often form receptor clusters for 
subsequent invagination. CME by a long margin is the best characterised 
endocytic pathway so far identified. The 100-120 nm clathrin coated pits 
then pinch off from the plasma membrane and loose the clathrin coat before 
entering the cytoplasm and rapidly fusing with early/sorting endosomes that 
then direct traffic to other cellular locations such as the lysosomes or for 
recycling. CME helps in the intake of metabolites, hormones, low-density 
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lipoprotein, transferrin, growth factors and even certain viruses (Kaksonen 
and Roux, 2018)(Marsh and McMahon, 1999). 
1.8.2. Caveolae Mediated Endocytosis 
Endocytosis mediated by caveolae does not involve clathrin coats and is 
associated with approximately 60-80nM wide flask-shaped invaginations 
that are formed on regions of plasma membrane that are enriched in 
cholesterol and termed lipid rafts. These cholesterol- and sphingolipid-rich 
invaginations are commonly found in fibroblasts, smooth muscles, type I 
pneumocytes, adipocytes and endothelial cells (Rothberg et al., 1992). The 
caveolar pathway aids in the endocytosis of albumin, autocrine motility 
factor, tetanus and cholera toxins and even viruses like polyoma and simian 
40 (Kumari et al., 2010).  
1.8.3. Macropinocytosis 
Macropinocytosis (cell drinking) is associated with the engulfment of 
relatively large amounts of extracellular fluid. These 0.2-10µM 
macropinosomes basically originate from plasma membrane ruffles and is a 
highly coordinated triggered process which has been best described to 
occur in cells activated with growth factors such as EGF and PDGF that 
through binding to their cognate receptors cause cell signalling, actin 
rearrangement and membrane ruffling. These ruffles fold in and back to the 
plasma membrane and at the same time engulfs the extracellular fluid to 
give rise to an increase in fluid phase endocytosis.  There is evidence to 
suggest the process is constitutive in some cells and commonly occurs in 
immature dendritic cells with a role in immune surveillance. Intracellular 
pathogens including shigella, salmonella influenza, VACVand HIV-1  have 
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all been shown to exploit macropinocytosis as a means of entry into cells 
(Kumari et al., 2010). Actin is critical for macropinocytosis to occur and 
several actin regulating roteins have thus been shown to be involved in this 
process including Pak-1 and cdc42. 
1.8.4. Phagocytosis 
Phagocytosis is the preferred route by which cells like macrophages 
internalize large particulate matter like cell debris, microorganisms and 
apoptotic cells. The engulfed materials then find its way to internal 
membrane compartments called phagosomes which then fuse with 
lysosomes to form phagolysosome wherein the contents are degraded. Both 
macropinocytosis and phagocytosis have common features like the large 
size of internalized cargo, similar membrane modelling pathways during 
internalization and pathways initiated by phosphoinositide 3 kinase (PI3K) 
dependent processes (Kumari et al., 2010) .  
1.9. Autophagy 
Autophagy is an evolutionarily conserved catabolic pathway wherein 
damaged organelles or protein aggregates targeted for elimination are 
sequestered within double membraned vesicles called autophagosomes, 
which are then shuttled towards lysosomes for degradation. It helps in the 
maintenance of cellular homeostasis and in the combat of cellular stress 
induced during nutrient limiting conditions. Autophagy often serves as a 
cellular defence against invading pathogens like viruses, by either targeting 
them for degradation in lysosomes or by facilitating the induction of humoral 
immune responses through antigen presentation. However, many viruses 
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are known to promote or subvert the autophagy machinery to their 
advantage (Kudchodkar and Levine, 2009)(Dong and Levine, 2013).  
1.9.1. Mechanism of Autophagy 
There are mainly three types of autophagy namely microautophagy, 
chaperone-mediated autophagy and macroautophagy. In microautophagy, 
cytoplasmic components are directly engulfed by protrusions from the 
lysosomal membrane, while chaperone-mediated autophagy involves the 
selective degradation of cytoplasmic components which are marked by 
KFERQ-like sequences. This further involves specific interactions with the 
lysosomal LAMP 2a protein that spans the lysosomal membrane.  This 
protein is often used via immunofluorescence to label components of 
autophagy and the late endocytic pathway 
Macroautophagy (hereby referred as autophagy) is the most widely studied 
form of autophagy and involves the de novo formation of a phagophore that 
eventually develops into a double membraned vesicle called 
autophagosome (Fig 1.6). The autophagosome may then fuse with 
endosomes to form Amphisomes or fuse with the lysosome to form the 
autolysosome wherein the components are degraded by lysosomal 
hydrolases (Klionsky, 2007). Much of the information about the mechanisms 
of autophagy in mammalian cells came from work using yeast. Ohsumi’s 
group initially studied autophagy in Saccharomyces cerevisiae and 
thereafter, he and many others like Klionsky and Thumm conducted 
pioneering research in the field and characterized more than 30 autophagy-
related (Atg) genes in yeasts. Many of these Atg genes have known 
homologues in mammalian cells (Xie and Klionsky, 2007). There are mainly 
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three steps involved in the autophagy pathway: Initiation, elongation and 
fusion. A brief outline of the steps is shown in (Fig 1.6).  
 
 
Fig 1.7Autophagy pathway. Autophagy is a cellular process by which cells 
eliminate unwanted cellular components by encapsulating them in double 
membrane vesicles called autophagosomes that then fuse with lysosomes 
and are degraded. Several steps are involved in this process. Nucleation 
involves the formation of an isolation membrane from various membrane 
sources (endoplasmic reticulum, Golgi, plasma membrane or mitochondria). 
This matures to form a phagophore which then elongates to form a double 
membrane vesicle called autophagosome that sequesters cellular 
components (senescent organelles like mitochondria, intracellular 
pathogens like viruses) targeted for degradation. The autophagosome then 
matures and fuses with lysosomes to form an autolysosome that degrade 
the components within. Wortmannin is a PI3Kinhibitor that inhibits formation 
of autophagosomes, while chloroquine increases the pH of lysosomes and 
prevents autolysosome formation. The key proteins involved in autophagy 
are indicated. - Adapted from (Petkova et al., 2013) 
 
1.9.1.1. Initiation 
Autophagy is initiated when cells are under stress, for example during 
starvation of essential nutrients and amino acids. Although a variety of 
signaling cascades can trigger autophagy in response to different stresses, 
the classic example is that of mTOR (mechanistic target of Rapamycin) 
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inhibition. The serine/threonine kinase mTOR, is a critical regulator of 
autophagy and also responds to changes in the extracellular environment 
and controls autophagy and various cellular pathways like initiation of 
mRNA translation, cell growth and proliferation, and cytoskeletal 
reorganization (Ravikumar et al., 2010).The mTOR is associated with the 
Unc-51 like kinase 1/2 complex (ULK1/2-ATG13-FIP200-ATG101) that is 
composed of ULK 1/2, ATG13, the focal adhesion kinase family interacting 
protein of 200 kDa (FIP200) and ATG101. Under nutrient rich conditions, 
mTOR phosphorylates the ULK1/2-FIP200-Atg13 complex and this inhibits 
autophagy by keeping the ULK1/2 kinase activity in check. However, when 
mTOR is inhibited either by Rapamycin or by the activity of AMPK (5’ AMP-
activated protein kinase) during starvation (Kim et al., 2011), mTOR hypo-
phosphorylates ULK1/2 and this leads to the induction of autophagy. This is 
followed by the translocation of the activated ULK1/2 complex to specific 
endoplasmic reticulum (ER) domains in the cytoplasm that are thought to be 
associated with the formation of the pre-autophagosomal structure (PAS). 
The ULK1/2 complex then recruits the Class III PI3K complex to produce 
phosphatidylinositol 3-phosphate (PI3P), this first step towards the de novo 
synthesis of the phagophore or isolation membrane. The process is also 
aided by function of two effector proteins of PI3P namely DFCP1 (double-
FYVE-containing protein 1) and WIPI (WD-repeat protein interacting with 
phosphoinositides) (Axe et al., 2008). The Class III PI3K complex consists 
of the mammalian autophagy protein Beclin-1, p150, Atg14L and ultraviolet 
irradiation resistance-associated gene (UVRAG) and is the major effector of 
autophagosome synthesis.  
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1.9.1.2. Elongation 
Elongation of the phagophore to form the autophagosome involves Atg12–
Atg5 -Atg16 complex that is catalysed by the function of several ubiquitin 
like conjugation systems. Initially the Atg7 (E1 like enzyme) and Atg10 (E2 
like enzyme) form the Atg12–Atg5 complex and then Atg16 becomes non 
covalently attached to Atg5, resulting in the Atg12–Atg5-Atg16 complex 
(Klionsky, 2012)  This complex is known to attach to the growing 
phagophore and possibly contributes to the curvature of the growing 
autophagosome. In the next step, Atg4 protease cleaves the microtubule 
associated protein, light chain 3 (LC3) at its C-terminus to form LC3-I and 
the Atg3 (E2 like enzyme) adds the lipid Phosphatidylethanolamine (PE), 
forming LC3-II / LC3-PE (Fig 1.7) Once lipidated with PE, the LC3-II 
becomes associated with both the inner and outer membranes of the mature 
form of the autophagosome and hence is used as a marker for monitoring 
autophagy flux (Ni et al., 2011).  
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Fig 1.8 Conversion of LC3-I to LC3-II. During the induction of autophagy, 
LC3 is first cleaved by the protease enzyme Atg4 to form LC3-I. The 
enzyme Atg3 then lipidates LC3-I by adding PE to form LC3-II. The LC3-II 
then binds to the inner and outer membranes of the growing 
autophagosome before fusing with lysosome.  
 
 
1.9.1.3. Fusion 
The final step in autophagy involves the fusion of the autophagosome with 
the lysosome to form the autolysosome, wherein the contents are degraded 
by the cocktail of hydrolytic enzymes present in lysosomes. This is followed 
by the recycling of the building contents to the cytosol for the synthesis of 
new macromolecules (Ravikumar et al., 2010).  
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1.10. MeV induced autophagy 
Both MeV-Ed and MeV have been shown to induce successive phases of 
autophagy in infected cells to promote virus spread and to escape from the 
host apoptosis machinery(Meiffren et al., 2010, Richetta and Faure, 2013). 
The virus by itself is not destroyed by autophagy, but it helps in delaying the 
antiviral host immune defence. MeV-Edinduces two successive phases of 
autophagy, the first mediated by the CD46-GOPC scaffold protein mediated 
pathway and the second by the MeV C protein-IRGM pathway. However, in 
the case of MeV, since the virus does not use the CD46 receptor, the first 
wave of autophagy does not occur during its life cycle. Instead, the MeV 
IRGM pathway coupled with the autophagy induced by the syncytia 
formation helps the virus to escape from host mediated immune responses 
(Richetta et al., 2013).  
IRGM (immunity regulated GTPase M) form a part of Immunity 
Related Guanosine Triphosphatases or IRGs that mainly serve as an innate 
immune mechanism for the clearance of pathogens (Li et al., 2009). They 
have been implicated in the induction of autophagy in response to many 
viral infections by interacting with autophagy-associated proteins ATG5, 
ATG10, MAP1CL3C and SH3GLB1. Moreover, the siRNA knockdown of 
IRGM has been shown to inhibit autophagy induced by MeV, Hepatitis C 
virus (HCV) and HIV-1 (Gregoire et al., 2011).  
1.11. Hypothesis 
Initial studies on cf2642 had shown that the drug inhibits both vaccinia 
and measles viruses and that antiviral activity against the former was 
shown to occur at early (2 hr) time points post treatment(Farleigh, 2014). 
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Given that both these viruses are enveloped, and that cf2642 possesses 
a lipophilic side chain, leads to the attractive hypothesis that the antiviral 
effects of this compound may be a direct result on virus/cell membranes, 
thereby affecting virus entry or early events occurring therein.The goal of 
this PhD project is to evaluate this hypothesis and, more importantly, to 
identify the precise host target of cf2642 which results in the inhibition of 
viruses predominantly replicating in the cytoplasm.An antiviral compound 
that targets a key component of the host cell machinery, which results in 
its antiviral activity and at the same time does not induce cytotoxicity, is 
an important stride towards the development of antiviral compounds that 
restrict the development of drug resistant viruses.  
 
1.12. Aims and Objectives 
a) To elucidate the effects of cf2642 on intracellular membrane trafficking. 
b) To perform endocytic characterization in HeLa and VeroSLAM cells.   
c) To perform mode of action studies based on both live and non-virusbased 
receptor-clustering assays  
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Chapter 2 - Materials and Methods 
2.1. Materials 
2.1.1. Cell lines 
1. HeLa: (ATCC, CCL-2) - Human epithelial cells: established from the cervical 
adenocarcinoma of a black 31-year old female. This cell line contains 
Human Papilloma Virus 18 oncogenes (E6 and E7)  
2. VeroSLAM: (ECACC) African Green Monkey Kidney cells stably expressing 
the human signalling lymphocytic activation molecule receptor (ECACC 
Catalogue number - 04091501).  
2.1.2. Virus 
 
1. MeV: Measles virus wild-type strain isolated from a patient with acute 
measles (Erlangen, Germany, 1990) -Kind gift from Jurgen Schneider-
Schaulies, Universitat Wurzburg, Germany.(Erlenhoefer et al., 2001) 
2. MeV-GFP: Wild-type IC (Ichinose)-B strain of measles virusexpressing 
Green Florescent Protein (GFP) - Kind gift from Prof. Yusuke Yanagi, 
Kyushu University, Japan.(Hashimoto et al., 2002) 
2.1.3. Equipment 
2.1.3.1. Plastics and glassware 
All general use tissue culture plasticware, laboratory disposables and 
organic solvents were purchasedfrom Fisher Scientific - Loughborough, UK. 
Supplier details and catalogue numbers of other materials are listed in 
Appendix C. General usage chemicals and reagents were supplied by 
Sigma-Aldrich (Poole, UK) unless otherwise indicated in Appendix C.  
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2.2. Methods 
2.2.1. Cell Culture 
2.2.1.1. Cell culture medium 
All cells were maintained in 1x Dulbecco’s Modified Eagles Medium (DMEM) 
containing 4.5g/L (25mM) glucose and L-glutamine without sodium pyruvate 
supplemented with 10% (v/v) fetal bovine serum (FBS) in the absence of 
antibiotics (complete media). Cells were incubated in humidified incubators 
under tissue culture (TC) conditions ( 37ºC with 5% CO2). For maintenance 
of VeroSLAM cells, the medium was supplemented with 0.4 mg/mL 
geneticin to maintain the stable expression of SLAM.  
2.2.1.2. Routine cell maintenance 
All cell lines were maintained as per the requirement for each experiment 
and to not allow them to be over-confluent. Cells were split once they 
reached 70-80% confluence. The medium in the flask was first aspirated 
and cells were washed once with 2 mL sterile PBS (phosphate buffered 
saline) to remove traces of FBS. For trypsinization, PBS was aspirated, 
replaced with 2 mL 0.05% trypsin EDTA (Ethylenediaminetetraacetic acid) 
and the flask was placed in the incubator for 5 min to allow cells to detach. 
Cells were then collected in 8 mL complete media and centrifuged at 300 x 
g for 4 min. As per the split-ratio for each cell line (see Table 2.1), the 
appropriate volume of medium was used to re-suspend the cells before 
being transferred to new T-75 tissue culture flasks.  All cell lines were 
maintained up to a passage number of 25, after which the cells were 
discarded and a fresh batch was revived for use (see section 2.3.4 - 
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Thawing cells). Passage number refers to the number of times a cell line 
was split previously. 
Table 2.1 - Split ratios for cell lines used for this project. The ratios are for 
subculture after 3-5 days  
 
Cell line Split ratio 
HeLa 1:6 
A431 1:4 
VeroSLAM 1:6 
B95a 1:4 
 
2.2.1.3. Freezing cells 
All low-passage number cell lines received from their respective source (see 
section 2.1.1) were first grown to 70-80% confluence and stocks made for 
future use. For preparing cell stocks, the cells were trypsinized, centrifuged 
at 300 x g for 4 min and re-suspended in cell freezing medium (45% DMEM, 
45% FBS and 10% DMSO) at a density of 2 x 106 cells/mL. The cells were 
then transferred to cryogenic vials, placed in a Mr. Frosty Freezing container 
and stored at -80°C for up to 24 hours, after which the vials were transferred 
to a liquid nitrogen cylinder for long-term storage.  
2.2.1.4. Thawing cells 
The revival of cells stored in liquid nitrogen was done by placing cryogenic 
vials in a 37°C water bath to allow for rapid thawing. Once completely 
thawed, cells were transferred into a sterile 15 mL tube containing 10 mL 
complete medium and centrifuged at 300 x g for 4 minutes to remove all 
traces of DMSO. The supernatant was then discarded, cell pellet re-
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suspended in 15 mL complete media and transferred to a sterile T-75 tissue 
culture flask. After overnight incubation to allow the cells to adhere, the 
medium in the flask was replaced with fresh complete media to get rid of 
floating dead cells.  
2.2.1.5. Mycoplasma testing 
Note: During the second year of my PhD research work at the School of 
Pharmacy, it was found that the cells that were used during the first-year 
work at the School of Medicine were contaminated with mycoplasma. 
Following this, it was decided that all the work done during that period had 
to be repeated using mycoplasma free cells. This aspect of the work was 
done in collaboration with Dr. Joachim Bugert’s laboratory at the 
Bundeswehr Institute for Microbiology in Munich, Germany. All the 
subsequent work at the School of Pharmacy were done with mycoplasma 
free cells, confirmed by routine mycoplasma screening checks done in the 
laboratory.  
Mycoplasma contaminations were ruled out with routine testing by 
mycoplasma PCR (LookOut mycoplasma detection kit, Sigma). The 
procedure was followed as per the manufacturer’s instructions. Cells were 
grown to 90-100% confluence and 1 mL of medium was transferred to a 
sterile 1.5ml Eppendorf tubes. The contents were centrifuged at 500 x g for 
5 minto remove any cell debris that might be present. The tubes were then 
placed on a heating block and heated to 95°C for 5 min to prepare stable 
templates for PCR analysis. These served as the test samples. Two sets of 
ready-made PCR reaction tubes were provided with the detection kit. The 
Test Reaction tubes which contained only the primers were used for testing 
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the samples and negative control. The Positive Control Reaction tubes 
contained the primers along with positive control DNA.  
For mycoplasma detection, 2 µL of each test sample was added to the Test 
Reaction tubes. 2 µL of deionized water served as the negative control. No 
samples were added to the positive control reaction tubes. 23µL of DNA 
polymerase rehydration buffer (dNTPS) was added to the Test Reaction 
tubes and 25µL of the buffer to the Positive Control Reaction tubes, so that 
all tubes had equal volumes. JumpStart™ Taq DNA Polymerase (0.5 µL) 
was then added to all tubes, the contents were mixed by gently tapping and 
the tubes were transferred to a thermocycler. The temperature cycle was set 
as per the conditions below:  
  
  
 
 
 
 
 
The results were analyzed by agarose gel electrophoresis.  
2.2.2. Agarose gel electrophoresis 
 
A 1.5 % agarose gel was used for electrophoresis. Briefly, 3 g agarose was 
added to 200 mL TAE buffer (40 mM Tris, 20 mM acetic acid, 1 mM EDTA) 
1 cycle 94 °C for 2 minutes (Initial 
denaturation) 
 
x40 cycles 94 °C for 30 seconds 
(Denaturation) 
 55 °C for 30 seconds 
(Annealing) 
 72 °C for 40 seconds 
(Elongation) 
 
Cool down to 4–8 °C 
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and heated in a microwave on full power until the contents were fully 
dissolved. The mixture was then allowed to cool for few minutes and 25 µL 
of ethidium bromide (10mg/mL) was added.  The agarose mixture was then 
poured in to a gel box and a 10-well comb was placed, supported by a 
groove provided in the gel box. After 60 min, once the gel was solidified, the 
comb was carefully removed and the gel was submerged in 1X TAE buffer. 
The wells were loaded with 8 µL each of the samples and controls, 
alongside 4 µL of a 100bp DNA ladder (50 µg/mL) and run at 80V for 2 hr 
until the bands were well separated. The gel was then imaged using a Bio-
Rad ChemiDoc Imaging system.  
2.2.3. Immunofluorescence microscopy (IF) 
2.2.3.1. Seeding of cells 
Cells maintained in complete media were seeded onto 12 well tissue culture 
plates containing sterile round glass coverslips. The plate was incubated for 
24 hr under TC conditionsto allow for 70-80% confluence before fixation. 
The following seeding densities were used: 
HeLa - 120,000 cells/well 
VeroSLAM - 80,000 cells/well  
The below sections detail the basic protocols that were followed for the 
corresponding experiments. The treatment of cells and incubation times 
prior to this varies depending on each experimental condition.  
2.2.3.2. Fixation 
2.2.3.2.1. Paraformaldehyde fixation and permeabilization 
Cells were first washed 3 times (3x) with warm PBS and 500µL of 3% 
paraformaldehyde (PFA) solution was added per well. After 15 min 
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incubation, the cells were washed 3x with PBS and permeabilized with PBS 
containing 0.1% Triton X-100 and 50mM ammonium chloride (NH4Cl) for 5 
min. The cells were again washed 3x with PBS. In some cases, 
permeabilization of PFA fixed cells was done by 5 min incubation with PBS 
containing 0.01% saponin and 50mM NH4Cl. 
2.2.3.2.2. Methanol fixation 
Cells were washed 3x with ice-cold PBS and 500 µL of ice-cold methanol 
(stored at -20ºC) was added per well. Immediately after this, the plate was 
kept in a -20°C freezer for 3 min The plate was then brought to room 
temperature (RT) and the cells were quickly washed 3x with PBS to remove 
all traces of methanol. No permeabilization step was done here.  
2.2.3.2.3. Immunolabeling 
2.2.3.2.3.1. Antibodies 
The information about all primary and secondary antibodies used for 
immunolabeling are provided in Table 2.2. The table also includes 
information on the antibodies that were used for SLAM-receptor clustering 
experiments (section 2.2.16).  
The antibody dilutions used for immunolabeling are mentioned in the table 
and were based on information provided in the product-data sheets. In some 
cases, in-house standardizations were done to determine the appropriate 
dilutions to be used.  
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Table 2.2 - Primary and secondary antibodies, dilutions and fixation 
methods used for Immunolabeling  
Target protein 
and organelles 
Primary 
Antibody and 
Dilutions 
used  
Secondary 
Antibody  
(1:500 
Dilution) 
Fixation 
method 
Early Endosome 
Antigen - 1 
Early endosomes  
Goat polyclonal 
anti-EEA1: N-19, 
Santa Cruz sc-
6415 
1:200 Dilution  
Donkey anti-
Goat Alexa 
Fluor - 488: A-
11055, 
Invitrogen  
PFA 
LAMP-1 
Late endosomes 
and lysosomes  
Mouse 
monoclonal anti 
LAMP1 - FITC: 
H4A3, Santa 
Cruz sc-20011 
1:250 Dilution   
Nil 
(Directly 
labelled primary 
antibody)  
Methanol 
LAMP-1 
 
Rabbit polyclonal 
anti LAMP1: 
L1418, Santa 
Cruz 
Chicken anti 
Rabbit Alexa 
Fluor-647 
 
LC3B (Microtubule 
associated protein 
Light Chain 3B) 
Autophagosomes  
Rabbit polyclonal 
anti-LC3B: 
#2775, Cell 
Signalling  
 
1:500 Dilution      
Chicken anti-
Rabbit Alexa 
Fluor-488: A-
21441, 
Invitrogen  
Methanol 
Rab5 
Early endosomes  
Rabbit 
Monoclonal anti-
Rab5: #3547 Cell 
signalling  
 
1:500 Dilution  
 
 
Chicken anti-
Rabbit Alexa 
Fluor-488: A-
21441, 
Invitrogen 
Methanol 
Rab7 
Late endosomes 
and lysosomes   
Rabbit 
Monoclonal anti-
Rab7: #9367, 
Cell signalling  
Chicken anti-
Rabbit Alexa 
Fluor-488: A-
21441, 
Invitrogen 
Methanol 
SLAM (Signalling 
Lymphocyte 
Activation Molecule) 
SLAM receptors  
*Mouse 
monoclonal anti 
SLAM/CD150 
[IPO-3]: Abcam 
ab2604 
1:250 Dilution  
*Chicken anti-
mouse Alexa 
Fluor-647: 
21463, 
Invitrogen  
PFA 
Tubulin 
Microtubules  
Mouse 
monoclonal anti-
α-tubulin: T9026, 
Sigma Aldrich)  
1:2000 Dilution  
Chicken anti-
mouse Alexa 
Fluor-647: 
21463, 
Invitrogen 
Methanol  
*These antibodies were also used for live imaging in SLAM-receptor 
clustering experiments (see section 2.2.16)   
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2.2.3.2.3.2. Direct Immunolabeling 
Cells grown on glass cover slips were fixed with 3% PFA for 15 min, washed 
3x and permeabilized for 5 min with PBS containing 0.01% saponin and 
50mM NH4Cl. After washing the cells again, the cover slips were incubated 
for 30 min with blocking buffer (2% FBS, 2% BSA in PBS). This was done 
by first pipetting small drops (approximately 100 µL) of the blocking buffer 
on a parafilm placed on the flat surface of a workbench.  The parafim is 
placed on a moist surface so that it remains fixed and the number of drops 
of blocking buffer varied depending on the number of conditions. Incubation 
of cells with blocking buffer was done by placing the cover slips cell-side 
down over these drops. This was followed by 60 min incubation with 100 µL 
of LAMP1-FITC antibody (1:250 dilution)diluted in blocking buffer containing 
1 µg/mL Hoechst 33342. While incubating the cells with primary antibody, 
the coverslips were placed in dark. The cells on coverslips were then 
washed 3x 5 min with PBS by first aspirating the medium present in the 
wells and washing once with 500 µL PBS per well. The contents were again 
aspirated, fresh PBS added, and incubated for 5 min. This was again 
repeated twice. Finally, the coverslips were placed on to glass slides using 
10 µL Dako fluorescence mounting medium and allowed to dry at RT for 2 
hr. The glass slides with the coverslips were then either used directly for 
imaging by confocal microscopy (see section 2.2.7.1) or stored in a 
refrigerator at 4ºC until used.  
2.2.3.2.3.3. Indirect Immunolabeling - Single antibody 
The cells that were fixed on cover slips were first incubated with 150 µL 
blocking buffer (2% FBS, 2% BSA in PBS) for 30 min. This was followed by 
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60 min incubation with 100 µL of the primary antibody diluted in blocking 
buffer (Table 2.2). Cells were then washed 3x 5 min with PBS and incubated 
for 30 min with blocking buffer containing the appropriate anti species Alexa 
Fluor secondary antibody (Table 2.2) and Hoechst (1 µg/mL). Again, the 
cells were washed 3x5 min with PBS, mounted on to glass slides using 10 
µL Dako fluorescence mounting medium and allowed to dry at RT for 2 hr. 
The glass slides containing the coverslips were then either used directly for 
imaging (see section 2.2.7.1) or stored in a refrigerator at 4ºC until used.  
2.2.3.2.3.4. Indirect Immunolabeling - Double antibody 
As mentioned above, the cells that were fixed on cover slips were first 
incubated with 150 µL blocking buffer (2% FBS, 2% BSA in PBS) for 30 min. 
This was followed by 60 min incubation with 100 µL of the primary antibody 
diluted in blocking buffer. Cells were then washed 3x5 min with PBS and 
incubated for another 60 min with 100 µL blocking buffer containing an 
appropriate dilution of the second primary antibody. This antibody was of a 
different species from that of the first primary antibody used. The cells were 
then washed 3x5 min with PBS and incubated with blocking buffer 
containing 1 µg/mL Hoechst 33342 and two appropriate anti-species Alexa 
Fluor secondary antibodies (1:500) corresponding to the primary antibodies 
used. After a final 3x5 min washing step, the cells were mounted on to glass 
slides using 10 µL Dako fluorescence mounting medium and allowed to dry 
at room temperature for 2 hr. The glass slides containing the coverslips 
were then either used directly for imaging (see section 2.2.7.1) or stored in a 
refrigerator at 4ºC. 
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2.2.4. Direct Fluorescence methods 
 
2.2.4.1. Rhodamine phalloidin 
Rhodamine Phalloidin was used for the staining of actin filaments. Cells on 
cover slips were fixed with 3% PFA and permeabilized with PBS containing 
either 0.1% Triton X-100 or 0.05% saponin, and 50mM NH4Cl. The cells 
were then incubated with staining solution containing 0.5 μg/mL Rhodamine 
phalloidin and 1 μg/mL Hoechst33342 diluted in PBS. After an incubation 
period of 15 min in dark, the cells were washed 3x 5 min with PBS and 
mounted on glass slides using 10μL Dako fluorescence mounting medium.  
The glass slides with the coverslips were then either used directly for 
imaging (see section 2.2.7.1) or stored in a refrigerator at 4ºC. 
2.2.5. Live cell Microscopy 
2.2.5.1. Mitotracker staining 
HeLa cells were seeded in 35mm MatTek imaging dishes at a seeding 
density of 270,000 cells/mL and incubated for 24 hr to reach confluence. 
After appropriate treatment conditions, the medium was aspirated and 
replaced with 50nM MitoTracker Red CMXRos solution prepared in serum 
free DMEM. After 5 min incubation, the medium was removed, cells washed 
2x with warm PBS, and replaced with fresh imaging media (DMEM without 
Phenol red, supplemented with 10% FBS) before live imaging (see section 
2.2.7.1).  
2.2.6. Lysosome labelling with Dextran-fluorophore conjugates 
 
Cells were seeded in 35mm MatTek live cell imaging dishes, the following 
seeding densities were used: HeLa - 150,000 cells/well and VeroSLAM - 
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120,000 cells/well, and incubated for 24 hr to reach confluence. The cells 
were then pulsed for 3 hr with 0.2 mg/mL 10kDa Dextran Alexa Fluor 488 
(diluted in complete media) by incubating the cells with 200μL of the 
preparation at TC conditions. The dishes were then washed 2x with sterile 
warm PBS and 1 mL complete medium was added. After an 8hr chase at 
TC conditions, the cells were treated/not with 10µM cf2642 for 12 hr at TC 
conditions and then pulsed with 0.2 mg/mL 10kDa Dextran-Alexa 647 for 3 
hr in the presence/absence of 10µM cf2642 at TC conditions. The cells were 
then chased for a further 3 hr w/o of 10µM cf2642 and live images were 
acquired by confocal microscopy (see section 2.2.7.1). The dispersal of 
lysosomes was calculated by drawing concentric ROIs at 1µM distance from 
each other around the nucleus. The intensity of fluorescence was then 
calculated at 0, 1, 2 and 3µM from the nucleus using ImageJ-Fiji. For this 
purpose, a macro was created as shown in Appendix B. The java program 
first splits the red and green channels and creates a nucleus mask to 
exclude the background and select only the area occupied by the nucleus. 
This is then used to draw concentric ROIs at 1µM distance apart, up to 3 µm 
around the nucleus.The red and green intensities are measured and the 
output is displayed in a table. A sample image is shown below, which shows 
the composite image to be analyzed, the split red and green channels, the 
nucleus mask and finally the 3 µm ROI around the nuclei.  
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2.2.7. Microscopy 
2.2.7.1. Confocal microscopy 
Confocal fluorescence microscopy images were acquired on a Leica SP5 
inverted confocal laser scanning microscope. A 63x HCX PL APO 63x 1.4 
NA oil-immersion objective (Leica Type F immersion oil)  was used for all 
confocal experiments in this thesis. Lasers 405, 488, 543 and 633 nm were 
used interchangeably and the “Gain” and “Off-set” settings were optimized 
for each experiment to obtain image acquisition without saturation. The 
Leica Application Suite X (LAS X) software was used for capturing images. 
The sequential scanning mode was used to prevent bleed-through resulting 
due to spectral overlap of excitation/emission spectra of the different 
fluorophores used. Images were scanned at 400 Hz with a line average of 
three, to reduce noise. For live imaging experiments, the laser scanning 
speed was increased to either 700Hz or 1000Hz for fast imaging. The TC 
conditions required for live imaging was facilitated using an Ibidi gas 
incubation system which includes a temperature stage that maintains the 
temperature at 37ºC and provides a humidified atmosphere supplied with 
5% CO2 within a closed environment.  
2.2.8. Western Blotting 
The below sections detail the basic protocols that were followed for the 
corresponding experiments. The treatment of cells and incubation times 
prior to this varies depending on each experimental condition.  
2.2.8.1. Seeding of cells 
Cells were seeded in 6-well tissue culture plates in complete media and 
allowed to incubate for 24 hr under TC conditions before treatment. The 
64 
 
cells were subjected to different treatment conditions before collecting 
lysates. The following seeding densities were used.  
HeLa - 240,000 cells per well  
VeroSLAM - 160,000 cells per well   
 
2.2.8.2. Lysate collection and preparation 
2.2.8.2.1. Lysate collection 
The medium was first aspirated from all wells, cells washed twice with ice-
cold PBS and 150μL of NP-40 lysis buffer (150 mM NaCl, 50 mM Tris base 
pH 8 and 1% Nonidet P-40 with protease inhibitors) was added to each well. 
The plate was then placed on ice and moved to a belly dancer shaker for 15 
min to allow proper contact of the lysis buffer to all parts of the well. The 
contents were then scraped using a cell scraper, transferred to ice-cold 1.5 
mL centrifuge tubes and centrifuged at 13,800 x g for 10 min. The 
supernatants were then pipetted into fresh 1.5mL centrifuge tubes placed on 
ice.  
2.2.8.2.2. Quantification of total protein content by BCA assay 
 
The protein concentration of the cell lysates was determined by 
bicinchoninic acid (BCA) assay. Bovine serum albumin (BSA) protein 
standards were prepared in lysis buffer at concentrations ranging from 0 to 1 
mg/mL. Cell lysates were diluted 1:5 in lysis buffer so that they fit within the 
working range of the BSA protein standards. 200μL of working BCA solution 
(49 parts bicinchoninic acid with 1part copper sulphate pentahydrate) was 
then pipetted into a 96 well plate.Triplicatemeasurements for both BSA 
standards and samples were made. 10 μL of the standards/samples were 
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added to the wells, the plate was incubated at 37ºC for 30 min and 
absorbance was measured at 562 nm using a plate reader. The 
concentration of total protein of cell lysates were measured using a 
calibration curve created by plotting the absorbance measurements against 
standard protein concentrations prepared with bovine serum albumin (BSA)  
2.2.8.3. Preparation of cell lysates 
 
Sample concentrations were adjusted to make 100µL of 1µg/µL protein per 
sample and a suitable volume of 4x loading buffer (2% sodium dodecyl 
sulphate [SDS], 10% glycerol, 0.02% bromophenol blue, 62.5 mM Tris-HCL) 
were added to each of the samples. The samples were then denatured by 
heating at 95°C for 5mins and centrifuged at 13,800 x g for 30 s.  
2.2.8.4. Western Blotting protocol 
2.2.8.4.1. Preparation of SDS-PAGE gels 
The SDS-PAGE gels were cast and run on a Bio-Rad Mini-Protean II SDS-
PAGE kit. Both the front and back plates were properly cleaned and wiped 
with ethanol and assembled in the clamp frame so that they were secured 
within the casting stand. Both the Resolving and stacking gels were 
prepared as per the list of ingredients in Tables 2.3 and 2.4 below. In both 
cases, Tetramethylethylenediamine (TEMED) was added only at last. 
Western blotting protocol used here was as per Laemmli’s protocol 
(Laemmli, 1970).  
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Table 2.3 - List of ingredients for preparation of Resolving gel  
% of Gel 12% 
Total Volume 10 mL 
40% acrylamide/Bis 3 mL 
3 M Tris pH 8.8 1.25 
mL 10% SDS 100 µL 
10% APS (freshly made) 75 µL 
TEMED 7.5 µL 
 
 
Table 2.4 - List of ingredients for preparation of Stacking gel  
% of Gel 10% 
Total Volume 10 mL 
40% acrylamide/Bis 1.1 mL 
1 M Tris pH 6.8 1.3 mL 
Distilled water  7.22 
mL 0.1% Bromophenol blue  300 µL 
10% SDS 
 
 
100 µL 
10% APS (freshly made) 75 mL 
TEMED 100 µL 
 
The stacking gel was first poured between the glass plates and allowed to 
reach up to 3/4th of the height, giving enough space for the stacking gel.  
Isopropanol (500µL)  was added over the top in order to get an even 
surface. Once the resolving gel was set, the isopropanol was removed by 
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washing 2x with distilled water. Any excess water between the plates was 
removed and the stacking gel was poured up to the top. A 10 well plastic 
comb was carefully placed, avoiding the formation of air bubbles. The gel 
was then allowed to dry and the comb was carefully removed. The gel - 
glass plate apparatus was then carefully transferred to the SDS-PAGE tank, 
immersed in running buffer (385 mM glycine, 250 mM Tris base, 0.5% SDS) 
and the samples were loaded.  
2.2.8.4.2. Sample loading and SDS-PAGE 
15 µg protein from each sample was loaded onto a 4% acrylamide stacking 
gel alongside 10 µL of the protein standard molecular weight marker. 
Protein separation was done at 100 V on a 12% acrylamide resolving gel for 
90 min.  
2.2.8.4.3. Protein transfer and Ponceau staining 
 
A Bio-Rad Mini Trans-Blot Electrophoretic Transfer Cell apparatus was used 
to transfer proteins onto a Polyvinylidene fluoride (PVDF) membrane, as per 
the manufacturer’s instructions. Protein transfer was done at 100V for 1 hr 
at 4°C. The membrane was then washed gently in distilled water.  
The PVDF membrane was immersed in Ponceau S solution for 5 min. The 
membrane was rinsed once in distilled water and checked for proper protein 
transfer. The membrane was then gently rinsed in distilled water until all 
traces of the stain was removed.  
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2.2.8.4.4. Protein detection by immunoblotting 
 
The PVDF membrane was first blocked with 5% milk prepared in PBST 
(0.025% Tween20 in PBS) solution. The membrane was then incubated 
overnight in a cold room 4°C on a belly dancer shaker with primary 
antibodies (see Table 2.5) diluted in 2% milk. The primary antibodies used 
were as follows:  
The membrane was washed again for 3x 5 min in PBST and incubated for 1 
hr at RT (on a shaker) with the secondary antibody diluted in 2% milk in 
PBST. 
Table 2.5 - Primary and secondary antibodies for Western blot  
Primary Antibody Secondary Antibody 
Rabbit Anti-LC3B antibody 
-  1:1000 dilution 
(Abcam ab51520) 
Goat anti rabbit IgG, 
HRP - 1:2000 dilution 
 (Fisher 31460) 
Mouse GAPDH antibody -  
1:1000 dilution  
(Abcam ab8245) 
Goat anti-mouse IgG, 
HRP - 1:2000 dilution  
(Fisher 31430) 
 
The membrane was washed a further 3 x 5 min in PBST before 
development. The detection of proteins was done using SuperSignal West 
Femto chemiluminescence reagent. 1 mL each of the reagents were mixed 
and together and applied to the PVDF membrane and incubated at RT for 5 
min. The excess solution was removed and the membrane was directly 
imaged using a Bio-Rad ChemiDoc system.  
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2.2.8.4.5. Quantification of bands 
The quantification of band intensities from digital images was done using 
Fiji/ImageJ software. Initially, the “Rectangle” selection tool was used to 
draw a narrow box enclosing the bands corresponding to the protein of 
interest.  
The Analyze>Gels>Select First Lane command was used to select the box 
and identify it as lane “1”.  
Profile plots were then drawn with the Analyze>Gels>Plot Lanes command 
and the resulting plot showed the relative density of all the bands within the 
selected box. The plots provided information about the size (width of peak) 
and darkness (height of peak) of the bands.   
The width of the peaks represented the size/area of the bands and the peak 
height represented the shade/darkness of the bands. The “Straight” line tool 
was then used to draw a line across the base of all the peaks and the 
“Wand” tool was used to select all the peaks. Now the measurements 
corresponding to the band intensities appeared as a pop up window, which 
were then exported to excel for analysis. The values for band intensities we 
normalized to the loading control for the final analysis.  
2.2.9. Cell viability 
Cell viabilities were determined using the CellTiter-Blue® cell viability assay 
as per the manufacturer’s instructions. Cells were seeded in black 96-well 
plates and incubated  for 24 hr under C conditions to reach 70-80% 
confluence. After treatment of the cells, 20μL of CellTiter-Blue reagent was 
added to each of the wells and the plates were incubated for 4hr. 
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Staurosporine (1 µM) was used as positive control for cytotoxicity and 
DMSO was used a vehicle control. At the end of the incubation period, 
fluorescence (544Ext/590Ems) measurements were acquired using a 
Fluostar Optima fluorescent plate reader. 
2.2.10. LDH cytotoxicity Assay 
Cell viability was measured using LDH cytotoxicity Assay Kit as per the 
manufacturer’s instructions. Briefly, VeroSLAM cells were seeded in 96 well 
tissue culture plates and incubated at TC conditions for 24 hr prior to 
treatment of cells. Cells were treated or not with 10µM cf2642 for 24 hr, 
followed by which 50 µL of the contents from each well were transferred to a 
flat bottom 96 well tissue culture plate and 50 µL of the Reaction Mixture 
was added to all wells. The plates were incubated for 30 min in dark and 50 
µL of Stop solution was added to all wells. After gentle tapping to remove 
bubbles, absorbance was measured at 490nm using a plate reader. The 
cells were incubated with the following controls were used for the calculation 
for LDH release and cytotoxicity. 
 Spontaneous LDH Activity Controls (sterile ultrapure water) 
 Maximum LDH Activity Controls (10X lysis buffer)  
 Positive control (prepared by diluting 1 µL LDH positive control in 10 mL 1% 
BSA in PBS)  
 Blank (complete medium only) 
The LDH release was calculated by subtracting the absorbance at 650 nm 
(background) from that of 450 nm. This value was used to calculate the 
percentage of cytotoxicity as per the formula: 
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% Cytotoxicity = (Compound-treated LDH activity – Spontaneous LDH 
activity) / Maximum LDH activity – Spontaneous LDH activity × 100 
 
2.2.11. Production of MeV stocks and titration  
2.2.11.1. Production of MeV stock 
VeroSLAM cells were maintained in five T-150 tissue culture flasks 
containing DMEM supplemented with 2.5% FBS, 10mM HEPES (4-(2-
hydroxyethyl)-1-piperazineethanesulfonic acid) and 25mM Magnesium 
sulphate (MgSO4) in the absence of geneticin. The HEPES served to 
maintain the pH of the extracellular medium and MgSO4 stabilized the virus 
particles released from infected cells (Weiss et al., 2012). For virus 
inoculation, media from the flasks was aspirated and 2 mL of MeV stock 
(TCID50 titre - 104 virions/mL) was added gently to come in contact with the 
cell monolayer. The flasks were tilted sideways to allow even contact with all 
cells and then incubated for 1 hr under TC conditions for virus adsorption. 
Then 15mL of fresh complete medium was added to the flasks and further 
incubated for up to 72 hr. The cells were observed under the microscope to 
check for cytopathic effects (CPE) - appearance of multinucleated giant cells 
confirmed the presence of CPE. The cells were then scraped from the walls 
of flasks, mixed with the medium and passed through 25-gauge hypodermic 
syringe needles to release intracellular virus particles. The resulting virus 
stock was centrifuged at 800 x g for 15 min to remove cell debris. The stock 
was then supplemented with 20% FBS and stored as 2 mL aliquots at -80ºC 
until needed.  
72 
 
2.2.12. Titration of MeV stocks by TCID50 assay 
50% tissue culture infective dose (TCID50) method, also known as end 
point dilution assay, was used to titrate the MeV virus stocks. B95a cells 
were seeded in a 96 well plates and grown to ~80% confluence. A series of 
eight 10-fold dilutions of the virus was prepared in complete media and 
added to the corresponding wells. Both virus and non-infected (mock) 
controls were also made. The plate was incubated for 3 days and observed 
for CPE. Virus titer was calculated based on the method previously 
described by Reed and Muench (Reed and Muench, 1938). An estimation of 
the number of virus particles in the stock was made based on the average 
lowest dilution at which CPE was observed.  
2.2.13. MeV syncytia assay 
VeroSLAM cells were seeded 6 well tissue culture plates at a density of 
160,000 cells per well and incubated for 24 hr at TC conditions. Cells were 
then infected with MeV at MOI 0.5 in the presence or absence of 10µM 
cf2642 and incubated for 12 hr at TC conditions. Bright field images were 
captures using a Leica DMIRB inverted microscope equipped with a 10x 
objective. 
2.2.14. MeV plaque assay 
2.2.14.1. Crystal violet solution 
A 1 L crystal violet solution was prepared by diluting 2.5 g crystal violet in 50 
mL 37% formalin, 100 mL of ethanol and 850 mL distilled water.  
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2.2.14.2. Plaque assay 
VeroSLAM cells were seeded in a 6 well tissue culture plate at a density of 
200,000 cells per well and incubated for 12 hr at TC conditions. Cells were 
then infected with MeV at MOI 0.5 in the presence or absence of 1, 5 and 
10µM cf2642 and incubated at TC conditions for 12 hr. At the time of 
infection/treatment, a 24 well plate was seeded with VeroSLAM cells so that 
they are confluent after 12 hr when the above mentioned incubation period 
is completed. After the 12 infection/treatment period, the supernatants from 
all wells were carefully transferred to a sterile 24 well plate and three 5-fold 
dilutions were made using complete medium. The diluted supernatants were 
then used to infect the previously prepared 24 well plate with VeroSLAM 
cells. Infection was done by incubating cells with the supernatants (all 
dilutions) for 60 min to allow virus adsorption. The contents were then 
aspirated and cells washed gently with warm PBS. An overlay (500 µL) 
containing 1.5 % agarose dissolved in DMEM containing 2 % FBS was 
gently added to all wells and the plate was incubated for 3 days at TC 
conditions. A crystal violet staining solution (see above) was then added to 
all wells and the plate was left at RT for 4 hr. The contents of the wells were 
then aspirated and cells washed 4x with PBS until all residues of the 
staining solution were removed. The plate was then left to dry at RT before 
counting the plaques. The virus titres were calculated by counting the 
number of plaques in each well and multiplying it by ten to the power of the 
dilution factor. 
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2.2.15. MeVautophagy 
VeroSLAM cells were seeded in 6 well tissue culture plates at 160,000 cells 
per well and incubated for 24 hr at TC conditions to reach confluence. Cells 
were then infected with MeV at MOI0 0.5 in the presence or absence of 
10µM cf2642 and 50 µM chloroquine for 12 hr. Protein expression levels of 
LC3B and GAPDH were then analyzed by western blotting as in section 
2.2.8.4.  
2.2.16. SLAM-receptor clustering 
2.2.16.1. Antibody-mediated clustering of SLAM receptors 
 
The clustering of SLAM receptors in VeroSLAM involved the use of Alexa 
Fluor 647 conjugated secondary antibodies commercially available from 
Fisher. Since they contain 5 mM sodium azide which is toxic to cells, the 
preservative was first removed from the antibody.  
2.2.16.1.1. Purification of antibody using centrifugal filters 
Chicken anti-mouse Alexa Fluor - 647 antibody (300 µL see Table 2.2) was 
first diluted in 1 mL sterile PBS. Amicon Ultra 50K centrifugal filters contain 
two parts: a small tube with the 50 kDa filters at its bottom, which is inserted 
into a larger 0.5 mL collection tube.  The antibody-PBS solution was 
transferred equally to two 0.5mL filter tubes. These were inserted into their 
respective collection tubes and centrifuged at 13,800 x g for 10 min. The 
filter tube was then carefully removed, placed inside the collection tube in an 
inverted position, and centrifuged at 1000 x g for 2 min to transfer the eluate 
to the bottom of the tube. To collect any residual antibodies attached to the 
filter, this step was again repeated by adding 20 µL PBS to the filter device.  
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2.2.16.1.2. Calculation of dye-protein ratio 
In order to use the new purified antibody solution for experiments, it was 
important to determine whether there was any loss in the protein:dye 
conjugation (dye:protein or F/P molar ratio). The F/P ratio provides 
information about the number of fluorophore dye molecules that are 
conjugated to the antibody (protein) binding sites. The ratio obtained was 
then compared to the value for the original antibody solution. Measurement 
of the F/P ratio was done using a UV spectrophotometer.  
2.2.16.1.3. Measurement of absorbance 
The absorbance measurement was done using a UV spectrophotometer. A 
blank value was first set using a cuvette filled with 200µL PBS. The 
absorbance at two different wavelengths AMAX (absorbance at 650nm) and 
A280 (Absorbance at 280 nm)were measured using a Cary 60 UV 
spectrophotometer. Similarly, absorbance was measured for the control 
chicken anti-mouse Alexa Fluor-647 antibody taken directly from the vial 
(without filtration) and the filtered antibody. The antibody solutions were 
diluted 1:50 in PBS for absorbance readings.   
Calculation of the protein concentration and dye-protein mole ratio was done 
as per the formula: 
Protein concentration (M) = [A280 - (AMAX x CF) / ε] x Dilution factor  
Moles dye per molecule protein = [AMAX of labelled protein/ (ε´ x protein 
concentration (M))] x Dilution factor  
 Extinction molar coefficient (ε) of IgG = 210,000M-1 cm-1 
 Extinction coefficient of the dye/fluorophore molecule (ε´) of Alexa Fluor 647 
= 270,000  
 Correction factor (CF) = A280/AMAX of the fluorophore = 0.3   
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 Dilution factor = 50 (1:50 dilution)  
 
2.2.16.1.4. Clustering of SLAM receptors  
2.2.16.1.4.1. Seeding of cells 
VeroSLAM cells were seeded in 35 mm glass bottom MatTek dishes at a 
cell density of 160,000 cells per dish and incubated for 24 hr at TC 
conditions to reach 70-80% confluence.  
2.2.16.1.4.2. Fixed cell imaging 
2.2.16.1.4.2.1. Dose response of Alexa Fluor-647 conjugated secondary 
antibodies 
Live VeroSLAM cells were first incubated with 2 µg/mL mouse anti SLAM 
antibody (see Table 2.2) diluted in complete DMEM for 30 min w/o 10µM 
cf2642 at TC conditions. The cells were then washed 3x with warm PBS and 
incubated with 2, 6 and 10µg/mL chicken anti mouse Alexa Fluor-647 
secondary antibody for 60 min in the presence or absence of 10µM cf2642 
at TC conditions. This was followed by a further 3x wash with PBS and cells 
were further incubated (chase) w/o 10µM cf2642 for 60 min at TC 
conditions. Finally, the cells were washed 2x with warm PBS and fixed with 
3% PFA for 15 min and permeabilized for 5 min with PBS containing 0.05% 
saponin and 50 mM NH4Cl. Immunolabelling with LAMP1-FITC antibody 
was done to label the lysosomes (see section 2.2.3 for IF protocol).  
For the quantification of internalized SLAM positive vesicles, the images 
were first split in to red (SLAM), green (LAMP1) and blue (nuclei) channels. 
Region of interests (ROIs) were then drawn around cells to include only the 
internal region of the cells. This was done by using the SLAM labelling of the 
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plasma membrane and Hoechst stain of the nucleus as a guide. A macro 
(see Appendix 1) was used to measure the following parameters: total 
number, area and integrated density of the internalized SLAM-positive 
vesicles. The measurements were taken for 30 cells per condition.  
2.2.16.1.4.2.2. Indirect SLAM-receptor clustering – 2 and 6 hr  
 
Live VeroSLAM cells were incubated with 2 µg/mL mouse anti SLAM 
antibody diluted in complete DMEM for 30 min w/o 10µM cf2642 at TC 
conditions. The cells were then washed 3x with warm PBS and incubated 
with 6 µg/mL chicken anti mouse Alexa Fluor-647 secondary antibody for 60 
min in the presence or absence of 10µM cf2642 at TC conditions. This was 
followed by a further 3x wash with PBS and cells were further incubated 
(chase) w/o 10µM cf2642 for either 1 or 5 hr at TC conditions. Finally, the 
cells were washed 2x with warm PBS and fixed with 3% PFA for 15 min and 
permeabilized for 5 min with PBS containing 0.05% saponin and 50 mM 
NH4Cl. Immunolabelling with LAMP1-FITC antibody was done to label the 
lysosomes (see section 2.2.3 for IF protocol).  
Cells without SLAM-clustering served as the no-clustering controls wherein 
the cells were incubated with the primary mouse anti-SLAM antibody w/o 
cf2642 as mentioned above, washed 3x with warm PBS and incubated with 
complete media w/o cf2642 for either 1.5 or 5.5 hr before fixing the cells. In 
this case, immunolabelling was done to label both SLAM (mouse anti-SLAM 
antibodies) and the lysosomes (LAMP1-FITC antibodies).  
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2.2.16.1.4.2.3. Indirect SLAM-receptor clustering using unconjugated 
secondary antibodies.  
Live VeroSLAM cells were incubated with 2 µg/mL mouse anti SLAM 
antibody diluted in complete DMEM for 30 min on ice. The cells were then 
washed 3x with warm PBS and incubated with 6 µg/mL goat anti mouse 
Alexa Fluor-647 secondary antibody for 60 min in the presence or absence 
of 10µM cf2642 at TC conditions. This was followed by a further 3x wash 
with warm PBS and cells were further incubated (chase) w/o 10µM cf2642 
for either 1 or 5 hr at TC conditions. Finally, the cells were washed 2x with 
warm PBS and fixed with 3% PFA for 15 min and permeabilized for 5 min 
with PBS containing 0.05% saponin and 50 mM NH4Cl. Immunolabelling 
was done with Rabbit anti-LAMP1 antibodies to label the lysosomes and 
donkey anti-goat Alexa Fluor-488 secondary antibodies to label the SLAM 
receptors. (see section 2.2.3 for IF protocol and Table 2.2 for details on 
primary and secondary antibodies used).  
Cells without SLAM-clustering served as the no-clustering controls wherein 
the cells were incubated with the primary mouse anti-SLAM antibody w/o 
cf2642 as mentioned above, washed 3x with warm PBS and incubated with 
complete media w/o cf2642 for either 1.5 or 5.5 hr before fixing the cells. In 
this case, immunolabelling was done to label both SLAM (mouse anti-SLAM 
antibodies) and the lysosomes (Rabbit anti-LAMP1 antibodies).  
2.2.16.1.4.2.4. Indirect SLAM-receptor clustering in live cells 
VeroSLAM cells were seeded in 35 mm glass bottom MatTek dishes at a 
cell density of 100,000 cells per dish and incubated for 24 hr at TC 
conditions to reach 70-80% confluence. Cells were then pulsed for 2 hr with 
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0.2 mg/mL 10 kDa Dextran Alex Fluor-488 and chased for 18 hr to label the 
lysosomes. Cells were then incubated with 2 µg/mL mouse anti SLAM 
antibody diluted in complete DMEM for 30 min w/o 10µM cf2642 at TC 
conditions. The cells were then washed 3x with warm PBS and incubated 
with 6 µg/mL chicken anti-mouse Alexa Fluor-647 secondary antibody for 60 
min in the presence or absence of 10µM cf2642 at TC conditions. This was 
followed by a further 3x wash with warm PBS and cells were further 
incubated (chase) w/o 10µM cf2642 for either 1 or 5 hr at TC conditions. 
Live images were then captured by confocal microscopy (see section 
2.2.7.1).  
Cells without SLAM-clustering served as the no-clustering controls wherein 
the Detran-488 labelled cells were incubated with the primary mouse anti-
SLAM antibody w/o cf2642 as mentioned above, washed 3x with warm PBS 
and incubated with complete media w/o cf2642 for either 1.5 or 5.5 hr before 
imaging. Cells were incubated with either vehicle (DMSO) or cf2642 to serve 
as controls without incubation with any antibodies. For the secondary 
antibody controls, cells were initially incubated for 30 min w/o cf2642, 
washed and incubated with 6 µg/mL chicken anti-mouse Alexa Fluor-647 
secondary antibody for 60 min w/o cf2642, washed and incubated for either 
1 or 5 hr w/o cf2642 at TC conditions.  
2.2.16.1.4.3. Actin labelling  
VeroSLAM cells were seeded in 35 mm glass bottom MatTek dishes at a 
cell density of 100,000 cells per dish and incubated for 24 hr at TC 
conditions to reach 70-80% confluence. Cells were incubated with 2 µg/mL 
mouse anti-SLAM antibodies w/o 10µM cf2642 for 30 min at TC conditions 
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and clustered with 6 µg/mL chicken anti mouse Alexa Fluor - 647 antibodies 
in the presence of absence of cf2642 for 60 min.  Cells were then chased for 
either 30 or 60 min w/o 10µM cf2642 at TC conditions. This was followed by 
fixation of cells with 3% PFA and permeabilization for 5 min with PBS 
containing 0.05% saponin and 50 mM NH4Cl. The actin filaments and nuclei 
were labelled by incubating cells for 30 min with PBS containing rhodamine 
phalloidin and 1 µg/mL Hoechst. Cells were then washed 2x with PBS and 
the MatTek dishes containing cells (with PBS) were used for imaging.  
 
2.2.17. Transferrin uptake assay 
Live VeroSLAM cells were initially incubated with serum free DMEM for 30 
min at TC conditions, followed by which cells were incubated with serum 
free medium containing 1X cell mask deep red plasma membrane stain and 
5 µg/mL transferrin conjugated with Alexa Fluor-488 (Tf-488) for 30 min on 
ice. Cells were then chased at 37ºC for up to 30 min in the presence or 
absence of 10µM cf2642 and live images were captured at 10 min intervals. 
 
 
2.3. Dextran uptake assays 
 
2.3.1.1.1. Dextran uptake assay by MeV 
VeroSLAM cells were seeded in 24-well tissue culture plates at a seeding 
density of 40,000 cells/well and incubated for 24 hr at TC conditionsto reach 
~80% confluence. The cells were then washed with ice-cold PBS and gently 
scraped from the surface using the rubber end of a 1 mL syringe plunger. 
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Cells were then transferred to 1.5 mL Eppendorf tubes and centrifuged at 
300 x g for 4 min. The tubes cells were then placed on ice, infected or not 
with MeV (MOI 0-100) in ice-cold complete medium and incubated for 60 
min. Subsequently, the cells were moved to a 37°C water bath and 0.1 
mg/mL of 10kDa Dextran Alexa Fluor 488 (Dextran-488) with or without 
10µM cf2642 was added during the last 5 min of the 5, 15 and 30 min time 
points as shown in Fig 2.1. At the end of each time point, the tubes were 
placed on ice for 10 min, washed 2x with ice-cold FACS medium (PBS 
containing 10% FBS) and centrifuged at 300 x g for 5 min. Finally, the cells 
were fixed for 15 min with 3% paraformaldehyde (PFA), washed 2x with ice-
cold FACS medium and used for flow cytometry analysis (see section 
2.2.13.3.9).   
 
Fig 2.1 Methodology for Dextran-488 uptake assay using MeV. 
VeroSLAM cells were infected with virus at 4ºC for 60 min, moved to 37 ºC 
and Dextran - 488 w/o 10µM cf2642 was added at different time points as 
indicated. Initially, the cells were exposed to Dextran-488, only during the 
initial 5 min (marked in green), after which the cells are processed for 
analysis. For the 15 and 30 min time points, cells were first incubated at 
37°C for 10 and 25 min respectively, followed by the addition of Dextran-488 
during the last 5 min.  
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2.3.1.1.2. Dextran uptake assay by direct SLAM-receptor clustering 
The methodology followed here was similar to section 2.2.15.1 above, but 
without the use of live virus. VeroSLAM cells were seeded in 24-well tissue 
culture plates at a seeding density of 40,000 cells per well and 24 hr post 
seeding, the cells were washed with ice-cold PBS, scraped from the 
surface, transferred to 1.5 mL Eppendorf tubes and centrifuged at 300 x g 
for 4 min. The tubes were placed on ice and the cells incubated for 60 min 
with 6µg/mL of rabbit anti-SLAM polyclonal antibodies diluted in ice-cold 
complete medium. Subsequently, the cells were moved to a 37°C water 
bath and 0.1 mg/mL of 10kDa Dextran Alexa Fluor 488 (Dextran-488) with 
or without 10µM cf2642 was added during the last 5 min of the 5, 15 and 30 
min time points as shown in Fig 2.1. At the end of each time point, the tubes 
were placed on ice for 10 min, washed 2x with ice-cold FACS medium and 
centrifuged at 300 x g for 5 min. Finally, the cells were fixed for 15 min with 
3% paraformaldehyde (PFA), washed 2x with ice-cold FACS medium and 
used for flow cytometry analysis (see section 2.2.13.3.9).   
2.3.1.1.3. Dextran uptake assay by indirect SLAM-receptor clustering  
The methodology followed here was similar to section 2.2.17.1.3 above, but 
using a combination of primary and secondary antibodies to cluster SLAM 
receptors.  VeroSLAM cells were seeded in 24-well tissue culture plates at a 
seeding density of 40,000 cells per well and 24 hr post seeding, cells were 
incubated for 30 min with 2 µg/mL mouse anti-SLAM antibody at TC 
conditions. (see Table 2.2 for details about the antibody). Cells were then 
washed 2x in warm PBS and incubated with 6 µg/mL Alexa Fluor-647 
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conjugated polyclonal chicken anti-mouse antibodies for 60 min on ice. The 
cells were then gently scraped from the wells, transferred to 1.5 mL 
Eppendorf tubes and moved to a 37ºC water bath. Then 0.1 mg/mL of 
10kDa Dextran Alexa Fluor 488 (Dextran-488) with or without 10µM cf2642 
was added during the last 5 min of the 5, 15 and 30 min time points as 
shown in Fig 2.1. At the end of each time point, the tubes were placed on 
ice for 10 min, washed 2x with ice-cold FACS medium and centrifuged at 
300 x g for 5 min. Finally, the cells were washed 2x with ice-cold FACS 
medium and used for flow cytometry analysis (see section 2.2.13.3.9).   
2.3.2. Actin labelling in MeV infect cells 
VeroSLAM cells were grown over glass cover slips in 12 well plates and 24 
hr post seeding, the cells were infected or not with MeV (MOI-10) for 30 min 
in the presence or absence of 10µM cf2642. Cells were then washed with 
warm PBS and fixed with 3% PFA for 15 min. Cells were permeabilized with 
0.01% Trixon X 100 in PBS for 10 min, washed and further incubated for 30 
min with PBS containing 0.2 µM Alexa Fluor 647 Phalloidin and 5 µg/mL 
DAPI to stain Actin filaments and nucleus respectively. The cover slips were 
mounted on glass slides using Dako mounting fluid and allowed to dry at 
room temperature before imaging. (see section 2.2.7.1 for details on 
microscopy)  
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2.3.3. cf2642 MoA studies 
In order to study the MoA of cf2642 against MeV, a series of experiments 
were performed to test the effect of the drug on different stages of virus life 
cycle.  
2.3.3.1.1. Time of addition (ToA) assay 
 
VeroSLAM cells were seeded at a density of 40,000 cells per well in a 24 
well plate and incubated for 24 hr at TC conditionsso that cell confluence 
was at about 70-80% at the time of infection. Cells were then infected or not 
with MeV-GFP (MOI - 0.5) and treated with 10µM cf2642 at different time 
points pre and post-infection. At the end of the T0 + 12 hr time point, cells 
were further incubated for 12hr at TC conditions. Cells were then scraped 
from the wells using the rubber end of a 1 mL syringe plunger, re-
suspended in ice-cold FACS medium and centrifuged at 300 x g for 5 min. 
Finally, the cells were fixed for 15 min with 3% PFA and washed 2x with ice-
cold FACS medium. Flow cytometry analysis (see section 2.2.20.1.3) was 
performed to analyze the number of GFP positive cells.  
2.3.3.1.2. Measles entry and spread assay 
 
VeroSLAM cells were seeded in a 12 well tissue culture plate at 60,000 
cells/well and incubated at TC conditionsfor 24 hr to reach ~80% 
confluence. Cells were infected or not with MeV-GFP (MOI - 0.5) for 2 hr in 
the presence or absence of 10µM cf2642. Then the cells were washed 2x 
with sterile warm PBS and further incubated in the presence or absence of 
10µM cf2642 for further 24 hr at TC conditions. To study the effects of 
cf2642 on virus spread, cf2642 was either added either only during the initial 
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2 hr incubation step or only during the subsequent 24 hr incubation. The 
cells were then scraped from the wells, fixed with 3% PFA for 15 min and 
the percentage of EGFP positive cells was analyzed by flow cytometry (see 
section 2.2.13.3.9 below).    
2.3.3.1.3. Flow cytometry analysis 
 
The flow cytometry analysis involved in the cf2642 MoA studies varied with 
the type of instrument used, cell type, detection parameters and the gating 
of cells. Hence, the information pertaining to all these experiments are 
summarized in this section. 
Section 2.2.18.1.1 - The Dextran-488 fluorescence in MeV infected cells 
was analyzed on a BD FACSCanto II flow cytometer using a 488 nm laser 
and 530/30 filter. Cells were first gated using FSC-A/SSC-A to remove dead 
cells and debris, followed by FITC-A/FSC-A, to separate Dextran-488 
positive cells. 
Section 2.2.18.1.3- Dextran-488 fluorescence in SLAM-clustered cells was 
analyzed on a BD FACSVerse flow cytometer using a 488 nm laser and 
527/32 filter. Cells were first gated using FSC-A/SSC-A to remove dead 
cells and debris, followed by Alexa 488-A/FSC-A, to separate Dextran-488 
positive cells. 
Sections 2.2.20.1.1 and 2.2.20.1.2 - The analysis of EGFP positive cells 
was done on a BD FACSCanto II flow cytometer using a 488 nm laser and 
530/30 filter. Cells were first gated using FSC-A/SSC-A to remove 
clumped/aggregated cells formed as a result of virus induced CPE.  Then 
the cells were gated by FITC-A/FSC-A, to separate the EGFP positive cells. 
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2.3.3.1.4. Impedance assay 
Impedance assay measurements were acquired using an RTCA 
xCELLigence instrument (ACEA Biosciences). Initially, complete medium 
(100 µL) was added to all wells in a 16 well plate (E Plate-16) that is 
provided as part of the instrument. The plate was then placed inside the 
xCELLigence Instrument equipped with plate cradles, and the entire 
apparatus was placed inside an incubator at TC conditions. The 
xCELLigence software was then used to set the background values from the 
E plate-16 inside the incubator. The plate was then removed and VeroSLAM 
cells were seeded at 10,000 cells (in 100 µL complete medium) per well, 
followed by which the plate was replaced in the xCELLigence Instrument 
inside the incubator. The time intervals for acquiring the impedance 
measurements in real time was set using the xCELLigence software. During 
the initial 24 hr time period post seeding of cells, measurements were taken 
every 15 min. After 24 hr, the plate was removed from the incubator and 
infected or not with MeV at MOI 0.5 in the presence or absence of 1, 5 and 
10µM cf2642 in sterile conditions. The plate was then replaced in the 
incubator and remaining impedance measurement cycle was initiated. 
Impedance measurements were acquired at 1 min intervals from 24 to 27 hr 
post infection and at then 15 min intervals during 27 to 100 hr incubation 
periods. After completion of the cycle, the plates were removed from the 
incubator and discarded appropriately. The measurements were then 
exported into an excel sheet for analysis.  
2.3.3.1.5. Statistics 
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The statistics for all flow cytometry data represent Median Fluorescence 
Intensity (MFI) from three (or four) independent experiments. Statistical 
analysis was done using two-tailed unpaired Students t-test and a P value 
of < 0.05 was considered statistically significant. 
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Chapter 3 - Effect of cf2642 on cell viability, MeV 
autophagy and virus titres 
 
3.1. Introduction 
The MoA of cf2642 against MeV and VACVwas hypothesized to target a 
cellular pathway  that in turn contributes to the antiviral activity against both 
these viruses. (McGuigan et al., 2013). On that note, initial studies were 
performed to test the effect of cf2642 on cell viability of two cell lines namely 
HeLa and VeroSLAM that were used in this study. Subsequent experiments 
were performed to test the anti MeV effects of cf2642 in VeroSLAM cells 
using both microscopy and estimation of virus titers.   
Autophagy is a cellular process which involves the degradation of cellular 
components targeted for elimination(Dong and Levine, 2013).    See section 
1.8 for more details.MeV has been previously shown to induce autophagy in 
infected cells starting from 12 hr and up to 16 hr post infection. This, 
coupled with autophagy induced as a result of syncytia formation, serves as 
a feedback loop to maintain successive autophagy flux during infection. 
Since MeV induced autophagy facilitates in virus spread and escape from 
host mediated immune responses (Richetta et al., 2013),  the effect of 
cf2642 on this cellular process was investigated.  
In this chapter all MeV experiments were performed at the Bundeswehr 
Institute for Microbiology in Munich, Germany, while other experiments were 
performed in the School of Pharmacy, Cardiff University.  
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3.2. Results and Interpretation 
3.2.1. Analysis of cf2642 toxicity 
Viability assays were performed for both HeLa and VeroSLAM cells to 
assess the effect of cf2642 against a human (HeLa) as well as a non-human 
primate (VeroSLAM) cell lines. This was done to test whether any antiviral 
activity observed in the subsequent experiments were not just an artefact 
caused as a result of in vitro drug toxicity. Briefly, HeLa and VeroSLAM cells 
were treated with increasing concentrations of cf2642 and cell viability was 
analyzed at 12, 24, 48 and 72 hr post treatment using CellTiter-Blue assay.   
 
Fig 3.1 cf2642 causes a time and dose-dependent decrease in cell 
viability: HeLa and VeroSLAM cells were treated with 1, 5, 10µM cf2642 
and 1µM Staurosporine (STP) as positive control. Cell viability up to 72 hr 
post treatment was measured using CellTiter-Blue assay. Cell viability 
results for (A) HeLa and (B) VeroSLAM cells are shown as percentage of 
untreated (diluent) control. The error bars show mean ± SD of three 
independent experiments.  The results were quantified and shown as 
percentage increase of fluorescence intensity normalized to the control. 
Student’s t-test was performed to assess the p values; **p < 0.01, ***p < 
0.001.  
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Figure 3.1 (A) demonstrates no significant decrease of viability in HeLa cells 
in the presence of 1µM cf2642 even at 72 hr post treatment. A 13 and 24% 
decrease in viability was evident starting at 48 hr post treatment with 5µM 
and 10µM cf2642, respectively and more substantial cytotoxicity was 
observed for both drug concentrations at 72 hr post treatment.VeroSLAM 
cells showed different toxicity profiles (Fig 3.1 (B)) with significant toxicity in 
the presence of 1µM cf2642 noted only at the longer time points 48-72 hrs. 
Cell viability remained unaffected at 12hr post treatment with both 5 and 
10µM cf2642, but longer treatment time points showed a steady increase in 
cytotoxicity. In the presence of 10µM cf2642, cells remained completely 
viable at 12hr post treatment, after which, a 27% decrease in viability was 
observed at the 24hr time point. The positive control for cytotoxicity (1µM 
Staurosporine) showed > 90% loss in cell viability for both HeLa and 
VeroSLAM cells. Taken together, the findings indicate that treatment with 
10µM c2642 did not result in loss of viability up to 12hr post treatment in 
both cell lines tested. The steady decrease in cell viability of VeroSLAM 
cells after 12 hr indicates that this cell line is more sensitive to the effects of 
cf2642. In light of these data, a working concentration of 10µM c2642 or 
lower, was used for all subsequent experiments using HeLa and VeroSLAM 
cells. 
This difference in cytotoxicity profiles of L-ddBCNAs/cf2642 across different 
cell lines was previously reported by Dr. Laura Farleigh and was speculated 
to be due to the cell-targeting effects of the drug(s) on cell lines derived from 
different origins (Farleigh, 2014). Although HeLa and VeroSLAM cells were 
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not tested as part of that study, the same could hold true for these cell lines 
as well.  
While performing this experiment a change in colour of tissue culture 
medium from red to yellow in the cf2642 treated conditions, indicative of 
medium acidification. This phenomenon was first reported by Dr. Laura 
Farleigh who previously worked on cf2642 and it was shown that when the 
cell culture medium in cf2642 treated conditions were replaced after 16 hr 
post treatment, the cells were rescued from the toxic effects of the drug. 
Similar observations were noted in some subsequent experiments 
discussed in more detail in Chapter 4. Hence, the loss in cell viability over 
time may be an indirect effect of the drug. 
3.2.2. Effect of cf2642 on MeV induced syncytia 
MeV induced syncytia results in the formation of multinucleated giant cells 
and can be used to directly observe the effects of drugs against MeV, 
wherein the absence of syncytia formation would indicate antiviral activity 
(Mathieu et al., 2015). The effect of cf2642 on MeV induced syncytia was 
studied by infecting VeroSLAM cells with MeV in the presence or absence of 
the drug.   
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Fig 3.2. cf2642 inhibits MeV induced syncytia in VeroSLAM cells. Cells 
were infected with MeV at MOI 0.5 in the presence or absence of 10µM 
cf2642 and 12 hr post infection, images were captured using a wide field 
fluorescent microscope. Arrows indicate the presence of multinucleated 
giant cells. Images represents data from two independent experiments.  
 
Fig 3.2 illustrates the effects of cf2642 on MeV induced syncytia in 
VeroSLAM cells. Incubation of cells with cf2642 did not result in any 
differences in cell morphology when compared to the vehicle control. MeV 
infected cells showed extensive formation of syncytia seen as large 
multinucleated giant cells and contained a large number of nuclei that were 
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clustered together. No evidence of syncytia formation was observed in virus 
infected cells treated with cf2642. Previous studies have shown that cf2642 
inhibits MeV induced syncytia in B95a cells ( Marmoset B lymphocytes 
immortalized with Epstein Barr virus) which naturally express the 
SLAM/CD150 receptor for MeV entry (Farleigh, 2014). The inhibition of 
syncytia formation in VeroSLAM cells treated with cf2642 provides direct 
evidence that antiviral activity of the drug against MeV is not limited to B95a 
cells alone. 
 
3.2.3. Dose response effect of cf2642 on MeV titres 
Previous work done using cf2642 demonstrated the antiviral activity of the 
drug against MeV in B95a cells (marmoset B-lymphocytes transformed by 
Epstein Barr virus) (McGuigan et al., 2013). Since a major part of this thesis 
is focussed on the use of VeroSLAM cells, it was important to determine 
whether the antiviral activity previously observed in B95a cells can be 
replicated in this cell line.  The dose-dependent effect of cf2642 against 
MeV was therefore measured using virus plaque assays as described in 
2.2.14. 
Briefly, VeroSLAM cells were infected with MeV at MOI-0.05 and treated 
with the increasing concentrations of cf2642 from 1 to 10 µM. After a 12 hr 
incubation period, the supernatants were collected and used for plaque 
assays. Here, cells were fixed with paraformaldehyde 4 days’ post infection 
and the plaques were counted manually.  Virus titres were calculated by 
multiplying the average number of plaques in the wells with the virus dilution 
factor used for the assay.  
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Fig 3.3.  Dose dependent effect of cf2642 against MeV: VeroSLAM cells 
were infected with MeV at an MOI of 0.5 and treated or not with 1, 5 and 
10µM cf2642 as indicated. Post treatment, (12 hr) the supernatant was 
collected and plaque assay was performed to titrate the virus. The results 
are represented as percentage increase of plaques compared to the MeV 
control. Student’s t-test was performed to assess the p values; *p < 0.05, 
***p < 0.001. Error bars represent mean ± SE of three independent 
experiments.  
 
The results in Figure 3.3 demonstrate a significant 96% decrease in number 
of infectious MeV particles in the presence 10µM cf2642. A similar, but 
slightly reduced activity was observed in the presence of 5µM cf2642. The 
least activity was seen with 1µM cf2642, where only a 43% decrease in 
virus titre was observed. The data reveals a dose-dependent activity of 
cf2642 against MeV, with the maximum activity (IC90) seen at 10µM 
cf2642.However, previous data reported by McGuigan et al., showed the 
IC50 of cf2642 against MeV in B95a cells to be 7.5µM (McGuigan et al., 
2013). The activity of a cell-targeting antiviral like cf2642 may vary across 
cell lines and this may be a contributing factor for these differences in 
antiviral activity. The variations in cytotoxicity of cf2642 against HeLa and 
VeroSLAM cells seen in Figure 3.1 serves as an ideal example. Also, two 
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different assays were used for analysis (plaque assay in this study versus 
TCID50 assay in McGuigan et al. paper)(McGuigan et al., 2013). 
3.2.4. Effect of cf2642 on MeV induced autophagy - Immunofluorescence 
assay 
This was done to test the effects of cf2642 on MeV induced autophagy by 
confocal microscopy. VeroSLAM cells were infected in the presence or 
absence of cf2642 and 12 hr post infection, labelled for LAMP1 and LC3 to 
label the late endosomes/lysosomes and autophagosomes respectively. 
Previous work done using cf2642 in HeLa cells, showed that the drug 
caused the scattering of lysosomes towards the cell periphery (Farleigh, 
2014). The LAMP1 labelling was done to test whether the same results were 
also observed in VeroSLAM cells. 
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Fig 3.4 Microscopy analysis of the effect of cf2642 on MeV induced 
autophagy. VeroSLAM cells were infected with MeV at MOI 0.5 and 
incubated in the presence or absence of 10µM cf2642. Post 
infection/treatment (12 hr), cells were fixed with ice-cold methanol and 
immunolabelled with LC3B and LAMP1 antibodies to label the 
autophagosomes and late endosomes/lysosomes respectively. Single 
section images show LC3 (green) and LAMP1 (red) labelling both as grey 
scale and merged images.  The nucleus was labelled with Hoechst 33342 
and is shown in blue. Arrows show enlarged LC3B positive 
autophagosomes and arrow heads indicate syncytia formation by the fusion 
of cells. Images are representative of three independent experiments (scale 
bar = 20 µm).  
 
Figure 3.4 demonstrates the presence of small LC3 positive structures in 
both the vehicle and cf2642 controls. No obvious differences in the number 
of these structures were found between the two conditions. Few cells 
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showed the presence of scattered LAMP1 positive vesicles in the cf2642 
control, compared to the perinuclear arrangement observed in vehicle 
control.Multinucleated-giant cells (syncytia) indicated by the presence of 
fused nuclei, were observed in the MeV control. Slightly enlarged LC3B 
positive autophagosomes were also observed in virus infected cells. The 
increased number of LC3 positive vesicles (autophagosomes) in virus 
infected cells were mostly located around the vicinity of syncytia. The 
autophagosomes were in close proximity with LAMP1 positive late 
endosomes/lysosomes and indicate the formation of autolysosomes as part 
of an ongoing autophagy flux (Yoshii and Mizushima, 2017). No syncytia 
were seen in virus infected cells treated with cf2642, and the large 
autophagosomes seen in the MeV control were reduced. An inherent 
disadvantage of using IF assay for the study of autophagy is that it cannot 
be used to accurately measure an ongoing autophagy flux. In such cases, 
the results must be supported by western blot assays in the presence of 
lysosome inhibitors (see below). (Yoshii and Mizushima, 2017, Mizushima et 
al., 2010). This could be the reason why no significant increase of 
autophagosomes in MeV control was observed by confocal microscopy.  
3.2.5. Effect of cf2642 on MeV induced autophagy – Western blot analysis 
 
The effect of cf2642 on MeV induced autophagy was analyzed using 
western blot analysis to assess the expression levels of LC3 protein, a 
marker for autophagy (Yang et al., 2013). Three isoforms of LC3 namely 
LC3A, B and C exist in humans and they undergo various post translational 
modifications during autophagy. Soon after synthesis, this protein is first 
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cleaved at the carboxyl terminus to yield LC3-I and during the induction of 
autophagy, it is lipidated to form LC3-II (Mizushima et al., 2010) (see section 
1.8 in chapter 1). The LC3B antibody used for western blotting and IF 
assays below, detects endogenous levels of total LC3B protein.  
Cells were infected with MeV at an MOI of 0.5 either in the presence of 
absence of 10µM cf2642 and chloroquine controls. Following 
infection/treatment (12 hr), the cells were harvested and analyzed by 
western blotting. (see section 2.2.15 for methods).  
 
 
Fig 3.5. cf2642 inhibits MeV and induced autophagy: (A) VeroSLAM 
cells were infected with MeV at MOI 0.5 and treated in the presence or 
absence of 10 μM cf2642 and 50 μM Chloroquine as indicated. Post 
infection (12 hr), LC3-II expression was analyzed by western blot- one 
representative assay is shown. (B) Bar chart shows the relative intensity of 
LC3-II normalized to the GAPDH control. Student’s t-test was performed to 
assess the p values; *p < 0.05, **p < 0.01. Error bars represent mean ± SE 
of three independent experiments.  
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Fig 3.5 A-B shows that minimal expression of LC3-II was observed in both 
vehicle control and cf2642 treated conditions (lanes 1 and 2 respectively), 
while LC3-II was significantly increased in the presence of chloroquine (lane 
3). There was slightly increased LC3-II expression in the MeV control (lane 
4), that was reduced in the presence of cf2642 (lane 6). MeV infection in the 
presence of chloroquine saw a significant increase in LC32 expression (lane 
5) and this was reduced in the presence of cf2642 (lane 7). Overall, low 
expression of LC3-I was seen in all conditions except in virus infected cells 
treated with both cf2642 and chloroquine (lane 7) (Fig 3.5 A). 
Autophagy is a degradative cellular process that occurs as part of the cells 
mechanism of getting rid of damaged organelles, dysfunctional proteins, or 
infectious microorganisms (Parzych and Klionsky, 2014, Rozières et al., 
2017). Like many other viruses, MeV also induces autophagy as part of its 
life cycle and this helps in improving virus spread and escaping the host cell 
mediated immunity (Richetta et al., 2013). To test whether cf2642 inhibited 
MeV induced autophagy in VeroSLAM cells, a western blot analysis was 
performed to test the expression levels of the autophagy marker LC3-II in 
cells infected with MeV w/o 10µM cf2642. LC3-II is often used as a marker 
for autophagy flux changes because it is the only protein which stably 
associates with the autophagosome complex. Hence during an autophagy 
flux, the increase in the number of autophagosomes would lead to an 
increase in intracellular LC3-II levels. Autophagy is a dynamic process 
occurring in cells and while studying differences in autophagy flux using 
western blot analysis, it is important to confirm that the inhibition of 
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autophagy seen as a decrease in LC3-II protein levels is not because of an 
increased autophagy flux that results in rapid degradation of the protein 
(Loos et al., 2014). This can be solved using a lysosomotropic agent like 
chloroquine, which blocks the fusion of autophagosome-lysosome resulting 
in the accumulation of LC3-II positive autophagosomes in the cell 
(Mizushima et al., 2010). Hence, when cells are undergoing an autophagy 
flux, an increase in LC3-II expression in the presence of chloroquine, 
compared to that in the absence of the drug, will represent the overall 
number of autophagosomes that would have been degraded by autophagy 
(Yoshii and Mizushima, 2017). The western blot results show low levels of 
LC3-II expression in the vehicle control, indicating basal autophagy and this 
was unaffected in the presence of cf2642. The sharp increase in LC3-II 
expression seen in the presence of chloroquine indicates accumulation of 
autophagosomes due to the inhibition of autopahgosome-lysosome fusion. 
The MeV control caused only a slight increase in autophagy and this was 
partially reduced in the presence of cf2642, as seen by the slight decrease 
in LC3-II expression. No significant differences in LC3-II expression levels 
was seen between the chloroquine control and MeV + chloroquine 
condition, suggesting that the MeV-induced autophagy was minimal. 
However, when cf2642 was present along with MeV and chloroquine, this 
caused a significant decrease in autophagy compared to the MeV + 
chloroquine condition. This peak in LC3-II expression seen in both these 
conditions is the result of amplified LC3-II accumulation in the cell as a 
result of the inhibition of autophagosome-lysosome fusion by chloroquine. 
Since the virus induced increase in LC3-II expression was minimal, it is 
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difficult to interpret these results in terms of autophagy inhibition by cf2642 
and further experiments using longer infection/treatment time points may be 
required for conclusive data.  
3.3. Summary 
Previous work performed using cf2642 has shown the antiviral activity of this 
drug against both MeV and VACVin vitro and that a common cellular target 
might be affected. A series of L-ddBCNAs with varying lipophilic side chain 
lengths were tested against these two viruses and a structure activity 
relationship showed that the antiviral activity was dependent on the length of 
the lipophilic side chain of these compounds(McGuigan et al., 2013).  Prior 
to beginning MoA experiments using cf2642, the effect of cf2642 on cell 
viability was tested using two different cell lines namely HeLa and 
VeroSLAM. Although VeroSLAM cells were found to be more sensitive to 
the effects of cf2642, both cell lines remained viable at 12 hr post treatment. 
Viral plaque assay results showed a dose dependent decrease in MeV titer 
which demonstrated that the anti-MeV activity of cf2642 was not only limited 
to B95a cells, as shown in previous studies by Dr. Farleigh, but was 
effective also in VeroSLAM cells. This was also supported by the fact that 
treatment with cf2642 inhibited MeV induced syncytia in these cells. Based 
on the hypothesis that cf2642 inhibits a cellular target, subsequent work was 
focussed on testing the effects of this drug on a cellular process called 
autophagy that is crucial for the infectious cycle of MeV. Western blot 
analysis of autophagy did not reveal a significant increase in LC3-II 
expression in the presence of MeV and hence, a clear effect of cf2642 on 
this process was not observed. Confocal microscopy analysis revealed the 
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appearance of large LC3 positive structures in MeV control, that was mostly 
reduced in the presence of cf2642.  
Note: Upon initiation of my period in the School of Pharmacy, it came to 
notice that the VeroSLAM cells used to perform some of the earlier 
experiments (sections 3.2.3 and 3.2.5) in this chapter may have been 
contaminated with mycoplasma. This was identified when the cells were 
moved from the Department of Medical Microbiology to the School of 
Pharmacy. The exact period of contamination is unknown.  Figure 3.2.3 in 
this Chapter was obtained from the original cells. Attempts to repeat the 
analysis were unsuccessful and the period in Germany did not allow multiple 
attempts. However, it has already been shown that cf2642 at these 
concentrations was used her inhibit MeV replication and VACV plaque 
formation (Farleigh, 2014).All the other data in this chapter were repeated in 
mycoplasma free cells at the School of Pharmacy or the Bundeswehr 
institute and the original data is not shown in this thesis.  This issue has also 
affected my ability to add other experimental data into this short chapter.  All 
experiments presented in the longer Chapters 4 and 5 were performed in 
mycoplasma free cells.  
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Chapter 4 - Endocytic characterisation to 
elucidate the effects of cf2642 on cells 
 
4.1. Introduction 
 
The previous chapter explored the consequences of cf2642 treatment on 
MeV titers and its effects of virus induced cytopathic effects in VeroSLAM 
cells. The aim of the experiments in this chapter are to elucidate the 
pharmacological properties of cf2642 in an effort to understand the effects of 
the drug on cells, irrespective of MeV infection. On this account, endocytic 
characterisation studies were done in an effort to understand the effects of 
cf2642 on different subcellular structures.   
Endocytic characterisation is a home laboratory term that involves studies 
on the spatial distribution of intracellular vesicles and organelles that are 
involved in endocytosis. This includes not only the different components of 
the endolysosomal pathway, but also organelles such as theGolgi network 
that are indirectly involved in endocytosis. This methodology is based 
exclusively on the use of fluorescence microscopy, where subcellular 
structures are labelled either using live or fixed cell microscopy. While live 
cell imaging allows the direct visualization of endocytic structures using 
fluorescent endocytic probes, fixed cell imaging involves halting cellular 
processes at specific points in time to label subcellular structures or 
organelles with specific antibodies or dyes. The spatial organization of the 
cell cytoskeleton is critical to all endocytic events (Smythe and Ayscough, 
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2006) and hence this also forms an integral component of endocytic 
characterisation.  
The use of dextran conjugated fluorophores has been widely used as non-
invasive optical imaging probes for the study of endocytosis by live cell 
microscopy (Varshosaz, 2012, He et al., 2018). Dextran are high molecular 
weight hydrophilic polysaccharides that are non-toxic to cells, relatively inert 
and contain α-1,6-polyglucose linkages resistant to cellular glycosidases, 
making them ideal for use as live cell probes (Hu et al., 2009).  Dextran 
does not bind to a cellular receptor; thus it may enter cells through a number 
of endocytic pathways. It has been widely used as a marker for growth 
factor induced macropinocytosis(Jones, 2007).  It has been shown that 
dextran accumulates in LAMP1 positive lysosomes after endosomal 
trafficking throughRab7 positive late endosomes(Humphries IV et al., 2011). 
When incubated with cells as a fluorescent probe, dextran can enter and 
label the entire endolysosomal system. The use of dextran in experiments 
performed in this chapter involves a pulse-chase process wherein, cells are 
first “pulsed” with dextran-conjugated fluorophores for a brief time period (1-
3 hrs) to allow uptake. Following this, cells are washed to remove any 
conjugates that may be present on the cell surface and in the extracellular 
medium. Cells are then incubated with fresh cell culture medium to allow a 
much longer “chase”, to proceed; here the probe will be transported to 
lysosomes or potentially recycled. At the end of the chase period only 
lysosomes will be labelled with the probe and this then allows live cell 
imaging confocal microscopy the opportunity to assess whether any other 
molecule internalised to cells via endocytosis is also delivered to lysosomes. 
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Additionally, it allows for selective analysis of the effects of agents on the 
distribution of lysosomes.  
4.2. Results and Interpretation 
4.2.1. Effect of cf2642 on lysosomal scattering in HeLa cells 
 
A previous study reported that lysosomes scatter towards the cell periphery 
when HeLa cells were incubated with cf2642(Farleigh, 2014). This 
phenomenon was detected by immunolabelling the lysosomes using CD63 
(LAMP III) antibodies. Here the experiment was repeated in live HeLa and 
VeroSLAM cells which has the inherent advantage that the effects of cf2642 
on lysosomal positioning can be visualized in real-time by labelling them 
with fluorophore conjugated dextran. Briefly, HeLa cells seeded in glass 
bottom MatTek dishes were pulse-chased with two different dextran Alexa 
Fluor conjugates (see methods section 2.2.6 in Chapter 2) in the presence 
of absence of cf2642.  This allowed for analysis of the localisation of dextran 
by qualitative visualisation and also via labelling the nucleus, determining 
the position of the lysosomes as function of their distance away from the 
nucleus could also be analyzed. 
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Fig 4.1. cf2642 causes the scattering of LE/lysosomes in HeLa cells. 
Cells were subjected to 3 hr pulse with 0.2 mg/mL Dextran-488 and 8 hr 
chase followed by a 12 hr incubation w/o 10µM c2642. Cells were then 
further pulsed for 3 hr with 0.2 mg/mL Dextran-Alexa 647 and chased for 3 
hr w/o 10µM cf2642 before live imaging.(A) shows cells treated with vehicle 
(DMSO) and (B) shows cf2642 treated cells. Arrows indicate colocalization 
of Dextran-Alexa 488 and 647 labelled late endosomes/lysosomes and 
dotted arrows show aggregated lysosomal structures.(C) The dispersal of 
lysosomes up to 3 µM from the nucleus was calculated by drawing 
concentric ROIs up to 3 µM distance from nucleus. The intensity of 
fluorescence is plotted against distances from the nucleus. The error bars 
show mean ± SE of three independent experiments.  (Scale bars = 20 µm) 
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Results show that Dextran-488/647 labelled LE/lysosomes in the vehicle 
control were mostly grouped together and localized in close proximity with 
the nucleus and that there was colocalization between the two fluorophores 
(Fig 4.1 A). In the presence of cf2642, the labelled endocytic vesicles 
appeared to be more scattered and positioned away from the nucleus. 
There was no evidence that the drug was impeding the delivery of Dextran 
647 to Dextran 488 labelled structures (Fig 4.1 B). The maximum projection 
image also suggests that cf2642 is also affecting the morphology of the 
lysosomes manifest as aggregated structures in Figure 4.1 B zoom. The 
peripheral LE/lysosomes in cf2642 treated cells labelled with Dextran-647 
were of higher intensity than that of the controls (Fig 4.1 C).  
The initial 3 hr pulse with Dextran-488 and 8 hr chase allowed the 
internalization and transport of the fluorophore probe via the endolysosomal 
pathway to lysosomes. At this point in the experiment only lysosomes are 
fluorescent as the probe had been emptied from other endocytic organelles 
or recycled.  The subsequent analysis in the absence or presence of cf2642 
allowed for selective subcellular distribution of lysosomes (Dextran-488) and 
also Dextran-647 that had been pulsed to label the entire endolysosomal 
system. Shown was the expected colocalization of the two probes and no 
evidence that cf2642 was inhibiting traffic of dextran (647) to lysosomes. 
Noted however was a very pronounced effect of the drug on the subcellular 
localisation of lysosomes. At the end of the experiments the Dextran-488 
fluorescence was low and this may be due to the fact that some of it was 
being recycled  (Baravalle et al., 2005).  
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4.2.2. Effect of cf2642 on lysosomal scattering in VeroSLAM cells 
 
Since VeroSLAM cells were used in most experiments of this thesis, the 
experiment in section 4.2.1 above was repeated to test the effect of cf2642 
on lysosomal positioning in these cells. The protocol used here was the 
same as done for HeLa cells(see methods section 2.2.6 in Chapter 2).  
 
 
 
 
109 
 
 
Fig 4.2. Late endosomes/lysosome dispersal in VeroSLAM cells: Cells 
were subjected to 3 hr pulse with 0.2 mg/mL Dextran-488 and 8 hr chase 
followed by a 12 hr incubation w/o 10µM c2642. Cells were then further 
pulsed for 3 hr with 0.2 mg/mL Dextran-Alexa 647 and chased for 3 hr w/o 
10µM cf2642 before live imaging. (A) shows cells treated with vehicle 
(DMSO) and (B) shows cf2642 treated cells. Arrows indicate colocalization 
of Dextran-Alexa 488 and 647 labelled late endosomes/lysosomes and 
dotted arrows show aggregated lysosomal structures. (C) The dispersal of 
lysosomes up to 3 µM from the nucleus was calculated by drawing 
concentric ROIs up to 3 µM distance from nucleus. The intensity of 
fluorescence is plotted against distances from the nucleus. The error bars 
show mean ± SE of three independent experiments.  (Scale bars = 20 µm) 
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In general, the lysosomes were more scattered in control VeroSLAM cells 
(Fig 4.2 A) compared with Hela and there was not an obvious effect on 
distribution of these organelles in cells treated with cf2642.The drug treated 
cells did however highlight large aggregates of fluorescence that was not 
noted in the HeLa cells (Fig 4.2 B Zoom). The overall fluorescence 
intensities of both Dextran-488 and 647 labelled vesicles were much higher 
compared to that of HeLa cells observed above. However, no significant 
differences in fluorescence intensities of these vesicles were observed 
between the control and cf2642 treated cells (Fig 4.2 C). As observed in the 
case of HeLa cells above, treatment of VeroSLAM cells did not have any 
effects in the endocytic uptake of dextran labelled fluorophores.  
4.2.3. Endocytic Characterisation 
 
As part of endocytic profiling studies, immunolabelling of various endosomal 
compartments were performed in both HeLa and VeroSLAM cells at various 
time points.  
4.2.3.1. Effect of cf2642 on Rab5 labelled vesicles in HeLa and 
VeroSLAM cells 
 
Rab5 is a GTPase of the Ras superfamily that are localized on the early 
endosomes and regulate their maturation to late endosomesand is a widely 
used marker for early endosomes (Pfeffer, 2017). Labelling of Rab5 positive 
vesicles were performed to test whether cf2642 had any effect on the 
localisation of early endosomes. Briefly, cells were treated or not with 10µM 
cf2642 at two different time points and fixed, before immunolabelling. (see 
section 2.2.3.2.3.3 in Chapter 2).  
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Fig 4.3 Effect of cf2642 on Rab5 in HeLa cells. Cells were treated or not 
with 10µM cf2642 for (A) 2 hr or (B) 12 hr and fixed with ice-cold methanol 
before immunolabelling with a Rab5 specific antibody. The data represent 
one representative image of three independent experiments. (Scale bars = 
20 µm) 
 
Figure 4.3 highlights scattered and perinuclear localization of Rab5 positive 
structures in the control cells of both 2 and 12 hr time points. Cell treated 
with cf2642 at the 2 hr time point were very similar to control cells but a 
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longer (12 hr) incubation with the drug resulted in a more scattered 
localisation compared to the shorter 2hr time point investigated here.  
 
 
Fig 4.4 Effect of cf2642 on Rab5 in Vero SLAM cells. Cells were treated 
or not with 10µM cf2642 for (A) 2 hr or (B) 12 hr and fixed with ice-cold 
methanol before immunolabelling with a Rab5 specific antibody. The data 
represent one representative image of three independent experiments. 
(Scale bars = 20 µm) 
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Perinuclear localization of Rab5 positive structures in VeroSLAM cells were 
similar to that of HeLa cells above. cf2642 caused the scattering of Rab5 
vesicles 12 hr post treatment, though the positioning of these vesicles 
remained unchanged when treated for 2 hr (Figure 4.4). The data also 
highlights that the antibody used here also recognizes monkey Rab5; the 
same is true for antibodies recognizing EEA1 and Lamp1 below. 
The scattering of Rab5 positive vesicles were prominent only after 
prolonged (12hr) treatment of both HeLa and VeroSLAM cells, indicating the 
this is associated with the late, rather than early effects on the drug on cells. 
It also shows that this scattering of vesicles is not limited to lysosomes as 
seen earlier (section 4.3.1).  
 
4.2.3.2. Effect of cf2642 on EEA1 labelled vesicles in HeLa and 
VeroSLAM cells 
 
EEA1 mediates the homotypic fusion of early endosomes and is a major 
effector of Rab5 GTPases (Mills et al., 1999)(Stenmark et al., 1996). Given 
that cf2642 causes the scattering of Rab5 positive vesicles (section 4.4.1), 
the effect of this drug on EEA1 positive structures was tested in both cell 
lines. 
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Fig 4.5 Effect of cf2642 on EEA1 in HeLa cells. Cells were treated or not 
with 10µM cf2642 for (A) 2 hr or (B) 12 hr and fixed with 3% 
paraformaldehyde, permeabilized and immunolabelled with a EEA1 specific 
antibody. The data represent one representative image of three independent 
experiments. (Scale bars = 20 µm) 
 
The results show shows perinuclear EEA1 labelled structures particularly 
enriched in a juxtanuclear region in HeLa cells. As observed for Rab5, the 
drug caused a scattering of these structures that was particularly prominent 
at the 12 hr time point. Although the cells manipulation used here did result 
in EEA1 scattering in control cells, the perinuclear positioning of these 
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vesicles was clearly observed in cells 12 hr post treatment with cf2642 (Fig 
4.5). Since the scattering of vesicles in the was seen only at 12 hr post 
treatment, which could mean that either this requires prolonged incubation 
with the drug or that it is associated with the late effects of cf2642.  
 
116 
 
 
Fig 4.6 Effect of cf2642 on EEA1 in VeroSLAM cells. Cells were treated 
or not with 10µM cf2642 for (A) 2 hr or (B) 12 hr and fixed with 3% 
paraformaldehyde, permeabilized and immunolabelled with a EEA1 specific 
antibody. The data represent one representative image of three independent 
experiments. (Scale bars = 20 µm) 
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EEA1 labelling in VeroSLAM cells also revealed predominantly juxtanuclear 
localization of these vesicles and no differences were observed between 
control and cf2642 treated cells at 2 hr time point. These vesicles were 
much more scattered in control cells 12 hr post treatment, similar to the 
cf2642 treated cells (Fig 4.6). It is unclear why the EEA1 labelled vesicles in 
12 hr treated vehicle controls were scattered, but may be associated with 
the manipulation of cells during the experiment. Since there were no 
differences between the control and cf2642 treated cells at this time point, it 
is not possible to interpret the data as being a true effect of cf2642.  
 
4.2.3.3. LAMP1 labelling in HeLa and VeroSLAM cells 
 
LAMP1 is a very widely used lysosomal marker and has been shown to 
mediate fusion of lysosomes and autophagosomes; there is also evidence 
that the protein is located on late endosomes (Eskelinen, 2006). Given that 
cf2642 inhibited measles induced autophagy, its effect on LAMP1 labelled 
structures was tested. Cells were incubated in the presence or absence for 
10µM cf2642 for 12 hr and fixed before immunolabelling for this protein.  
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Fig 4.7 Effect of cf2642 on LAMP1 positive structures. (A) HeLa and (B) 
VeroSLAM cells were treated or not with 10µM cf2642 for 12 hr and fixed 
with 3% paraformaldehyde, permeabilized and immunolabelled with a 
LAMP1 specific antibody. Arrows show the presence of amorphous LAMP1 
positive structures. The data represent one representative image of two 
independent experiments. (Scale bars = 20 µm) 
 
The results in Figure 4.7 highlight that LAMP1 positive structures in both 
HeLa and Vero SLAM cells are highly enriched in a juxtanuclear cluster. 
Most notably in HeLa cells the LAMP1 phenotype in cf2642 treated cells 
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was very different with the vesicles scattered all over the cytoplasm. A 
similar but less pronounced difference was observed in VeroSLAM cells that 
were noted for having large amorphous LAMP1 labelled 
structures.Lysosomes are known to be positioned at the cell periphery in 
responses to decreased intracellular pH (Heuser, 1989). The cf2642 
scattering phenomenon observed in this study may therefore be a 
consequence of this effect and this merits further investigation. Commercial 
probes such as 5-(and-6)-carboxyl seminaphthorhodafluor (SNARF-1) are 
available for measuring intracellular pH (Ramshesh and Lemasters, 2012). 
The laboratory has experience of performing experiments with this probe 
and given more time these would be interesting experiments to perform 
Overall, the results from experiments 4.3.1 to 4.3.3 has shown that the 
scattering of vesicles was common to Rab5, EEA1 and LAMP1 positive 
structures, indicating that the effects of cf2642 is not limited to any single 
population of endocytic vesicles. As MeV has been recently shown to enter 
cells by endocytosis, (Delpeut et al., 2017, Goncalves-Carneiro et al., 2017) 
these effects could conceivably affect the ability of the virus to effectively 
use this process for entry and replication. This study did not however show 
that endocytosis was required for viral replication. Previous unpublished 
studies in our group have strongly suggested that the drug does not affect 
MeV entry (Farleigh, 2014)) but it remains to be seen whether subsequent 
downstream traffic is affected by the drug.  
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4.2.3.4. Effect of cf2642 on actin network 
 
Actin filaments provide structural integrity to cells and the actin cytoskeleton 
is heavily implicated in endocytosis, especially at locations of the initiation of 
endocytic processes at the plasma membrane (Carlsson, 2018, Mooren et 
al., 2012). Actin has particular relevance in driving the formation of plasma 
membrane ruffles that are extremely prominent in macropinocytosis 
(Falcone et al., 2006). Actin depolymerising drugs such as cytochalasin D 
are well characterised  inhibitors  of this process (Dutta and Donaldson, 
2012) 
 
121 
 
 
Fig 4.8 Effect of cf2642 on actin network. (A) HeLa and (B) VeroSLAM 
cells were treated or not with 10µM cf2642 for 12 hr and fixed with 3% 
paraformaldehyde and labelled with rhodamine phalloidin to visualize the 
actin network. Arrows indicate actin ruffles. The data shows one 
representative image of three independent experiments. (Scale bars = 20 
µm) 
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Cells were incubated for 12 hrs with diluent control or cf2642 prior to fixing 
and labelling with the actin probe Rhodamine-Phalloidin, followed by 
confocal microscopy. Results in Figure 4.8 show clear labelling of actin 
microfilaments in both cell types. VeroSLAM cells in the absence of cf2642 
showed evidence of actin ruffles, but these were mostly absent in the drug 
treated cells. No differences were observed between control and cf2642 
treated HeLa cells. The absence of any observable effects on the actin 
cytoskeleton in the presence of cf2642 provides more evidence to the fact 
that the drug is non-toxic at this time point. For example, cytotoxicity 
resulting in apoptosis of cells would cause extensive changes to the actin 
network including cell rounding and membrane blebbing (Desouza et al., 
2012).  
 
4.2.3.5. Effect of cf2642 on the Golgi network 
 
The goal of this study was to explore the possible effects of cf2642 on the 
Golgi apparatus that is heavily involved in both secretory and endocytic 
pathways.  Membrane traffic between the endoplasmic reticulum (ER) and 
the Golgi complex is also critical for the assembly of enveloped viruses like 
MeV and VACV(Vale-Costa and Amorim, 2016, Brimacombe et al., 2011). 
In such cases, defects on ER to Golgi traffic can have significant inhibitory 
effects on virus egress from cells. To label the Golgi control of cf2642 
treated cells were treated with BODIPY FL C5- ceramide (Chazotte, 2008) 
an established fluorescent probe to tag this organelle for fluorescence 
microscopy.  
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Fig 4.9 Effect of cf2642 on Golgi network. (A) HeLa and (B) VeroSLAM 
cells were treated or not with 10µM cf2642 for 12 hr and incubated on ice 
with 5µM BODIPY FL C5 - ceramide for 30 min, washed and incubated for 
30 min with fresh medium at TC conditions. Nuclei were labelled with 
Hoechst before imaging. The data shows one representative image of three 
independent experiments. (Scale bars = 20 µm) 
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Typical perinuclear localisation of the BODIPY-ceramide labelled Golgi 
apparatus was seen in HeLa cells but a quite different localisation was seen 
in VeroSLAM cells where this probe showed high heterogeneity within the 
cell population with many cells showing more scattered labelling that is not 
typically observed with this probe. In some cells, the probe labelled distinct 
structures, almost completely surrounding the nucleus. No obvious 
differences were observed in this localisation, in both cell types, after 
incubation with cf2642 (Fig4.9). Enveloped viruses like measles use the 
cellular secretory pathway for membrane biogenesis and any disruption of 
this process could invariable hamper the virus lifecycle. The BODIPY FL C5- 
ceramide marker used here is a well-documented fluorescent structural 
marker for labelling the Golgi apparatus (Chazotte, 2008). The absence of 
any observable changes between control and cf26642 treated cells shows 
that the secretory pathway is not affected.  
 
4.2.4. LDH cytotoxicity assay for the study of plasma membrane 
damage 
 
Lactate dehydrogenase (LDH) is a cellular enzyme that is released into the 
extracellular environment upon plasma membrane damage (Chan et al., 
2013b) Here it can be measured as the added lactate is converted to 
pyruvate via the reduction of NAD+ to NADH in the presence of LDH. The 
enzyme diaphorase then uses NADH to reduce the tetrazolium salt (INT) 
present in the assay reagent into a red formazan product, that is directly 
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proportional to the amount of LDH released. The level of formazan formation 
can be calculated by measuring absorbance at 490 nm. (see section 2.2.10 
in Chapter 2 for methodology). This assay was done to test whether the 
cf2642 effects observed above were caused by plasma membrane damage; 
an unidentified agent obtained with the assay kit was used as a positive 
control for membrane permeabilization. 
 
 
Fig 4.10 cf2642 causes the release of LDH in VeroSLAM cells. 
VeroSLAM cells were treated with increasing concentrations of cf2642 as 
indicated and 24 hr post treatment, the amount of LDH released into the 
extracellular medium was measured using the LDH cytotoxicity assay. (A) 
shows the amount of LDH released and (B) indicates the corresponding 
cytotoxicity. Student’s t-test was performed to assess the p values; *p < 
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0.05, **p < 0.01. Error bars represent mean ± SE of three independent 
experiments. 
 
Data in Figure 4.10 A and B show the amount of LDH released as a product 
of enzyme activity and the cytotoxicity calculated as per manufacturer’s 
instructions.  The results indicate a dose dependentincrease of LDH release 
from cells in the presence of cf2642 that is significant at 5µM or higher. 
However, this release caused <5 % toxicity compared to 12% observed with 
the LDH positive control. Though a significant amount of LDH was released 
form cells with cf2642 at 5µM or higher, this only resulted in a 4.4 % 
increase in cytotoxicity. This suggest that the noted 27% decrease in 
viability by cf2642 (Chapter 3) was most likely the result of apoptosis 
induction and not cell necrosis (Chan et al., 2013a, Wang et al., 2014).  It 
does however remain to be determined if cf2642 effects on plasma 
membrane permeability occur at early time points and that the cells can 
overcome this by repair and that released LDH is degraded (Kendig and 
Tarloff, 2007).  This could be tested by performing the same LDH release 
assays at much earlier time points after cf2642 addition. 
4.3. Summary 
 
The findings from live imaging experiments using dextran fluorophores 
demonstrated that treatment of HeLa and VeroSLAM cells with 10µM cf2642 
did not have any effects on the constitutive uptake of extracellular cargo via 
endocytosis and their subsequent transport along the endocytic pathway. 
Although the labelled LE/lysosomes were scattered in the presence of 
cf6242, this was also evidence of mislocalisation of early edosomes 
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highlighted by Rab5 and EEA1positive structures. It remains to be seen 
whether this scattering phenomenon induced by cf2642 can have effects in 
MeV entry. Recent publications have shown the MeV uses an alternate 
mode of cell entry, to fusion with the plasma membrane, utilising a clathrin-
independent endocytic uptake mechanism called macropinocytosis. MeV 
particles that enter via this pathway are localized in large vesicles called 
macropinosomes (Goncalves-Carneiro et al., 2017, Delpeut et al., 2017). It 
is not known how the virus escapes these vesicles to underdo replication, 
but any effects of cf2642 on these structures and subsequent maturation 
may have direct effects on MeV entry occurring via macropinocytosis. No 
apparent differences were observed in the Golgi network labelled with 
BODIPY FLC5 ceramide markers. Some of the effects observed in this 
chapter may have been caused by cf2642 cell injury and plasma membrane 
permeability. The results from actin labelling suggested this was not the 
case as no effects were observed but an LDH assay was performed to 
investigate this. Thisshowed no plasma membrane permeabilization strongly 
suggesting that cf2642 induced toxicity is most likely due to the induction of 
apoptosis and this occurs only after 12-14 hr post treatment with the drug.  
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Chapter 5: Investigation into the mechanism by 
which cf2642 inhibits MeV infection 
 
5.1. Introduction 
 
Previous work has shown that the antiviral effect of cf2642 against VACV 
occurred within two hours post infection. A range of possible targets were 
tested which indicated that the drug did not affect virus entry but targeted a 
cellular component that is required throughout the virus life cycle (Farleigh, 
2014). Since the antiviral activity of cf2642 was seen against both VACVand 
MeV, it was speculated that the drug possibly affected a commonly used 
membrane microdomain. (McGuigan et al., 2013). Similar MoA studies 
when performed with MeV (rather than VACV) in a different cell line could 
provide more insights into the cellular targets of cf2642. An added 
advantage of such an approach is that these findings can then be correlated 
with the previous MoA data to narrow down the precise cellular target of 
cf2642 that hinders the life cycle of both viruses. The experiments described 
in this chapter were performed to elucidate the early effects of cf2642 on 
VeroSLAM cells that in turn contributes to its anti-measles activity.  
MeV entry is initiated by specific interaction between the virus H protein and 
its receptor SLAM/CD150 (Laksono et al., 2016). This is in turn followed by 
a cascade of events involving conformational changes of the virus H and 
fusion (F) proteins, culminating in virus entry via the fusion of virus and host 
cell plasma membrane at neutral pH (Plemper et al., 2011a) (see section 
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1.1.3 in Chapter 1). As described in 1.7.3 macropinocytosis is an endocytic 
pathway that manifests as actin-dependent plasma membrane protrusions 
or ruffles driving large volumes of the extracellular milieu into cells. These 
membrane ruffles fold back upon the cells, thereby enclosing the 
extracellular components within large intracellular structures called 
macropinosomes (Kerr and Teasdale, 2009). Macropinocytosis has also 
been exploited by enveloped viruses including Ebolavirus, influenza A, 
VACVand Nipah virus (Mercer and Helenius, 2009).  
The entry of MeV Ed via interaction with CD46 receptors has been shown to 
result in the internalization and subsequent downregulation of these 
receptors from the plasma membrane. The initial MeV Ed - receptor 
interaction on the plasma membrane of susceptible cells results in clustering 
of CD46 receptors and their internalization via a macropinocytosis-like 
pathway involving the formation of pseudopodia and membrane 
protrusions(Crimeen-Irwin et al., 2003). A similar phenomenon was also 
shown to occur when the CD46 receptors are clustered using antibodies in 
the absence of live virus .  This is different from the constitutively occurring 
pathway wherein CD46 receptors are internalized via clathrin mediated 
endocytosis and recycled back to the cell surface via the recycling pathway 
(Crimeen-Irwin et al., 2003). Recent studies using SLAM positive cells have 
intriguingly shown a similar macropinocytosis-like entry mechanism for 
MeV(Delpeut et al., 2017, Goncalves-Carneiro et al., 2017). However, to 
date there has not been any study involving the antibody-mediated 
clustering of SLAM to study MeV entry.  
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This chapter was primarily focused on MoA studies pertaining to the 
hypothesis that the effects of cf2642 on MeV induced macropinocytosis as 
an alternative uptake mechanism to  that of direct fusion with the plasma 
membrane. The experiments and data are presented below. 
5.2. Results and Interpretation 
5.2.1. MeV induced uptake of Dextran-488 in VeroSLAM cells 
 
The administration of MeV to SLAM positive cells in vitro has been shown to 
result in extensive membrane protrusions and blebs, similar to 
macropinocytosis. These changes occur very early during the virus-cell 
interaction and are thought to occur as a result of the clustering of SLAM 
receptors on the membrane surface (Goncalves-Carneiro et al., 2017). 
Another study reported the use of fluorescent dextran during the early 
periods of MeV interaction with VeroSLAM cells, to show that MeV entry can 
also occurs via a macropinocytosis-like pathway. In this study, an increased 
uptake of Dextran conjugates was shown to occur at 15 min post 
administration of MeV with cells, and was speculated to be a direct result of 
virus induced SLAM receptor clustering (Delpeut et al., 2017). As part of the 
MoA studies in this chapter, initial experiments were performed to test 
whether this finding can be replicated in our laboratory setting.   
VeroSLAM cells were exposed to MeV as previously described (Delpeut et 
al., 2017), but with minor modifications. Firstly, the optimum MOI of MeV 
which can induce high uptake to Dextran-488 at 15 min post administration 
of virus was determined. VeroSLAM cells were washed with ice-cold PBS 
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and infected with MeV (MOI 0-100) for 60 min. This was followed by the 
addition of Dextran-488 on ice at different time points and the uptake was 
measured by FACS after bringing the cells to 37ºC and fixing with 3% PFA. 
(see methods section 2.2.18.1.1 for details and section 2.2.20.2.3 for details 
on flow cytometry analysis) 
 
 
Fig. 5.1. Dextran-488 uptake induced by MeV is dependent on the MOI. 
VeroSLAM cells were infected or not with MeV of increasing MOI’s 5, 10, 50 
and 100 on ice for 1 hr and moved to 37°C for 15 min. 0.1 mg/ml, Dextran-
488 was added during the last 5 min and the fluorescence intensity was 
analyzed by flow cytometry. The results were quantified and shown as 
percentage increase of Dextran-488 intensity normalized to the non-infected 
controls. The results represent data from 1 experiment. 
 
The data in Fig 5.1 depicts the effect of increasing MOIs on the uptake of 
Dextran-488 in VeroSLAM cells. Results as n=1 suggest that there is a 
relationship between virus numbers and dextran endocytosis with 100 MOI 
giving a clear increase in this process. This MOI was then used in the 
subsequent experiment that also allowed the investigation of whether 
cf2642 could influence this increase in dextran uptake. The effect of time, 
following viral infection, on dextran uptake was also analyzed. 
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Fig 5.2. MeV stimulates Dextran-488 uptake in VeroSLAM cells, and is 
inhibited by cf2642. Cells were infected or not with MeV (MOI-100) on ice 
for 60 min and moved to 37°C for the indicated time periods. 0.1mg/mL 
Dextran-488 in the presence of 10µM cf2642 or vehicle (DMSO) was added 
during the last 5 min and the fluorescence intensity was analyzed by flow 
cytometry. The vehicle control served as a measure of steady state uptake 
of Dextran-488. (A) The results were quantified and shown as percentage 
increase of Dextran-488 intensity normalized to the vehicle control. 
Student’s t-test was performed to assess the p values; *p < 0.05. Error bars 
represent mean ± SE of four independent experiments. (B) Histogram 
overlays illustrating the effect of cf2642 on Dextran-488 intensity. Data from 
one representative experiment is shown. 
 
Results in Fig 5.2 shows a 41% increase in Dextran-488 uptake over the 
vehicle control occurring at 15 min post administration of MeV in VeroSLAM 
cells and this was reduced to control levels in the presence of 10µM cf2642. 
Surprisingly dextran uptake was reversed to control levels after 30 mins. This is 
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also clearly evident by the shift in fluorescence intensity as seen in the 
histogram overlay in Fig 5.2B. Uninfected controls when treated with cf2642 
resulted in minor, non-significant increases in Dextran-488 uptake at both 5 and 
15 min time points. At all three time points, MeV infected cells when treated 
with cf2642, caused the reduced uptake of Dextran-488. In agreement with 
previous reports (Delpeut et al., 2017), Dextran-488 uptake experiments 
demonstrated that MeV induces a transient increase in fluid-phase uptake in 
VeroSLAM cells at 15 min post-administration of virus. In the presence of 10µM 
cf2642, this effect was significantly reversed after only very short incubations. 
Here, the clear effects of virus induced macropinocytosis required MOI of 100 
that is higher than previously used to show these effects (Delpeut et al., 2017). 
However, these published studies were performed in serum starved cells that 
are much more responsive to plasma membrane activation of receptors. The 
induction of macropinocytosis and associated changes in cell membrane 
morphology occurring during MeV entry into SLAM positive cells has been 
speculated to be a direct result of SLAM receptor clustering mediated by the 
virus particles (Goncalves-Carneiro et al., 2017). 
5.2.2. Dextran-488 uptake induced by SLAM-receptor clustering with 
polyclonal antibodies 
 
SLAM receptor clustering using antibodies was done to mimic MeV induced 
effects on cells in a virus-free setting. By replicating virus-induced effects on 
cells using this technique, it is possible to better characterize the cell 
targeting effects of cf2642. The addition of polyclonal antibodies against 
plasma membrane receptors is a well characterized method for inducing 
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clustering (Crimeen-Irwin et al., 2003). SLAM was initially performed to test 
whether the virus induced Dextran-488 uptake shown in Fig 5.2 can be 
replicated in the absence of live MeV. This was done by using polyclonal 
antibodies against the SLAM to cluster these receptors. The methodology 
followed was similar to that described in section 5.1, except that polyclonal 
anti-SLAM antibodies were used instead of live virus (see section 2.2.18.1.2 
in methods and section 2.2.20.2.3 for details on flow cytometry analysis) 
. 
 
Fig 5.3.Clustering of SLAM receptors stimulates Dextran-488 uptake in 
VeroSLAM cells, and is inhibited by cf2642. Cells were incubated with 
6µg/mL polyclonal rabbit anti SLAM antibody for 60 min on ice, moved to 
37°C for the indicated time periods and 0.1mg/mL Dextran-488 in the 
presence of 10µM cf2642 or vehicle (DMSO) was added during the last 5 
min. Cells were then fixed with 3% PFA, washed with PBS and the 
fluorescence intensity was analyzed by flow cytometry. The results were 
quantified and shown as percentage increase of Dextran-488 intensity 
normalized to the vehicle control. The vehicle control served as a measure 
of steady state Dextran-488 uptake. Student’s t-test was performed to 
assess the P values; *p < 0.05. Error bars represent mean ± SE of four 
independent experiments 
 
Results shown in Fig 5.3 depicts a significant increase in Dextran-488 
uptake occurring at 30 min post addition of polyclonal anti-SLAM antibodies. 
This is also significantly reduced close to control levels in the presence of 
10µM cf2642. Comparatively low levels of uptake of Dextran-488 was 
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observed in the no antibody control - vehicle and cf2642 controls at all three 
time points, but none were statistically different from the controls. A similar 
increase was also observed with the cf2642 control at 5 min time point. 
Slightly higher uptake of Dextran-488 was seen in clustered cells at 5 min in 
the presence of cf2642, but this was also not statistically significant. 
Polyclonal anti-SLAM antibodies caused a significant increase in fluid-phase 
uptake of Dextran-488, but in this case at a later (30 min) time point 
compared to live virus (15 min). No significant increase in Dextran-488 
uptake was observed at this time point in the no cluster controls using 
monoclonal anti-SLAM antibodies. This confirms that the observed increase 
in fluid-phase endocytosis at 30 min is a direct result of SLAM-receptor 
clustering. This early induction of fluid-phase endocytosis with MeV 
suggests that the virus promotes earlier activation of macropinocytosis via 
SLAM interaction and/or interaction with another plasma membrane 
component. Moreover, the interactions of MeV and SLAM antibodies 
targeting this receptor may be disparate because of the differences in SLAM 
- binding sites on the virus particles (hemagglutinin) and antigen binding 
sites on the polyclonal antibodies. A previous study on the clustering of 
CD46 receptors induced either with measles vaccine strain (MeV-Vac) or 
antibodies showed that the valence of interactions between the virus and its 
receptor has a major influence on the cells response to these events 
(Crimeen-Irwin et al., 2003). Overall, the clustering induced results mimics 
the effects of MeV on macropinocytosis and associated increase in fluid-
phase endocytosis, and these processes are inhibited by cf2642.  
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5.2.3. Indirect SLAM-receptor clustering with primary-secondary 
antibody combination 
The objective behind using this method was to enable the observation of, 
what are postulated to be, changes associated with SLAM-receptor 
clustering by confocal microscopy. The non-availability of good directly 
labelled monoclonal antibodies against SLAM for confocal microscopy, 
restricts the use of direct SLAM clustering for IF assays. Thus an indirect 
method for clustering SLAM was used. VeroSLAM cells were briefly 
incubated (30 min) with mouse anti-SLAM monoclonal antibodies at 37ºC. 
This was then followed by incubation of cells with an anti-mouse secondary 
antibody that is conjugated with Alexa Fluor - 647. In a virus-free setting, 
these secondary antibodies mimics MeV particles that come into contact 
with cells during the initial stages of virus-cell interaction. The effect of 
SLAM clustering was then analyzed by microscopy at different time points 
post clustering w/o cf2642. An added advantage of using this methodology 
for IF experiments is that the fluorescence signal associated with SLAM, 
that is labelled by the Alexa Fluor -647 conjugated secondary antibody, is 
not lost upon fixation with PFA.  This allows the use to unlabelled anti-SLAM 
primary antibodies for these experiments.  
5.2.3.1. Calculation of protein concentration and dye:protein 
molar ratio for the Alexa fluor antibody used for SLAM 
clustering 
 
The indirect clustering of SLAM receptors was done using a commercially 
available Alexa Fluor-647 conjugated secondary antibody which contains 5 
mM sodium azide (NaN3) as a preservative. Since the experiment involves 
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incubation of live cells with this antibody, the NaN3 content was removed 
using centrifugal filtration (see methods section 2.2.16.1.1). 
 
Fig 5.4 Absorption spectrum of chicken anti mouse Alexa Fluor-647 
antibody solution. The commercially available chicken anti-mouse Alexa 
Fluor - 647 secondary antibody solution was purified by centrifugal filtration 
and absorbance measured at 280 to 650 nm using a Cary60 UV 
spectrophotometer. The values were compared with the unfiltered antibody 
(control). Figure shows the absorption spectrum for (A) Unfiltered antibody 
and (B) filtered antibody solutions.   
Absorption spectra (Fig 5.4) and molar extinction coefficients were used to 
calculate the numbers of fluorophores in the antibody, dye:protein  ratio (see 
methods section 2.2.16.1.2). The protein concentration for the unfiltered 
control and filtered antibody solutions were calculated to be 1.9 and 1.6 
mg/mL respectively. Using these protein concentration values, the 
dye:protein  molar ratio were found to be 2.0 for the unfiltered control and 
1.8 for the filtered antibody.   
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5.2.3.2. Dose-dependent response of Alexa Fluor-647 
conjugated secondary antibodies on SLAM internalization 
 
During live MeV infection, cells may be exposed to different titres of live 
virus particles during the virus entry. Hence, to best mimic MeV infection in 
a non-infectious setting by SLAM clustering, the cells were exposed to 
increasing concentrations of secondary antibody. This was also used to 
determine the optimum secondary antibody concentration to be used for 
subsequent SLAM clustering experiments.  
Briefly, live VeroSLAM cells were first incubated with 2 µg/mL anti-mouse 
SLAM antibody and then clustered with increasing concentrations of Alexa 
Fluor-647 secondary antibody at 37ºC in the presence or absence of 10µM 
cf2642. The cells were then fixed and incubated with LAMP1 antibodies 
directly labelled with the fluorophore FIT to label lysosomes. The 
fluorescence signal from directly labelled secondary antibodies (no primary) 
served as the label for SLAM receptors. The amount of internalized SLAM 
was then calculated using imagej (see methods section 2.2.16.1.4.2.1 for 
details). 
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Fig 5.5. Effect of secondary antibody concentration on SLAM 
internalization in VeroSLAM cells. Cells were incubated for 30 min with 
monoclonal mouse anti-SLAM antibody and then incubated for 60 min with 
increasing concentrations of anti-mouse Alexa Fluor-647 conjugated 
secondary antibodies. After a 60 min chase, cells were fixed with 3% PFA 
and labelled with LAMP1-FITC antibody to label lysosomes. The single 
section images show incubations with (A) 2 µg/mL, (B) 6 µg/mL and 
(C)10µg/mL secondary antibody. (D) The average number of Internalized 
SLAM positive vesicles per cell were quantified using imagej by drawing 
ROIs for 30 cells per condition, and to include only the internal region of 
cells. Arrows indicate the aggregation of LAMP1 positive lysosomes in close 
proximity to the SLAM labelled plasma membrane in cf2642 treated cells. 
Arrowheads show internalised SLAM in punctate structures. Images are 
representative of three independent experiments. (Scale bar =20µm).  
 
The data shown in Fig 5.5 indicates an increase in internalized SLAM 
positive vesicles, with increasing concentration of the Alexa Fluor-647 
conjugated secondary antibody used for clustering. This was significantly 
reduced by half in the presence of cf2642 in cells clustered with 2 and 6 
µg/mL secondary antibody (Fig 5.5D). The drug treated cells also showed 
the aggregation of LAMP1 positive lysosomes close the plasma membrane. 
A more pronounced labelling of SLAM was also observed with increasing 
concentrations of the secondary antibody. No significant cf2642 induced 
decreases in SLAM internalization was observed at 2 and 10µg/mL 
secondary antibody concentrations. The results indicate that the optimum 
concentration of secondary antibody to be used for indirect SLAM clustering 
was 6 µg/mL. No significant increases in internalization of SLAM was seen 
using higher concentration of antibody (10µg/mL), which could be because 
the antibody binding sites of SLAM receptors on the plasma membrane are 
completely occupied by these antibodies. Treatment with cf2642 caused the 
reduced internalization of SLAM and the tight grouping of LAMP1 labelled 
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lysosomes near the plasma membrane and this may be attributed to the 
effects of cf2642 on the plasma membrane. Lysosomal exocytosis and 
membrane resealing are known to occur in response to plasma membrane 
damage (Reddy et al., 2001, Tam et al., 2010). Whether cf2642 causes 
plasma membrane damage is not clear, but such effects do not affect cell 
viability at this concentration and at such short time points (see section 3.1 
in Chapter 3. 
 
5.2.4. Dextran-488 uptake induced by indirect SLAM-receptor 
clustering 
 
Based on the dose response assay in section 5.6 above, all subsequent 
indirect SLAM-receptor clustering experiments were done using 6 µg/mL of 
the Alexa Fluor-647 conjugated secondary antibodies. The dextran uptake 
experiment by indirect SLAM clustering was done to test whether the results 
obtained with direct SLAM clustering in section 5.2 can be replicated using a 
combination of primary and secondary antibodies. If a similar trend in 
Dextran uptake can be obtained using this methodology, it gives more 
credence for the use of SLAM clustering as a non-virus based assay to 
mimic virus - cell interaction in vitro. 
Indirect clustering of SLAM receptors was done by briefly incubating live 
VeroSLAM cells with monoclonal mouse anti-SLAM antibodies at 37ºC, 
followed by washing and incubating with Alexa Fluor - 647 conjugated 
polyclonal anti-mouse secondary antibodies on ice. This is followed by the 
addition of Dextran-488 at 5, 10 and 15 min time points w/o 10µM cf2642 as 
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done previously in sections 5.2 and 5.3 (see section 2.2.18.1.3 in methods 
and section 2.2.20.2.3 for details on flow cytometry analysis) 
 
 
Fig 5.6.Indirect Clustering of SLAM receptors stimulates Dextran-488 
uptake in VeroSLAM cells, and is inhibited by cf2642. Cells were first 
incubated with 2 µg/mL mouse anti-SLAM antibody for 30 min at 37ºC, washed 
and then incubated with 6 µg/mL polyclonal anti-mouse Alexa Fluor-647 
antibody (cluster)  for 60 min on ice. The cells were then moved to 37°C for the 
indicated time periods and 0.1 mg/mL Dextran-488 in the presence of 10µM 
cf2642 or vehicle (DMSO) was added during the last 5 min. Fluorescence 
intensity was analyzed by flow cytometry. The results were quantified and 
shown as percentage increase of Dextran-488 intensity normalized to the 
vehicle control. The vehicle control served as a measure of steady state 
Dextran-488 uptake. Student’s t-test was performed to assess the P values; *p 
< 0.05. Error bars represent mean ± SE of three independent experiments. 
 
A 73% increase in Dextran-488 uptake over the vehicle control, was seen in 
SLAM clustered cells at the 30 min time point (Fig 5.6) and this was 
significantly reduced in the presence of 10µM cf2642. Slight increases in 
Dextran-488 uptake was observed in the cf2642 controls and in clustered 
cells at 5 and 15 min time points. A 5% decrease in Dextran-488 uptake was 
seen in clustered cells at 5 min, but was not statistically significant. The 
results were similar to that of direct clustering wherein an increased dextran-
488 uptake was observed at 30 min. In this case, the fluorescence intensity 
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of internalized dextran was less than that of direct clustering, which could be 
a consequence of differences in SLAM receptor-antibody interactions at the 
plasma membrane.  
 
5.2.5. Effect of cf2642 on SLAM internalization and localization of 
lysosomes 
 
The clustering of SLAM by MeV has been shown to cause the 
downregulation of these receptors at 24 - 48 hr post infection (Tanaka et al., 
2002, Welstead et al., 2004). Since cf2642 was shown to causes a 
decrease in internalization of SLAM from the plasma membrane (section 
5.7), the effect of cf2642 on extended clustering periods was studied. Any 
effects on the internalization and subsequent downregulation of SLAM may 
hinder MeV pathogenesis by affecting the ability of the virus to re-infect 
susceptible cells (Welstead et al., 2004). 
Indirect clustering of SLAM was done as mentioned previously (section 5.7) 
and chased for either 1 or 5 hr after clustering with Alexa Fluor-647 
conjugated secondary antibodies. The 2 and 6 hr clustering time periods 
mentioned below are defined based on the total incubation times after the 
initial 30 min incubation with mouse anti-SLAM antibody. Cells were then 
fixed and labelled with LAMP1-FITC antibody to label the lysosomes. The 
fluorescence signal from directly labelled secondary antibodies served as 
the label for SLAM receptors (see methods section 2.2.16.1.4.2.2).  
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Fig 5.7 cf2642 causes reduced internalization of clustered SLAM 
receptors. Live VeroSLAM cells were incubated or not with mouse anti-
SLAM antibodies for 30 min and clustered or not for 1 hr with chicken anti-
mouse Alexa Fluor-64 conjugated secondary antibodies at 37ºCin the 
presence or absence of 10µM cf2642. Cells were then chased for 1 hr or 5 
hr w/o 10µM cf2642 and immunolabelled with LAMP1-FITC antibody. (B) 
and (D) show cells after 2 hr (1 hr cluster + 1 hr chase) and 6 hr (1 hr cluster 
+ 5 hr chase) SLAM clustering respectively. Steady state levels of SLAM 
without receptor clustering at 2 hr and 6 hr post treatment or not with cf2642 
are shown in (A) and (C) respectively. Arrow heads indicate internalized 
SLAM positive vesicles. Arrows indicate the localization of LAMP1 labelled 
lysosomes near the plasma membrane and dashed arrows show small 
aggregates of SLAM labelling associated with the plasma membrane. 
Images are representative of three independent experiments. (Scale bar 
=20µm).  
 
The 2 hr clustering of SLAM receptors resulted in internalization of SLAM 
positive vesicles and this was partially inhibited in the presence of 10µM 
cf2642 (Fig 5.7B). No such receptor internalization was observed in cells 
without clustering at both 2 and 6 hr time points, both in the presence or 
absence of cf2642 (Fig 5.7 A,C). Treatment with cf2642 resulted in the 
mislocalization of LAMP1 positive lysosomes to close proximity with the 
SLAM-labelled plasma membrane that was not observed in control cells. 
Cells subjected to 6 hr SLAM-receptor clustering did not show prominent 
plasma membrane SLAM labelling that was more apparent in the presence 
of cf2642 (Fig 5.7 D).  The data indicate that extended clustering time 
periods resulted in almost complete loss of SLAM labelling from the plasma 
membrane. However, much of the SLAM labelling associated with the 
plasma membrane was retained in the presence of cf2642. This shows that 
the effect of cf2642 on SLAM internalization is not limited to the early time 
points post treatment. Controls without SLAM clustering showed uniform 
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labelling of the plasma membrane and no internalized vesicles, indicating 
that SLAM internalization is not a constitutive process and does not occur in 
the absence of clustering. It should be noted that the labelling methods used 
for the no-clustering controls was slightly different to that of the method used 
for clustered cells. In this case, cells were treated or not with cf2642 for the 
appropriate time periods, fixed and immunolabelled with SLAM and LAMP1. 
In the case of clustering, the cells were fixed and labelled only with LAMP1. 
Here, the SLAM labelling is associated with the fluorescence from the Alexa 
Fluor-647 conjugated secondary antibodies used for clustering. 
Interestingly, at 6 hr post clustering, the fluorescence signal from 
internalized SLAM vesicles was almost completely absent both in the 
presence and absence of drug.  
 
5.2.6. Effect of cf2642 on SLAM internalization and localization of 
early endosomes 
The above SLAM clustering experiments had shown the localization of 
lysosomes near the plasma membrane of cells in the presence of cf2642. 
To investigate whether this was specific to this organelle, cells treated in the 
same way were also labelled for EEA1, a marker of early endosomes. The 
methodology used for SLAM clustering was the same as before (section 
5.7), but immunolabelling was done using EEA1 antibodies (see methods 
sections 2.2.16.1.4.2.2 and 2.2.3.2.3.4)  
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Fig 5.8 cf2642 causes scattering of early endosomes in cells with 
clustered SLAM receptors. Live VeroSLAM cells were incubated or not 
with mouse anti-SLAM antibodies for 30 min and clustered or not for 1 hr 
with chicken anti-mouse Alexa Fluor-64 conjugated secondary antibodies at 
37ºCin the presence or absence of 10µM cf2642. Cells were then chased 
for 1 hr or 5 hr w/o 10µM cf2642, fixed with 3% PFA and immunolabelled 
with EEA1 antibody. (B) and (D) show cells after 2 hr and 6 hr SLAM 
clustering respectively. Steady state levels of SLAM without receptor 
clustering at 2.5 hr and 5.5 hr post treatment or not with cf2642 are shown in 
(A) and (C) respectively. Arrow heads indicate internalized SLAM positive 
vesicles. Arrows indicate the localization of EEA1 labelled early endosomes 
near plasma membrane and dashed arrows show small aggregates of 
SLAM labelling associated with the plasma membrane. Images are 
representative of two independent experiments. (Scale bar =20µm).  
 
Internalization of SLAM positive vesicles was observed upon 2 hr receptor 
clustering and this was partially inhibited with 10µM cf2642. EEA1 labelled 
early endosomes were seen in close proximity with the plasma membrane in 
cf2642 treated cells with 2 hr SLAM clustering (Fig 5.8 B). Few internalized 
SLAM positive structures were seen in the cells without clustering, 6 hr post 
treatment w/o cf2642 (Fig 5.8 C). Cells with 6 hr SLAM-receptor clustering 
showed very few internalized SLAM positive vesicles, and most of the 
plasma membrane associated SLAM labelling was retained in the presence 
of cf2642.  In the absence of cf2642, small aggregates or clumps of SLAM 
positive regions were observed in the plasma membrane (Fig 5.8 D). The 
similarity in localization of LAMP1 (section 5.8) and EEA1 positive vesicles 
near the plasma membrane refutes the earlier discussed possibility that this 
may be associated with plasma membrane damage (see section 5.6).  
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5.2.7. Method development - Indirect SLAM clustering 
5.2.7.1. Clustering with unconjugated secondary antibodies 
 
Previous experiments in section 5.8 and 5.9 showed only very few 
internalized SLAM positive vesicles at 6 hr post clustering. This may either 
be the result of downregulation and subsequent degradation of these 
vesicles in the lysosomes or it could be an artefact associated with the 
fluorescence tag of the directly conjugated clustering secondary antibodies 
used. Thus an alternate methodology for clustering of SLAM receptors was 
designed and investigated. VeroSLAM cells were incubated with monoclonal 
anti SLAM antibodies for 30 min on ice in the absence of cf2642 and then 
clustered using unconjugated goat anti mouse secondary antibodies for 1 hr 
w/0 cf2642. After suitable chase periods, cells were fixed and 
immunolabelled with anti-SLAM and LAMP1 antibodies (see methods 
section 2.2.16.1.4.2.3) 
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Fig 5.9 Indirect clustering with unconjugated secondary antibodies 
shows an altered labelling pattern of SLAM receptors. Live VeroSLAM 
cells were incubated or not with mouse anti-SLAM antibodies for 30 min on 
ice in the absence of cf2642 and clustered or not for 1 hr with goat anti-
mouse secondary antibodies at 37ºCin the presence or absence of 10µM 
cf2642. Cells were then chased for 1 hr or 5 hr w/o 10µM cf2642, fixed with 
PFA and immunolabelled with LAMP1 and anti-goat Alexa Fluor-488 
secondary antibodies to label the lysosomes and SLAM respectively. (B) 
and (D) show cells after 2 hr and 6 hr SLAM clustering respectively. Steady 
state levels of SLAM without receptor clustering at 2.5 hr and 5.5 hr post 
treatment or not with cf2642 are shown in (A) and (C) respectively. Arrows 
indicate localized areas of dense SLAM labelling in plasma membrane 
dashed arrows show small aggregates of SLAM labelling associated with 
the plasma membrane. Images are representative of three independent 
experiments. (Scale bar =20µm).  
 
In the absence of the secondary antibody to induce clustering, SLAM 
labelling was observed predominantly on the plasma membrane with some 
evidence of cytoplasmic localisation (Fig 5.9 A and C).  The phenotype was 
very different 2 hr post clustering where SLAM labelling was predominantly 
associated with vesicles scattered within the cytoplasm and more 
concentrated at the plasma membrane. A similar pattern was also observed 
in cf2642 treated cells, but with more prominent plasma membrane 
extensions (Fig 5.9 B). Cells incubated with the secondary antibody for 6 hr 
to induce clustering (Fig 5.9 D lower panel) showed almost no SLAM 
labelling on the plasma membrane that was still apparent in cf2642 
incubated cells.The absence of uniform plasma membrane labeling of SLAM 
as seen previously could be due to the initial incubation of primary antibody 
on ice or the affinities between clustering and post fixation secondary 
antibodies. Even with this new method, the internalized SLAM vesicles were 
still not visible 6hr post clustering. 
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5.2.7.2. Indirect SLAM-receptor clustering in live cells 
Since the use of unconjugated secondary antibodies did not improve the 
labelling of SLAM after 6 hr clustering, the protocol was repeated in live 
VeroSLAM cells. This can be used to determine whether the PFA fixation of 
cells at 6 hr post clustering has any effect on the fluorescence signal from 
Alexa Fluor-647 conjugated secondary antibodies. Cells were first pulse 
chased with Dextran-488 to label late endosomes/lysosomes and the 
indirect clustering of SLAM was done for 2 or 6 hr using Alexa Fluor-647 
labelled secondary antibodies, followed by live imaging. (see methods 
section 2.2.16.1.4.2.4) 
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Fig 5.10. SLAM clustering in live cells reveals localization of these 
receptors 6 hr post clustering. Live VeroSLAM cells were pulsed with 0.2 
mg/mL Dextran-488 for 2 hr and chased for 18 hr. Cells were then incubated 
or not with mouse anti-SLAM antibodies for 30 min at 37ºCin the presence 
or absence of cf2642, clustered or not for 1 hr with polyclonal Alexa Fluor-
647 conjugated chicken anti-mouse secondary antibodies and chased for 1 
or 5 hr w/o 10µM cf2642. Live images were captured at the respective time 
points. (A) and (B) show controls incubated or not with cf2642 for 2.5 hr and 
6.5 hr respectively. The no-clustering controls were incubated for 30 min 
with mouse anti-SLAM antibodies w/o cf2642, washed and incubated or not 
with cf2642 for either (C) 1.5 or (D) 5.5 hr. (E) and (F) show secondary 
antibody controls pertaining to the 2 and 6 hr clustering time points 
respectively. (G) shows cells with 2 hr clustering and (H) shows clustering 
for 6 hr. Images show SLAM in red and late endosomes/lysosomes in 
green. Arrow heads indicate internalized SLAM positive vesicles and blue 
arrows show the localization of late endosomes/lysosomes near the plasma 
membrane. Cyan arrow heads show co-localization of internalized SLAM 
positive vesicles and Dextran-488 labelled late endosomes/lysosomes. 
Cyan arrows show SLAM labelled plasma membrane retained in the 
presence of cf2642. Images are representative of three independent 
experiments. (Scale bar =20µm).  
 
The vehicle and cf2642 controls at both 2.5 and 6.5 hr post treatment 
showed cells with uniform localization of the Dextran-488 labelled late 
endosomes/lysosomes (Fig 5.10.0 A-B). No-clustering controls treated with 
cf2642 showed cells with late endosomes/lysosomes localized in tight 
groups, compared to the more dispersed positioning seen in vehicle controls 
(Fig 5.10 C-D).  SLAM clustering for 2 hr caused decreased internalization 
of SLAM positive vesicles in the presence of cf2642. Also, the Dextran 
labelled late endosomes/lysosomes were positioned near the plasma 
membrane and co-localized with the internalized SLAM positive vesicles. No 
differences in the plasma membrane labelling was observed between the 
vehicle and cf2642 treated cells at this time point (Fig 5.10 E-F). When 
clustered for 6 hr in the absence of cf2642, the SLAM labelling associated 
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with plasma membrane was completely lost and the internalized SLAM 
positive vesicles were co-localized with the Dextran-488 labelled late 
endosomes and lysosomes. However, in the presence of cf2642, much of 
the SLAM labelling associated with plasma membrane remained and far 
less co-localization with the late endosomes/lysosomes was seen (Fig 5.10 
G-H). Also, as seen with the 2 hr clustering, the late endosome/lysosomes 
in cf2642 incubated cells were positioned in close proximity with the plasma 
membrane. The retainment of SLAM labelling of plasma membrane 6 hr 
post clustering in the presence of cf2642 confirms previous findings 
observed in fixed cells. The overall decrease in co-localization between 
SLAM and Dextran-488 positive lysosomes in the presence of cf2642 is 
another indication of the reduced uptake of SLAM. The reduced 
internalization of SLAM even at 2 hr post treatment indicates cell-targeting 
effects of cf2642 at early time points post treatment. This could have a direct 
impact of MeV entry and interaction of virus particles with the SLAM 
receptors.  
5.2.8. Effect of cf2642 on transferrin uptake 
 
The effect of cf2642 on the internalization of cargo has been previously 
tested using fluorescence labelled dextran conjugates, but in this case, their 
uptake occurs via macropinocytosis and short incubations with cf2642 was 
not done (see section 4.3 in Chapter 4). Since receptor internalization has 
been shown to occur via CME(Le Roy and Wrana, 2005), and to test the 
effect of cf2642 on the uptake of cargo via this pathway, transferrin 
experiments were performed. (see methods section 2.2.17) 
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Transferrin is iron-binding glycoprotein that act as a shuttle for the delivery 
of iron to cells.  As an iron bound protein it binds to transferrin receptors on 
cell surfaces and the receptor complex is internalized as a constitutive 
process via CME to early endosomes. On the endocytic pathway a 
reduction in pH causes the release of iron into the endosomal lumen and 
then into the cytosol for use. The transferrin receptor-ligand complex, is then 
recycled back to the cell surface via recycling endosomes, ready for another 
round of iron uptake (Mayle et al., 2012).  
For transferrin uptake analysis VeroSLAM cells were first starved in serum 
free medium to deplete bovine transferrin form the system and incubated 
with Alexa Fluor-488- transferrin (Tf-488) and cell mask for 30 min at 4ºC; 
the latter is a commercial probe used to label the plasma membrane (Hagn 
et al., 2012). Cells were then chased w/o cf2642 for up to 30 min and 
images were captured every 10 min by confocal microscopy.  
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Fig 5.11. cf2642 causes the peripheral localization of transferrin loaded 
recycling endosomes. VeroSLAM cells were serum starved for 30 min in 
the absence of cf2642 and then incubated with Tf-488 and cell mask for 30 
min on ice. Cells were then chased at 37ºC for up to 30 min in the presence 
or absence of 10µM cf2642 and live images were captured at 10 min 
intervals. Data shows images captured at (A) 2 min, (B) 10 min, (C) 20 min 
and (D) 30 min time points. The cell mask labelled plasma membrane is 
shown in red and transferrin in green.  Arrows show the peripheral 
localization of transferrin-488 labelled vesicles. Images are representative of 
two independent experiments. (Scale bar =20µm). 
 
At the 2 min time point, transferrin labelled vesicles were mostly associated 
with the plasma membrane but the labelling by this protein appeared to be 
lower in the presence of cf2642 (Fig 5.11 A). After a 10 min chase, cf2642 
treated cells showed transferrin positive structures as small puncta but also 
grouped together, this compared with the more dispersed peripheral 
localization seen in the absence of drug. Small numbers of internalized cell 
mask positive structures were also observed in the presence of cf2642, 
compared to the vehicle control (Fig 5.11 B). On account of recycling, the 
total number of Tf-488 positive structures in the presence or absence of 
cf2642 steadily decreased over time and at 30 min post chase, cells showed 
increased presence of cell mask positive vesicles (Fig 5.11 C-D).The results 
demonstrate that cf2642 may alter the endocytic traffic of Tf-488, shown by 
the polarisation of Tf-488 vesicles as opposed to the peripheral localization 
of these vesicles in the absence of drug. Since there was no retention of the 
internalized transferrin at 30 min, it shows that the drug does not affect the 
normal cellular processes involved in transferrin recycling. 
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5.2.9. Effect of cf2642 on macropinocytosis 
5.2.9.1. Effect of cf2642 on SLAM-receptor clustering mediated 
macropinocytosis 
 
Previous experiments have shown that both direct and indirect clustering of 
SLAM receptors results in the increased uptake of Dextran-488 after 30 min 
(sections 5.2 and 5.3.3). Since this was significantly reduced in the 
presence of cf2642, it indicates that the drug possibly affects a cellular 
pathway like macropinocytosis, that has been shown to be involved in 
dextran uptake, predominantly in growth factor activated cells. MeV has 
been shown to utilize this endocytic pathway as an alternate means of 
cellular entry (Delpeut et al., 2017) and hence the effect of cf2642 on 
macropinocytosis was studied. Focus here was given to the arrangement of 
actin that mediates the cell ruffling and uptake associated with this process; 
subsequent experiments also investigated whether the MeV also affected 
the actin cytoskeleton.  
VeroSLAM cells were first incubated with mouse anti-SLAM antibodies and 
then incubated for 1 hr using polyclonal chicken anti mouse antibodies 
(clustering) w/o cf2642. After a further 30 or 60 min chase w/o cf2642, cells 
were fixed and actin filaments were labelled with rhodamine phalloidin (see 
methods section 2.2.16.1.4.3) 
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Fig 5.12 Crosslinking of SLAM receptors for 1.5 hr results in 
membrane blebbing. VeroSLAM cells were incubated or not with mouse 
anti-SLAM antibodies w/o 10µM cf2642 for 30 min at 37ºC and clustered or 
not with chicken anti mouse Alexa Fluor - 647 antibodies in the presence of 
absence of cf2642 for 1 hr.  After a 30 min chase, cells were fixed, 
permeabilized and labelled with rhodamine phalloidin and Hoechst to label 
actin filaments and nucleus respectively. Cells incubated only with vehicle 
control or cf2642 are shown in (A), and (B) shows no-clustering controls 
where cells were incubated with primary antibody but not clustered. (C) 
shows the secondary antibody controls and (D) shows cells with SLAM-
clustering w/o cf2642. Arrows indicate membrane blebs caused by actin 
protrusions. Images are representative of three independent experiments. 
(Scale bar =20µm). 
 
The vehicle, cf2642 controls, no-cluster (primary alone) and secondary 
antibody controls showed complete labelling of the actin cytoskeleton and 
very little indications of extensive actin protrusions or ruffles (Fig 5.12 A-C). 
Cells with crosslinked SLAM receptors showed the formation of actin ruffles 
as indicated by yellow arrows; actin protrusions were also observed to 
emanate from these cells. This effect was inhibited by cf2642 manifest as 
the control actin phenotype (Fig 5.12 D) (see discussion below).  
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Fig 5.13 Crosslinking of SLAM receptors for 2 hr results in extensive 
membrane bleb formation. VeroSLAM cells were incubated or not with 
mouse anti-SLAM antibodies w/o 10µM cf2642 for 30 min at 37ºC and 
clustered or not with chicken anti mouse Alexa Fluor - 647 antibodies in the 
presence of absence of cf2642 for 1 hr.  After a 60 min chase, cells were 
fixed, permeabilized and labelled with rhodamine phalloidin and Hoechst to 
label actin filaments and nucleus respectively. Cells incubated only with 
vehicle control or cf2642 are shown in (A), and (B) shows no-clustering 
controls where cells were incubated with primary antibody but not clustered. 
(C) shows the secondary antibody controls and (D) shows cells with SLAM-
clustering w/o cf2642. Arrows indicate membrane blebs caused by actin 
protrusions. Arrowheads indicate aggregates of actin labelling. Images are 
representative of three independent experiments. (Scale bar =20µm).  
 
The experiment in Fig 5.13 used the same antibody times points as used for 
the flow cytometry analysis shown in Fig 5.12. Experiments were then 
performed whereby the period after secondary antibody (clustering) 
incubation was increased from 30 to 60 min. This was to investigate whether 
more prominent effects could be see via this extended period. Fig 5.13 show 
in the presence or absence of cf2642 and in the absence of secondary 
antibody (no clustering), some actin labelling, identified as small folds 
protruding from the cell surface. (Fig 5.13 A,C). Extensive formation of 
ruffles and actin protrusions were seen in almost all cells clustered with the 
secondary antibody. This effect was almost completely reversed in the 
presence of cf2642 and these cells showed the presence of small patches 
on the cell surface with dense labelling of actin (Fig 5.13 D). 
Actin labelling results in Fig 5.12 and 5.13 showed the presence of ruffles 
and actin protrusions at the same time point as the Dextran uptake 
experiments, which confirms that this was due to the induction of 
macropinocytosis. However, a more pronounced induction of actin 
protrusions, along with cell shrinkage was observed after a further 30 min 
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chase (Fig 5.13), indicating that SLAM clustering induced macropinocytosis 
was an ongoing process and lasts for at least 2 hr post clustering. In either 
case, cf2642 inhibited these changes in the actin cytoskeleton, thereby 
supporting the previous data on inhibition of clustering induced dextran 
uptake. 
 
5.2.9.2. Effect of cf2642 on MeV induced SLAM clustering 
 
Previous experiments have shown that MeV interaction with VeroSLAM 
cells results in the increased uptake of Dextran (section 5.2). Here, the 
effect of virus on the actin cytoskeleton was tested by infecting VeroSLAM 
cells with MeV for a short period in the presence or absence of cf2642. (see 
methods section 2.2.19) 
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Fig 5.14 MeV infection in VeroSLAM cells results in actin cytoskeleton 
changes which is reversed in the presence of cf2642. Cells grown over 
glass coverslips were infected (C-D) or not (A-B) with MeV (MOI-10) in the 
presence of 10µM cf2642 or vehicle (DMSO) and incubated for 30 min at 37ºC. 
The cells were fixed, labelled using Alexa Fluor 647 Phalloidin and DAPI to 
visualize actin and nuclei respectively and analyzed by confocal microscopy. 
Single section images show actin labelling (grey scale) and also as merged 
images with nucleus labelling (blue). Yellow arrows indicate actin driven 
membrane protrusions in the MeV control. (scale bar = 20µm) 
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Figure 5.14 shows the usual labelling of actin in cells showing prominence 
close to the plasma membrane and on filaments. MeV caused a significant 
change in this localisation noting the appearance of numerous actin positive 
protrusions emanating from the plasma membrane. As a result, the virus 
infected cells appeared to be smaller than control cells. In the presence of 
cf2642, cells were of normal size and lacked any of the actin protrusions 
that were present in the MeV controls (Fig 5.14  C-D). cf2642 on its own, did 
not appear to have any effect on the actin arrangement (Fig 5.14 A-B). The 
effect of cf2642 on MeV induced changes in actin morphology shows the 
effect of the drug on virus induced macropinocytosis at these early time 
points. A 30 min incubation period with MeV was used in accordance with a 
previous report showing MeV (MOI-1) induced differences in actin 
morphology at this time point (Delpeut et al., 2017). An MOI of 10 was used 
in this experiment, taking into account the relatively high MOI used 
previously for the Dextran uptake experiment. The data suggests that MeV 
when used at MOIs between 10 and 100 induces changes in actin 
morphology and this may occur soon after virus infection. The virus induced 
Dextran-488 uptake that was observed at 15 min may perhaps be the time 
point at which MeV causes maximum effects on cell plasma membranes, 
culminating in virus entry via macropinocytosis. In reality MOIs of >10 are 
unlikely to occur in nature but taken together, the results suggest an effect 
of cf2642 on cell membranes occurs as early as 5 min post treatment and 
the MoA of cf2642 against measles may be attributed this cell-targeting 
activity of the drug. It still remains to be determined if the effects are limited 
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to the plasma membrane or whether the drug also has an effect on internal 
membranes that are critical for the virus life cycle- discussed below. 
 
5.2.10. cf2642 MoA studies 
5.2.10.1. Measles entry/spread assay sheds light on the MoA of 
cf2642 
 
Previous data in this chapter has revealed that MeV stimulates Dextran 
uptake and that the virus induces macropinocytosis in VeroSLAM cells at 
early time points post infection. Here, in the same experiment, the MoA of 
cf2642 was studied by testing its possible effect on virus entry as opposed 
to virus spread. VeroSLAM cells were first infected with MeV expressing 
green fluorescence protein (MeV-GFP) for 2 hr either in the presence or 
absence of 10µM cf2642. The cells were then washed and further incubated 
with 10µM cf2642 or not for 24 hr, this time without adding any fresh virus to 
the cells. (see methods section 2.2.20.1.2 and section 2.2.20.2.3 for details 
on flow cytometry analysis) 
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Fig 5.15 cf2642 inhibits MeV-EGFP spread. VeroSLAM cells were infected 
with MeV-GFP at MOI 0.5 for 2 hr in the absence or presence of 10µM 
cf2642, washed and further incubated with 10µM cf2642 or not for 24 hr and 
analyzed by flow cytometry. The results show the percentage of GFP 
positive cells normalized to virus control. To study the effects on MeV-GFP 
entry or spread, cf2642 was added either after the 2 hr viral incubation step 
(cf2642-a) or immediately prior to the initial 2 hr incubation with virus 
(cf2642-b). The percentage of GFP positive cells was measured by flow 
cytometry analysis and normalized to the untreated virus control. Error bars 
represent mean ± SE of three independent experiments. Student’s t test 
was performed to assess the p values; *< p,0.05.   
 
Vehicle (DMSO) had only negligible effects in the GFP signal (Fig 5.15). 
MeV-GFP infection in the presence of cf2642 caused a significant 75% 
decrease in cellular GFP fluorescence. There was a significant (approx.-
75%) decrease in fluorescencewhen the drug was incubated with cells 
throughout the experimental virus period or when added 2 hr post viral 
treatment.However, only a 31% decrease in cell fluorescence was observed 
when cf2642 was added only during the 2hr virus incubation step and this 
reduction in fluorescence was not statistically significant (Fig 5.15).  The 
rationale behind adding the drug at different stages of the experiment was to 
test which stage of the virus infection cycle, whether entry or spread, was 
being inhibited. When the cells are infected during the first 2 hr in the 
presence or absence of cf2642 (cf2642-b), the virus has the opportunity to 
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attach to cells and initiate virus entry. If cf2642 does inhibit virus entry, there 
will not be any infection occurring during the subsequent 24 hr incubation 
step and therefore no/less GFP signal by flow cytometry analysis. Next, 
when the cells are washed and treated with cf2642 during the 24 hr 
incubation step (cf2642-a), the cells that have already entered the cells 
initially will have a change to propagate. But if the drug inhibits spread, then 
the GFP signal associated with this will be less or absent. In the presence of 
cf2642, significant (76%) decrease in GFP positive cells was observed when 
the infected cells were treated during the 24 hr incubation step (cf2642-a), 
indicating that the drug affected virus spread. The 31% decrease associated 
with the cf2642-b condition was not statistically significant, and hence it can 
only be speculated that cf2642 partially affects MeV entry. This effect of 
cf2642 on virus spread may be a result of the drug’s effects on internal 
membranes which in turn inhibits virus-induced syncytia formation. The 
formation of syncytia by fusion of infected and non-infected cells is vital for 
the lateral spread of MeV particles and hence, any effects on this process 
will irreversibly affect the virus life cycle (Rima and Duprex, 2011b, Plemper 
et al., 2011a).  Another possibility could be that cf2642 affects the virus 
envelope during entry stages, thereby resulting in less efficient uptake 
and/or improper assembly and replication of MeV particles. 
 
5.2.10.2. Time of addition (ToA) assay 
 
The ToA assay was done to determine how long the addition of cf2642 can 
be postponed before it loses its antiviral activity; the assay has been used to 
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gain insights into the mechanism of action of antiviral compounds. 
(Daelemans et al., 2011)  For instance, a drug which targets the viral 
genome will have an effect only when added during the early time points 
post infection. When added at later time points, the drug will no longer be 
able to affect virus replication. VeroSLAM cells were first infected with MeV-
GFP and cf2642 was added at various time points pre and post infection, for 
up to 12 hr. After a further 12 hr incubation, the percentage of GFP positive 
cells was analyzed by flow cytometry. The following conditions were used: 
1. Blank - Cells without virus or drugs/DMSO   
2. Vehicle (DMSO) control  
3. T0 - 30 min (a) (30 min pre-treatment with 10µM cf2642, cells washed 2x 
and infected with MeV-GFP without cf2642) 
4. T0 - 30 min (b) (30 min pre-treatment with 10µM cf2642, cells washed 2x 
and infected with MeV-GFP with 10µM cf2642) 
5. Virus control (T0) - MeV-GFP infection, no cf2642 treatment  
6. Virus + cf2642 - MeV-GFP infection and cf2642 treatment done together 
7. T0 + 30 min (MeV-GFP infection, cf2642 treatment done 30 min post 
infection) 
8. T0 + 2hr (MeV-GFP infection, cf2642 treatment done 2 hr post infection) 
9. T0 + 4hr (MeV-GFP infection, cf2642 treatment done 4 hr post infection) 
10. T0 + 6hr (MeV-GFP infection, cf2642 treatment done 6 hr post infection) 
11. T0 + 8hr (MeV-GFP infection, cf2642 treatment done 8 hr post infection) 
12. T0 + 10hr (MeV-GFP infection, cf2642 treatment done 2 hr post infection) 
13. T0 + 12hr (MeV-GFP infection, cf2642 treatment done 2 hr post infection) 
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(see section 2.2.20.1.1 for methodology and section 2.2.20.2.3 for details on 
flow cytometry analysis) 
 
 
Fig 5.16 cf2642 time of addition (ToA) assay indicates sustained anti 
MeV activity. VeroSLAM cells were infected with MeV-GFP at MOI 0.5 and 
10µM cf2642 was added either 30 min prior to infection (T0-30 min), at the 
same time as infection (T0) or after various time points up to 12 hr post 
infection, as indicated.  Cells were incubated for a further 12 hr and 
analyzed by flow cytometry. The results are representative of three 
independent experiments and are shown as percentage of EGFP positive 
cells normalized to the untreated virus control. Error bars represent mean ± 
SE of three independent experiments. Student’s t test was performed to 
assess the p values; *< p,0.05, **<p,0.01, ***<p,0.001. 
 
The maximum activity of 10µM cf2642 against MeV-GFP was observed at 
the T0 min and T0+30 min time points when cf2642 treatment was 
performed either at the same time as virus infection or 30 min post infection 
respectively (Fig 5.16). Upon the addition of drug 30 min prior to infection of 
cells (T0 - 30 min), only a 50% decrease in virus associated GFP signal was 
observed, but this was not statistically significant. The GFP signal positively 
correlated with the time of addition of the drug that when added 12 hrs post 
infection still inhibited the fluorescence signal by 61%. Since a significant 
inhibition of MeV-GFP even when cf2642 was added 12 hr post infection, it 
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indicates that a cellular component that was required for MeV during its 
entire life cycle was being affected. This also supports the data from virus 
entry/spread assay wherein cf2642 was shown to only partially affect virus 
entry. If virus entry was being inhibited, the addition of cf2642 at or after 2 hr 
post infection would not have resulted virus inhibition.  
5.2.11. Impedance assay 
 
As part of MoA studies, the response of cells to MeV infection and cf2642 
treatment was studied using the RTCA xCELLigence instrument which uses 
non-invasive electrical impedance measurements to monitor changes in cell 
behaviour in terms of proliferation, morphology and adherence in real time 
(Pennington and Van de Walle, 2017).  Cells are made to grown in 
specialized tissue culture plates containing inter-digitated gold electrodes on 
its base. When a low frequency alternating current is applied, the cells 
impede the flow of ionic current across the monolayer, which is in turn read 
as cell impedance. As the cells grow over time, the ionic flow around or 
between the cells decreases, thereby increasing cell impedance (Abassi et 
al., 2004, Xing et al., 2006). The impedance of electron flow by the cells is 
reported as a unit less parameter called the Cell Index. The response of 
cells to infection by cell-fusion inducing viruses has been reported earlier 
and shown to produce characteristic cell index profiles (Watterson et al., 
2016).  
Briefly, VeroSLAM cells were seeded in 96-well impedance measurements 
plates and 24 hr post seeding, infected with MeV in the presence or 
absence of increasing concentrations of cf2642. Impedance measurements 
177 
 
were taken at various time points post infection. (see methods section 
2.2.20.1.4). 
 
 
Fig 5.17 Impedance assay shows the anti-viral activity of cf2642 in real 
time. VeroSLAM cells were seeded in duplicates in 16 well impedance 
measurement plates and 24 hr later, infected with MeV (MOI 0.5) in the 
presence or absence of increasing concentrations of cf2642 as indicated. 
Impedance measurements were taken in real time at every 15 min intervals 
during 0-24 hr incubation of cells post seeding, 1 min intervals during 24 to 
27 hr post infection and again at 15 min intervals during 27 to 100 hr. 
Measurements were plotted against cell index and time. (A) shows ell index 
plot from 0 to 10 hr and (B) shows the same cell index plot with error bars 
representing standard error from two independent experiments.  
 
The data depicts the increase in the cell index for all conditions during 0 to 
24 hr post seeding of cells and in the absence of virus (Fig 5.17). After a 
small dip at the virus addition time point, the cell index continued to increase 
for both the controls, and 1µM cf2642 control. The increase in cell index was 
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slightly reduced in cells treated with 5 and 10µM cf2642. The impedance of 
MeV control cells increased and at a similar rate to non-infected cells but 
then declined after 30 hr post infection.  MeV infected cells in the presence 
of cf2642 showed a reduced cell index during the first 66 hours and then a 
reduced rate of decline in cell index for the rest of the experiment. The rapid 
increase in cell impedance upon infection with MeV translates to the 
increase in surface area occupied by infected cells due to formation of 
syncytia. A similar profile was previously reported for Respiratory syncytial 
virus (RSV), which is a Class-1 fusion inducing virus like MeV(Watterson et 
al., 2016). The subsequent decline in impedance was most likely due to cell 
death and the resulting detachment of cells from the electrode surface. This 
is well documented when this assay is used test anti vital compounds 
against other viruses but time did not allow for parallel experiments using 
microscopy that would have clearly shown this cell death and detachment 
that resulted in the decline in cell index. The observation that loss of 
impedance measurements was inhibited in the presence of both 5 and 
10µM cf2642, strongly suggests inhibition of virus induced syncytia 
formation. Evidence for this was already provided in chapter 3, section 
3.2.2). 
5.3. Summary 
 
An understanding of the different stages of a virus life cycle is vital in the 
design, development and testing of different antiviral compounds. Initial 
experiments towards elucidating the MoA of cf2642 were to investigate 
whether receptor clustering could mimic early MeV-induced effects on cells 
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in a non-infectious context. The aim was to test the effects of cf2642 on 
macropinocytosis. Several experiments in this chapter highlighted that 
cf2642 was having effects on cells in the absence of virus. Focus was 
placed on endocytosis and the data show that the drug was able to affect 
the localisation of early and late endocytic structures. A major challenge was 
to associate these changes to effects on viral life cycle. For this, MeV 
experiments were performed together with the developments of assays 
mimicking the demonstrated effects of the virus on the SLAM receptor. The 
increased Dextran-488 uptake seen with both SLAM-receptor clustering and 
MeV infection was completely abrogated by only a 5 min incubation with 
10µM cf2642 and moreover, actin labelling studies confirmed this was likely 
to be due to the inhibition macropinocytosis induced membrane ruffles and 
actin protrusions by the drug. Live and fixed cell imaging revealed that 
internalization of SLAM receptor was partially inhibited in the presence of 
cf2642. The possible implication of this during live MeV infection could be 
that cf2642 affects virus entry or early events occurring during infection of 
cells. The MeV entry/spread assay clearly showed that the MoA of cf2642 
was associated with the inhibition of virus spread and only partially affected 
entry. This was also supported by the ToA data where in it was shown that 
cf2642 affects a cellular process used by the virus during its entire life cycle.  
The anti-MeV activity of cf2642 was further supported by the results from 
impedance assay, where the increased cell index associated with MeV 
infection was abrogated in the presence of 5 and 10µM c2642. Overall, the 
data from this chapter show that the antiviral activity of cf2642 against MeV 
is attributed to its effects on intracellular membranous compartments utilized 
180 
 
by the virus during its life cycle. The effects of cf2642 on MeV entry was not 
conclusive and further studies are required to ascertain whether the drug 
affects virus entry via macropinocytosis.  
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Chapter 6 - General Discussion 
 
Measles outbreaks continue to occur in both developed and developing 
nations of the world in spite of the availability of an effective vaccine against 
this disease (Fischer, 2018, Sundaram et al., 2019, Mensah et al., 2019). 
Due to the unavailability of an effective antiviral against measles, the control 
measures during such outbreaks are limited to quarantine of infected 
individuals and supportive therapy. In such a scenario, the availability of an 
effective antiviral that can be administered as an immediate post-exposure 
prophylaxis measure to non-immunized individuals and their immediate 
contacts can significantly reduce the spread of infection during measles 
outbreaks. Moreover, the long incubation period of measles prior to the 
onset of clinical symptoms offers a large window for such treatment 
measures (Plemper and Snyder, 2009). This supports the urgent need for 
research towards development of an effective antiviral against this disease 
(McCune and Reynolds, 2015).  
Ever since the synthesis of cf2642 by Prof. Chris McGuigan’s group at the 
Cardiff University School of Pharmacy, there has been considerable interest 
in elucidating the MoA of this drug. Initial studies revealed the antiviral 
activity cf2642 against both measles and VACVand suggested that a 
common cellular target might be affected (Farleigh, 2014). Since these 
studies were focussed on the anti-viral activity of cf2642 against VACV, the 
primary objective of this project was to understand the effects of this drug on 
measles virus. Such an approach has a distinct advantage that the findings 
from these two studies can be bridged together, thus providing conclusive 
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evidence in relation to the common cellular target that renders cf2642 
effective against these two different viruses.  As noted, measles also 
represents a current clinical problem whereas smallpox has been 
eradicated. 
VeroSLAM cells were used for the most part of this research since they 
express the SLAM/CD150 receptor used by MeV to gain cell entry (Lin and 
Richardson, 2016). Earlier PhD studies on this drug at Cardiff University 
suggested that there may be a cellular target for this drug that would explain 
the fact that there was variation in toxicity profiles when different cell lines 
were investigated as measles hosts, including B95A. (Farleigh, 2014). This 
was confirmed in this new study in HeLa and VeroSLAM models, where the 
latter was found to be more sensitive to the drug. The antiviral activity of 
cf2642 against MeV was shown earlier in B95a cells by the inhibition of virus 
induced syncytia (Farleigh, 2014). Similar results were observed using 
VeroSLAM cells and this gave us confidence that we could use these cells 
as a model for the measles virus and clustering studies in this thesis. In the 
VeroSLAM cells, a dose-dependent effect of cf2642 against MeV was 
shown using both virus-plaque and impedance assays. In the latter, an 
increased cell index caused by the formation of MeV induced syncytia was 
effectively inhibited by higher concentrations of the drug. The antiviral 
effects of cf2642 shown by these two different biological assays gives more 
credence to the concept that this drug is an effective agent against MeV.  
The ability of MeV to induce autophagy led to experiments investigating 
whether the drug had any effects on this cellular process. The inhibition of 
this virus induced autophagy by cf2642 provided evidence of a cellular 
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target for the drug.  Previous studies have shown that inhibition of MeV 
induced autophagy affects virus spread (Richetta et al., 2013). This was 
confirmed by results from the MeV-GFP entry/spread assay in Chapter 5 
wherein c2642 was shown to inhibit virus spread and only partially affect 
virus entry into VeroSLAM cells. 
Endocytic profiling and dextran uptake studies were performed in an effort to 
better understand the cell-targeting effects of cf2642 in both HeLa and 
VeroSLAM cells. Two major findings were discovered from these 
experiments. Firstly, cf2642 does not affect the endocytic uptake of both 
dextran and transferrin, and subsequent trafficking for the former through 
early to late endosomes and then to terminal lysosomes.   Secondly, there 
was very strong evidence to show that the subcellular localisation of 
endocytic structures in live and fixed cells was affected by the drug. This 
was mostly manifest as a scattering of organelles as opposed to them being 
more polarized, possibly organised, in untreated cells.   The reason for this 
is still unknown but does not seem to be due to disruption of the actin or 
tubulin (data not shown) cytoskeleton that hold these organelles in place in 
the cytoplasm. Of note here is that disruption of actin has been shown to 
affect the measles life cycle (Dietzel et al., 2013). New recent evidence 
suggests that endocytosis may be used by this virus for uptake into cells 
and it remains to be determined if this mislocalisation of endocytic structures 
somehow contributes to the effects of cf2642. A limitation of the study is that 
intermediate filaments were not studied; these cellular structures have been 
poorly explored in comparison to actin and microtubules but have been 
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implicated in controlling virus life cycles (Sripada and Dayaraj, 2010, Hertel, 
2011).  
Previous studies have revealed the absence of cf2642-induced cytotoxicity 
when the medium was changed after 16 hr treatment with the drug, and this 
was attributed to the rescue of cells from the  fact that the drug increases 
the  acidity of the extracellular medium (Farleigh, 2014). This effect merits 
further study including the possibility that the drug could activate the many 
processes by which cells pump out protons from the cytosol into the cell 
exterior (Ruffin et al., 2014).  Interesting candidates are Sodium Hydrogen 
exchangers such as NHE1 that regulate intracellular pH by pumping 
protons, in exchange for sodium, into the extracellular space. Drugs such as 
amiloride can inhibit these pumps and it would be interesting to see how this 
would affect the cf2642 induced acidification process. These agents, 
through inhibition of macropinocytosis, can inhibit the uptake of a number of 
different viruses including measles (Casey et al., 2010, Masereel et al., 
2003, Delpeut et al., 2017). Early experiments performed with one addition 
of drug and no recovery period, showed that 10µM cf2642 induced toxicity. 
However, the later dextran uptake experiments performed in Chapter 4 with 
the same cf2642, did not affect the cells. This may be attributed to the 
additional washing of cells after 12 hr treatment in these experiments thus 
reducing the possible effects of high acidity in the extracellular medium. 
Also, the cytotoxicity of cf2642 mediated by low extracellular pH is more 
likely the result of the induction of apoptosis rather that necrosis, as shown 
by the LDH release assay (Chan et al., 2013a).  
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An important and novel finding that resulted from this research project is the 
successful use of SLAM-receptor clustering to mimic the early effects of 
MeV in a non-infectious setting. Being able to replicate the effects of MeV 
on clustering of SLAM-receptors during the early stages of infection (Fig 
6.1), enables one to better understand virus-host interactions and also to 
screen the in vitro effects of cf2642 in the absence of live virus to investigate 
whether they have an effect on this process and the viral dynamics on the 
plasma membrane.  
 
Fig 6.1 Illustration of the early effects of MeV interaction with cells. 
During the early stages of virus-cell interaction, MeV particles first interact 
with the SLAM receptors on the plasma membrane and subsequently 
causes the clustering of these receptors, thereby leading to virus entry via 
macropinocytosis.  
 
The inhibition of both SLAM-receptor clustering and MeV induced uptake of 
Dextran-488 by only a 5 min incubation with cf2642 exemplifies the early 
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effects of this drug on cells; most probably at the level of the plasma 
membrane, but as mentioned, there is also the interesting possibility that the 
drug could also affect the virus envelope (Chapter 5). Confocal microscopy 
analysis clearly showed the stimulatory effects of MeV and also SLAM 
clustering on macropinocytosis manifest in both cases as prominent actin 
protrusions and blebs. The abrogation of these effects in the presence of 
cf2642 further supports the inhibition of Dextran-488 uptake by 
macropinocytosis. Moreover, macropinocytosis is also exploited by other 
enveloped viruses including adenovirus, Ebolavirus, influenza A, VACV and 
Nipah virus (Mercer and Helenius, 2009). This thesis showed that cf2642 is 
an inhibitor of MeV/SLAM receptor induced macropinocytosis suggesting a 
novel MoA against MeV, VACVand possibly other enveloped viruses that 
warrant further study.  
It is clear that cf2642 has effects on cells beyond the remit of interfering with 
them as hosts for MeV entry and replication.  
The drug possesses a hydrophobic modality to allow greater penetration 
across the plasma membrane, but it is unknown if this affects the structural 
integrity of any membrane that it encounters such that it is not so amenable 
to exploitation by viruses. This could include the plasma membrane and 
internal membrane structures that measles and other viruses make use of 
for their own gains. The putative effects of cf2642 on these membrane 
systems, and possibly the viral envelope suggest that much further analysis 
is warranted to investigate the potential of this drug as a broad spectrum 
antiviral targeting the entry and spread of other enveloped viruses.  
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Future work 
1. Further studies on the effects of cf2642 on MeV can be done by 
investigating the localisation of virus (e.g. MeV expressing gfp) traffic 
through endocytic compartments (early endosomes to lysosomes) in 
the presence or absence of drug. These could be based on 
microscopy methods utilising some of the probes used here and 
GFP-tagged variants of Rabs and other proteins labelling distinct 
endocytic stations (Vercauteren et al., 2011). 
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Appendix A: Macro for quantification of 
internalized SLAM positive vesicles 
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Appendix B: Macro for quantification of red and 
green fluorescence intensities 
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Appendix C: Products and suppliers 
 
 
Biorad (Hemel Hempstead, UK):  
 Precision plus protein dual colour standards (161-0374)  
 Clarity, Western ECL substrate (170-5060)  
 12% Mini-PROTEAN® TGX™ Precast Protein Gels, 10-well, 30 µl (#   
4561043) 
DAKO (Ely, UK):  
 Fluorescence mounting medium (S3023)  
Fisher Scientific (Loughborough, UK):  
 Coverslips No. 1 circle 16mm diameter (12313138)  
 PVDF membrane (10344661)  
 SuperSignal West Femto Chemiluminescent Substrate (34094)  
 40% acrylamide/Bis (10376643) 
 Thermo Scientific™ Pierce™ LDH Cytotoxicity Assay Kit (88953) 
Life Technologies (Paisley, UK):  
 DMEM (61965)  
 DMEM (11880) 
 Earle’s Balanced Salt Solution (24010043) 
 FBS (16000-044)  
 0.05% Trypsin EDTA (25300062)  
 Hoechst 33342 (H3570)  
 Rhodamine Phalloidin (R415)  
 Dextran, Alexa Fluor 647; 10,000 MW, Anionic, Fixable (11570266) 
 Dextran, Alexa Fluor 488; 10,000 MW, Anionic, Fixable (11530266) 
 CellMask™ Plasma Membrane Stain (C10046) 
 Transferrin from Human Serum, Alexa Fluor™ 488 Conjugate (T13342) 
 Alexa Fluor 647 Phalloidin (A22287)  
 DAPI (D1306) 
MatTek Corporation 
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 35mm glass bottom dishes, 1.5 thickness, 10mm diameter (P35G-1.5-10-C) 
Promega (Loughborough, UK)  
 CellTitre Blue viability assay (G8080)  
Roche Diagnostics (Burgess Hill, UK):  
 Complete Protease Inhibitor Cocktail Tablets (11836153001)  
Sigma Aldrich (Poole, UK):  
 Triton X-100 ()  
 BSA (A7906)  
 Ponceau S solution (P7170)  
 Tween 20 (P1379)  
 Rapamycin (R8781) 
 Wortmannin (W3144) 
 Chloroquine diphosphate salt (C6628) 
 Methyl Cellulose (M0387) 
 Crystal Violet (C3886) 
 LookOut Mycoplasma PCR Detection Kit (MP0035) 
 JumpStart™ Taq DNA Polymerase (D9307)  
 Ethidium Bromide (E1510)  
Millipore: 
 Amicon Ultra-0.5 Centrifugal Filter Unit (UFC505024) 
 
 
 
 
 
 
 
